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ABSTRACT OF DISSERTATION 
 
 
 
 
SYNTHETIC AROMATIC AGMATINE ANALOGS AS ALLOSTERIC 
MODULATORS OF THE N-METHYL-D-ASPARTATE (NMDA) RECEPTOR 
CHANNEL 
 
The N-methyl-D-aspartate (NMDA) receptors are highly regulated ligand-gated ion 
channels, which are affected by many substrates.  Overactivation of the NMDA receptor 
can lead to hyperexcitability and a number of neurotoxic effects and neurological 
diseases. Agmatine has been demonstrated to act allosterically as an inhibitory modulator 
at the polyamine recognition sites of the NMDA receptor complex.  The present study 
synthesized and evaluated a library of agmatine analogs for their ability to displace 
tritiated MK-801 from NMDARs in P2 membrane preparations from rat brains at ligand 
concentrations of 1 mM and 50 uM.  A full dose-response curve was generated for the 
most active compounds, in the presence and absence of a pathological level of spermidine 
(100 uM). A forty-five member subset of arylidenamino-guanidino compounds was 
synthesized and all were demonstrated to be NMDA receptor inhibitory modulators in the 
above assay. Three of these compounds generated biphasic curves, indicating activity at 
two binding sites: the postulated high-affinity agmatine binding site, and a low-affinity 
site (perhaps the channel itself).  (4-Chlorobenzylidenamino)-guanidine hydrochloride 
demonstrated an IC50 of 3.6 uM at the former site and 124.5 uM at the latter.  Several 
 
computer models were generated to direct further synthesis.  Based on the structure-
activity relationship of the arylidenamino-guanidino compounds, a pharmacophore model 
of the agmatine binding site of the NMDAR was proposed. 
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CHAPTER 1: BACKGROUND TO RESEARCH 
 
1.1 Introduction 
 
 The N-Methyl-D-Aspartate receptor complex has become one of the most 
important and studied targets for drug development due to its importance in the central 
nervous system, as well as its complexity and incredible number of modulatory 
molecules, hence individual targets.   NMDA receptors are highly regulated ligand-gated 
ion channels, which are affected by many substrates, including the endogenous ligand, L-
glutamate.  The cation channel is nonselectively permeable to Na+, K+, and Ca2+, but is 
blocked by Mg2+ at physiological conditions.  Overactivation of the NMDA receptor can 
lead to hyperexcitability and a number of neurotoxic effects and neurological diseases 
such as epilepsy, as well as Parkinson’s, Alzheimer’s, and Huntington diseases.  
Antagonism of the NMDA channel has also been shown to reduce toxicity due to alcohol 
withdrawal (Littleton et al., 2001).  However, the physiological function of this channel 
is crucial in learning and memory, and thus a therapeutic agent cannot be one which 
irreversibly inhibits channel flux. 
Overexcitation of this receptor and neurotoxicity can result from activation of an 
NMDA coreceptor, NR2B, by spermine and spermidine, polyamines which are 
biosynthesized from putrescine (the ureahydrolyzed form of agmatine).  Agmatine, a 
polyamine found in mammalian tissue (Li et al., 1994), has been investigated recently for 
its role in pain regulation, and may also be a neurotransmitter with its own transporter 
across the blood-brain barrier (Reis and Regunathan, 1999).  An endogenous ligand at 
imidazoline binding sites (Raasch et al., 2001), this compound has also been shown to 
have effects on learning and memory in rodents (McKay et al., 2002).  In addition, 
agmatine and its analogue arcaine are antagonists of the NMDA receptor in the brain, 
facilitating neuronal recovery.  This background focuses on the roles of polyamines, 
specifically agmatine, as allosteric modulators of the NMDA receptor complex.   
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1.2 NMDA Receptors 
 
 The majority of mammalian fast excitatory synaptic transmission is regulated in 
the brain by the excitatory amino acid (EAA) L-glutamate.  Therefore, its receptor 
channels have been identified as some of the most crucial in terms of physiological 
response as well as associated pathology. 
 Glutamate is synthesized in multiple metabolic compartments (Aureli et al., 
1997), and is present at resting conditions in the synaptic cleft at concentrations around 
0.6uM (Bouvier et al., 1992).  During excitatory synaptic transmission, this extracellular 
concentration will very briefly increase twenty-fold (Clements et al., 1992), after which 
the L-glutamate undergoes reuptake by the pre-synaptic and post-synaptic cell 
membranes of the neurons (Danbolt, 2001). 
 There exist two major classifications of glutaminergic receptors in the brain, the 
ionotropic receptors (iGluR) and the metabotropic receptors (mGluR).  The metabotropic 
glutamate receptors are G-protein coupled and eight genes for these have been identified.  
The ionotropic glutamate receptors are coded across at least fifteen genes and consist of 
three major and well-known families, named for their earliest discovered specific 
agonists: a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), kainic acid 
(KA)(McKay et al.), and N-methyl-D-aspartate (NMDA). 
 Unlike the other subfamilies of iGluRs, NMDA receptors at resting potential are 
blocked in their channel by Mg2+ in a voltage-dependent manner.  Also, while every 
iGluR is permeable to Na+ and K+ ions, the NMDA channels are also highly permeable to 
Ca2+ upon opening.  Among all of the glutamate receptors, the NMDARs have many 
crucial roles in neural physiology, and their implication in many pathological conditions 
have opened this receptor to much intense scrutiny as a target for fine modulation. 
  
1.2.1 NMDA Receptor Location and Structure 
 
 NMDA receptors exist as ligand-gated ion channels, formed as heteromultimeric 
protein complexes.  The two major subunit families are termed NR1 and NR2; the latter 
consists of four separate proteins (termed NR2A-NR2D) coded on four separate genes, 
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while the former is a single protein with only one associated gene.  In addition, an NR3A 
subunit has been shown to be expressed in the first post-natal week in mice; this subunit 
is only coimmunoprecipitated with NR1 and NR2B subunits, forming a receptor with 
lessened activity indicative of an unknown regulatory system (Das et al., 1998). 
 
COOH
NH2
M2
M4 M1 M3
NR1 Subunit
Gly
COOH
H2N
M2
M4M1M3
NR2 Subunit
Glu
C1
C2
N1
 
 
Figure 1.1 Representation of the NMDA receptor NR1 and NR2 subunits,  
showing NR1 exons involved in splice variants (adapted from Hynd et al., 2004) 
 
 Each NMDAR is assembled in vivo as either a tetrameric or pentameric channel 
complex, although it remains unknown as to which composition is exclusively formed, if 
not both.  The majority of NMDA receptors are composed of at least one NR1 subunit 
and at least one NR2 subunit.  It has been suggested that each NMDAR is likely to 
contain two NR1-subunits in each channel complex (Behe et al., 1995), and in vivo 
studies have shown that some NMDA receptor complexes are composed of more than 
one different NR2-subunit in addition to the NR1-subunit or subunits (Luo et al., 1997).  
Factors affected by the type of NR2 subunit, or subunits, incorporated into the channel 
complex include affinity for agonists, antagonists, and polyamines, sensitivity to 
blockage by Mg2+ and Zn2+, and channel conductance, as well as kinetics of deactivation.  
In Xenopus oocytes, a functional homomeric NR1 subunit complex is formed, which is 
indeed responsive to L-glutamate and glycine (Moriyoshi et al., 1991; Yamazaki et al., 
1992).  However, in mammalian expression systems, this NR1-only channel is able to 
bind the agonists as well as channel blockers, but does not display any functional 
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properties (Chazot et al., 1992; Grimwood et al., 1995).  Many studies have been 
performed to determine specific stoichiometry of NMDA receptors, and while many 
different combinations of subtypes have been proposed, a definitive conclusion as to the 
exact number and composition of subunits remains hazy.  
 The gene which expresses the NR1 subunit is composed of 22 exons over 31 kb in 
rats (Zimmer et al., 1995).  The human gene is very similar to the rat gene, save for the 
exclusion of rat exon 3 (Hollmann et al., 1993), leaving 21 exons.  In both species, this 
gene undergoes alternative splicing at three different exons, and these coding regions 
give identical amino acid sequences in both rat and human (Foldes et al., 1994).  These 
three exons code 21, 37, and 38 amino acids are titled N1, C1, and C2 respectively from 
the 5’ to 3’ end (Figure 1.1); they are exons 4, 20, and 21 in humans and 5,21, and 22 in 
rats (Durand et al., 1993).  Alternative splicing of these three exons results in eight 
variants of the NR1 subunit, which are denoted in subscript to designate the inclusion (1), 
exclusion (0), or undetermined (X) state of N1, C1, and C2 (Durand et al., 1993).  The 
relative abundance of these eight splice variants is 67% for the most commonly-found 
NR1011, 15% total for the four NR11XX variants, and 18% total for the remaining three 
NR10XX variants (Sugihara et al., 1992).  Alternative splicing has also been demonstrated 
in the NR2C subunit to some extent, however it has not been well characterized nor the 
functional differences well-researched (Ishii et al., 1993). 
 As the NR1 subunits are believed to be found in every functional NMDA receptor 
complex, they are well-distributed among most brain neurons, but the distribution of 
NMDA receptor complexes containing the specific NR2 subunits is more differentiated 
by location.  NR2A mRNA is almost as well-distributed as that of NR1, while the mRNA 
of the NR2B and NR2C subunits seem to have a more complementary distribution 
(Monyer et al., 1992).  Receptors which include the NR2A and NR2B subunits are found 
in most neurons throughout the cerebral cortex, hippocampus, and thalamus (Hollmann 
and Heinemann, 1994), and mRNA of both NR2A and NR2B have been found in the 
amygdaloid nuclei as well as the caudate-putamen (Monyer et al., 1992).  The NR2B 
subunits are also highly expressed in the medium-sized spiny projection neurons (MSNs) 
of the striata, relative to other NR2 subtypes (Christie et al., 2000; Landwehrmeyer et al., 
1995; Rigby et al., 1996).  The cerebellum contains the majority of the NR2C subunits, 
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and NR2A subunits are also expressed there; NR2A-C subunits are all expressed in the 
thalamic nuclei, but the hypothalamus does not contain the mRNA of any of the three 
subunits.  The cell type distribution is also different for these subtypes: while NR1 and 
NR2A mRNA are expressed in most cell types, the mRNA of NR2B is mainly found in 
granule cells, and NR2C mRNA is mainly expressed in tufted and mitral cells (Monyer et 
al., 1992).  The NR2D subunits are exclusively expressed in the brain stem and spinal 
cord (Hollmann and Heinemann, 1994). 
  
 
1.2.2 NMDAR Function 
 
 The NMDARs have been indicated in the governing of such important 
physiological functions as synapse formation, neuronal differentiation, and long-term 
potentiation; and are implicated in memory and special learning function, primarily 
during development.  As these receptors require very high levels of synaptic membrane 
depolarization in order to activate by removing the voltage-dependent Mg2+ channel 
block and allow Ca2+ to flow, they are well-suited for the induction of synaptic plasticity 
(Bliss and Collingridge, 1993).  It has also been found that NMDA receptor stimulation 
promotes the survival, maturation, and neurite outgrowth of neurons which have been 
isolated from cerebellum and hippocampus. 
 Receptor function is also closely related to the subunit composition of the NMDA 
receptor complex, as is seen in other types of EAA channels (Unwin, 1989).  In studies of 
whole-cell currents, the subunit combination of NMDA receptors affected the strength of 
voltage blockage by magnesium. NR1/NR2C and NR1/NR2D complexes possess much 
weaker Mg2+ blocking action than the NR1/NR2A and NR1/NR2B NMDAR complexes, 
indicating that sensitivity to the endogenous voltage blocker differs directly according to 
the subunits involved (Liu et al., 1996; Monyer et al., 1992). 
 
1.2.3 NMDAR Pathology 
 
 Excitatory transmission, while being an integral part of NMDA receptor function, 
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has also been implicated in neuronal destruction.  L-Glutamate is the excitatory amino 
acid responsible for activation, and subsequently overactivation at excess levels, of 
NMDA receptors; the potential for overexcitation is normally overcome by uptake 
mechanisms removing extracellular L-Glu on both pre- and post-synaptic neuronal cell 
membranes as well as the membranes of adjacent glial cells.  Involved in this toxicity are 
overactivation of NMDA receptors and increase in the intracellular concentration of Ca2+ 
ions.  As AMPA and kainite receptors are not highly-permeable to calcium ions, 
NMDARs possess a much greater potential for introduction of excess intracellular Ca2+ 
concentrations, which initiate a neurodegenerative cascade leading to cell death.  In vivo 
studies supporting the involvement of NMDARs with neurodegeneration have correlated 
the accumulation of radiolabeled calcium with toxicity (Koh and Choi, 1991), as well as 
demonstrating that an application of toxic L-Glu levels in hippocampal neurons elevates 
intracellular Ca2+ concentrations for a full hour and leads to the death of 85% of the 
neurons in a 24-hour period (Dubinsky, 1993).  Excessive calcium ion influx may also be 
causative in neuronal death by triggering the activation of degradative enzymes such as 
calpains and capsases (Nicotera and Lipton, 1999).  In addition, many studies have shown 
that this neuronal cell death can be prevented by blocking NMDARs, and thus excess 
calcium influx.  Some of the pathology may be due in part to the rise in polyamine levels 
seen in various conditions, as some polyamines act as channel agonists (Paschen, 1992). 
 Seizures, and in particular epilepsy, have been long tied to glutamate receptors, 
specifically N-methyl-D-aspartate receptors.  L-Glutamate, and its interaction with EAA 
channels, has been implicated in the initiation and proliferation of some types of seizure 
activity (Meldrum et al., 1999).  NMDAR-mediated excitotoxicity may be the cause of 
the neuronal death following status epilepticus (Choi, 1988).  In vivo epilepsy models 
have shown that NMDA receptor activation is necessary in the development of seizure 
susceptibility, while other studies have suggested a role for NMDA receptors in the 
appearance of epileptiform discharges.  All classes of NMDAR antagonists have shown 
anticonvulsant properties including channel blockers, glycine site antagonists, and 
polyamine site antagonists (Chapman, 2000). 
 The actions of NMDA receptors, in particular with respect to polyamines, have 
been well investigated for their role in Alzheimer’s disease (AD).  While the excitotoxic 
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necrosis of neurons in AD may be due to the pathological persistent depolarization of the 
cell membrane leading to excess calcium influx, the levels of brain polyamines which are 
seen in Alzheimer’s may be the more direct effect which leads to said NMDAR 
overactivation (Dodd, 2002; Morrison and Kish, 1995).  In the temporal cortex of AD 
patients, the levels of spermidine (an NMDAR agonist) are greatly increased over control 
levels, while the levels of putrescine (a partial NMDAR antagonist) are decreased.  These 
two effects are likely caused by the increase in brain S-adenosylmethionine 
decarboxylase activity, which should increase the rate of conversion of putrescine into 
spermidine (see Figure 1.2, page 18) (Morrison et al., 1996).  In addition, the activity of 
ornithine decarboxylase (the main enzyme responsible for the biosynthesis of putrescine) 
is reduced in the occipital cortex, but increased in the temporal cortex in Alzheimer’s 
disease patients (Morrison et al., 1998).  There is evidence that there is a loss of NMDA 
receptor complexes containing the specific splice-variant NR11XX subunit in the areas of 
the brain afflicted by AD and most subject to neuronal cell loss (Mattson, 1997), but 
whether this is a cause or effect of the disease is unknown.  However, post-mortem brain 
tissue of Alzheimer’s disease patients is indeed observed to contain pathologically-
modified excitatory glutaminergic pyramidal neurons (Braak et al., 1993; Francis et al., 
1992). 
 Huntington disease, an inherited neurodegenerative disorder, has also been linked 
to NMDAR-mediated excitotoxicity (Li et al., 2003).  Specifically, Huntington disease 
(HD) affects the striatal medium-sized spiny projection neurons (MSNs), which contain 
NMDAR complexes with a relatively larger amount of NR2B subunits expressed than 
other NR2 subunits.  Indeed, brain tissue removed post-mortem from HD sufferers 
demonstrates the degenerative vulnerability of neurons with high levels of NMDA 
receptors (Albin et al., 1990; Young et al., 1988).  A mutation in the protein huntingtin, 
htt, is causative in the development of Huntington disease in humans (Huntington's 
Disease Collaborative Research Group, 1993).  It has been shown that the mutant htt 
potentiates both the currents and excitotoxicity mediated by N-methyl-D-aspartate 
receptor complexes which include at least one NR2B subunit (Li et al., 2003), as well as 
having a role in the induction of mitochondrial dysfunction (Panov et al., 2002).  This 
increase in NMDA activity over long periods of time and with patient aging may be too 
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much for the natural regulatory mechanisms to overcome, with the resulting oxidative 
stress and excess Ca2+ levels leading to increased calpain and capsase activity, htt 
proteolysis, and cell death (Li et al., 2003).  In studies done on rodents and non-human 
primates, it was found that striatal NMDAR overactivation indeed resembles the 
neurological and behavioral changes seen in Huntington disease patients (Beal, 1992).   
 Brain damage associated with concussive head injury as well as ischemia, 
hypoxia, and hypoglycemia may also be a direct result of overactivation of NMDA 
receptors following these conditions.  This excitotoxicity leads directly to necrosis or 
apoptosis (Johnston et al., 2000). 
 The NMDA receptors, specifically with regards to their regulation by polyamines, 
are crucial in the development and continuation of neuronal pathology demonstrated in 
drug abuse.  It has been postulated that the NMDARs are involved in the mechanisms of 
alcohol as well as cocaine and opioid drugs.  Chronic use of ethanol, an inhibitor of 
NMDARs (particularly those containing the NR2B subunit), can cause adaptations and 
desensitization which can lead to alcohol dependence (Lovinger et al., 1989).  
Furthermore, this NMDAR up-regulation which results from excess ethanol intake is 
known to directly result in the neurotoxicity associated with hyperexcitability 
demonstrated during the withdrawal period afterwards (Dodd et al., 2000).  Fetal alcohol 
syndrome may also be due to the interactions between ethanol and polyamines at 
NMDAR polyamine sites.  As polyamines positively modulate the NMDAR effects 
which facilitate neuronal growth and synapse formation during fetal development 
(Johnson, 1996), the inhibition of these potentiating effects by alcohol may indeed harm 
the fetal CNS. 
 
 
1.3 Regulation of NMDA Receptors 
 
1.3.1 Direct Channel Blockers 
 
 Regulatory sites on the NMDA receptor are abundant, and the list of modulators 
and binding sites is extensive.  The endogenous agonist is the excitatory amino acid L-
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glutamate, but as N-methyl-D-aspartate is specific for this receptor over the other EAA 
receptor types, the latter compound received naming privileges.  Biochemical and 
electrophysiological studies have shown that glycine enhances the effects of glutamate or 
NMDA on channel activation, and is therefore considered a co-agonist.  In fact, the 
gating occurs quite poorly in the absence of both of these neurotransmitters, a unique 
property of NMDARs among known neurotransmitter receptors.  Site-directed 
mutagenesis has shown that the binding of glycine probably occurs on the outer 
membrane-spanning domains of the NR1 subunits of the receptor complex (Kuryatov et 
al., 1994), while L-glutamate binds in a similar location of the NR2A and NR2B subunits 
(Anson et al., 1998; Laube et al., 1997) (Figure 1.1). 
 Magnesium ions block the channel at resting membrane potential in a highly 
voltage-dependent manner, on a location deep within the pore, closer to the intracellular 
side of the receptor.  The possibility of two separate Mg2+ binding sites has also been 
suggested due to studies showing voltage-dependent NMDA ion-channel blockage by 
both intracellular and extracellular magnesium (Johnson, 1996).  Curiously, in the 
absence of the endogenous agonist and co-agonist, low levels of Mg2+ enhances the 
binding of the standard channel-pore blocker [3H]MK-801, however, in the presence of 
the amino acids, Mg2+ reduces [3H]MK-801 binding.  The type of NR2 subunit associated 
with the NMDA complex also has an effect on Mg2+ activity, as those containing NR2C 
or NR2D subunits are less sensitive to blockage by Mg2+ than are those containing NR2A 
or NR2B subunits (Liu et al., 1996). 
 Zinc ions also have a complicated array of effects on the NMDA receptors.  Zn2+ 
seems to act as both a voltage-dependent channel blocker and as a non-competitive, 
voltage-independent inhibitor (Peters et al., 1987).  This channel blockage by zinc is 
much weaker than the voltage-dependent channel block by Mg2+.  In addition, Zn2+ may 
also potentiate a current induced by bound agonists at the NMDAR (Hollmann et al., 
1993).  While it is important to note that Zn2+ and Mg2+ bind at separate sites, it has been 
suggested that Zn2+ binds at two distinct sites on the NMDAR as well, one within the 
channel, and another outside the channel which is more sensitive to the membrane 
potential (Christine and Choi, 1990).  The subunit composition of the NMDA receptor 
also impacts the sensitivity to Zn2+: complexes containing the NR2A subunit have a 
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higher affinity for voltage-independent Zn2+ inhibition (Mori et al., 1992) than complexes 
containing the other three NR2 subunits, and those NMDA complexes which contain the 
NR2A or NR2B subunits also display more of the low-affinity voltage-dependent Zn2+ 
inhibition than the others (Paoletti et al., 1997). 
 Blockage of the NMDA receptor channel can also be achieved by a large number 
of synthesized molecules which are either drugs, or were designed as drug candidates.  
Phencyclidine (PCP) and the structurally similar drug ketamine are both NMDA channel 
blockers with slow kinetics, which have been used as dissociative anesthetics, but both 
are also commonly known to possess high abuse potential.  (+)MK-801, also known as 
dizocilpine or (+)-[3H]-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine 
maleate, is a very potent NMDAR channel blocker, which also has exhibited high abuse 
potential and is primarily used in displacement assays in order to judge the inhibitory 
properties of other molecules.  Dextromethorphan, an antitusive, is another effective 
channel blocker, with a stronger selectivity for NMDA complexes containing the NR2A 
subunit over those lacking it (Avenet et al., 1997).  A pair of similar amino-adamantane 
molecules, memantine and amantadine, are also potent channel blockers, which offer 
more potential as drugs than the previously mentioned channel blockers due to their 
faster kinetic profiles (Parsons et al., 1996).   Memantine and amantadine exhibit an 
improved clinical tolerance compared to MK-801 and phencyclidine due to faster 
blocking/unblocking of the NMDA channel, and have been used clinically to treat 
dementia and Parkinson’s disease without the neurotoxic and abuse effects of the other 
channel blockers (Kornhuber et al., 1994).   
 
1.3.2 Allosteric Modulators 
 
 Function of the NMDA receptor complex is also regulated in part by the pH levels 
of the extracellular solution (Traynelis and Cull-Candy, 1990).  The concentration of H+ 
ions at physiological pH are, in fact, very close to that of the IC50 of H+ ions for the 
NMDA receptor, thus any change in pH will alter channel activity to some degree (Tang 
et al., 1990).  The location of pH effect on the channel complex, or the H+ binding site, is 
located near the extracellular terminal of the NR1 protein subunit.  As protons do not 
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directly interfere with the channel, they are said to act as allosteric inhibitors of NMDAR 
activity.  NMDA receptor complexes containing the NR2C subunit have an IC50 for H+ 
inhibition around pH 6.2, while complexes containing the NR2A, B, or D subunits tend to 
have IC50 levels around pH 7.2-7.3 (Traynelis et al., 1995). 
 Ethanol also is a concentration-dependent inhibitor of NMDAR function 
(Koltchine et al., 1993; Mirshahi and Woodward, 1995).  Protein kinase inhibitors have 
been shown to counter the ethanol-induced inhibition in cerebellar granule cells (Snell et 
al., 1994), and it has been demonstrated that ethanol may enhance phosphorylation of 
tyrosine residues in the NR2B subunit, thereby increasing the receptor’s tolerance to 
ethanol inhibition (Miyakawa et al., 1997).  Homomeric NR10XX NMDAR complexes are 
less sensitive to ethanol-induced inhibition than the homomeric channels composed of 
NR1 subunits containing exon 4 (Koltchine et al., 1993), although the NR1 splice variant 
involved in NR1/NR2 heteromeric channels does not seem to have any bearing on 
ethanol sensitivity (Kuner et al., 1993).  NMDAR complexes containing the NR2C 
subunit are less sensitive to the modulatory effects of ethanol than those containing 
NR2A or NR2B subunits (Kuner et al., 1993; Masood et al., 1994). 
Endogenous oxidizing and reducing agents can also modulate NMDAR channel 
function from the extracellular milieu, with the former acting as an inhibitor and the latter 
in an activity-enhancing manner (Aizenman et al., 1989; McBain and Mayer, 1994).  This 
modulatory function is governed by the equilibrium between reduced (thiol) and oxidized 
(disulphide, or possibly sulphenic acid) states of two cysteine residues located on an 
extracellular loop of the NR1 subunit, Cys-744 and 798 (Lipton et al., 1996; Sullivan et 
al., 1994).  Not surprisingly, the subunit composition of the NMDA receptor complex 
governs the sensitivity to these redox substances; complexes containing the NR2A 
subunit undergo both reversible and persistent potentiation effects by reducing agents, 
while the NR2B-D subunits are only involved with complexes that undergo the persistent 
effects which can only be undone by the addition of an oxidizing agent (Kohr et al., 
1994).  This suggests separate, or additional, redox sites on the NR2A subunit, while the 
modulation demonstrated in other NMDAR complexes may be entirely governed by the 
previously mentioned cysteine residues of the NR1 subunit.  However, homomeric NR1 
channel complexes are completely insensitive to redox modulation (Sullivan et al., 1994). 
 11
 Polyamines exhibit their modulatory activity based on several key structural 
features, including number of amines, distance between amines, charge, and lipophilic 
and hydrophilic domains.  Both spermine and spermidine act as glycine-independent 
agonists, and potentiate binding of open-channel blockers.  Antagonists at the polyamine 
sites include putrescine (1,4-diaminobutane) and diethylenetriamine (DET), which serve 
to block or displace spermidine and spermine, as well as arcaine (1,4-diguanidinobutane) 
and long-chain diamines with eight or more carbons between primary amines (Romano et 
al., 1992).  Agmatine is believed to act as an inhibitory modulator at NMDARs at a 
separate site.  Inhibitory and potentiative effects are seen with short-chain diamines, with 
the general observation that lipophilic 1,3-diamines act as NMDA channel antagonists 
whereas hydrophilic 1,3-diamines have agonist properties (Lewin et al., 1998). A wide 
range of activities was also found in several studies of synthetic spermine and spermine 
analogues, containing linear as well as cyclic linkers. 
 While many channel-blockers and EAA binding site inhibitors have been shown 
to possess strong binding affinity, these classes of antagonist have very high abuse 
potential and exhibit neurotoxicity.  The polyamine sites are an interesting topic for 
research, as the antagonists at this site exhibit neither of these detrimental qualities, yet 
possess strong binding affinity.  However, of the modulatory sites of the NMDAR 
complex, the polyamine site is least well-understood in terms of its location, binding 
domain, and even the number of polyamine recognition sites. 
   
 
1.4 Polyamines  
 
1.4.1 Polyamines Background 
 
 The ubiquitous endogenous polyamines in eukaryotic tissue include spermidine, 
spermine, putrescine, and agmatine.  These compounds are all enzymatically synthesized 
products of the amino acid arginine, via the polyamine pathway (Figure 1.2).  While 
agmatine is formed exclusively from the decarboxylation of arginine by arginine 
decarboxylase (ADC), the favored route for the synthesis of putrescine proceeds by the 
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ureahydrolysis of arginine to ornithine, followed by the subsequent decarboxylation to 
putrescine by the enzyme ornithine decarboxylase, or ODC.  ODC is believed to be one 
of the major regulatory enzymes for maintaining proper cellular polyamine levels, along 
with S-adenosylmethionine decarboxylase later in the polyamine pathway (Figure 1.2).  
Ornithine decarboxylase itself is regulated by levels of cAMP and Ca2+ (Veldhuis and 
Hammond, 1981), and the degradation of the enzyme is accelerated by antizyme (Heller 
and Canellakis, 1981).  While the synthesis of putrescine from arginine through the 
agmatine intermediate is believed to exist in mammals, neither the ADC nor agmatinase 
enzyme is well-characterized (see Section 1.4.3).  Spermidine is the resulting product of 
the addition of aminopropyl moieties to one terminal putrescine amino moiety by 
putrescine aminopropyltransferase (PAPT); this step is followed by the same addition 
onto the other terminal “putrescine” amino moiety, catalyzed by spermidine 
aminopropyltransferase (SAPT).  The aminopropyl group that is transferred in both cases 
originates from decarboxylated S-adenosylmethionine (dcAdoMet), which is made 
available by the enzymatic decarboxylation of S-adenosylmethionine, a process that 
partially serves to regulate the cellular levels of spermine and spermidine (Morrison et 
al., 1993).  Composed of a propyl and a butyl chain, spermidine is not a symmetrical 
molecule, but it should be noted that SAPT specifically adds the aminopropyl group to 
the butylamine. 
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Figure 1.2 The biosynthetic polyamine pathway 
 
 The classic three polyamines, putrescine, spermidine, and spermine, are present in 
relatively high concentrations  in the CNS, putrescine at levels of roughly 4-70 nmol/g of 
tissue and the others around 50-1400 nmol/g (Seiler and Schmidt-Glenewinkel, 1975; 
Shimizu et al., 1964).  These molecules have essential roles in the growth and 
differentiation of cells in many different systems and tissue types, with a wide range of 
 14
concentrations throughout mammalian systems (Pegg, 1986; Tabor and Tabor, 1984).  
Their levels are regulated by a complex system of enzymatic synthesis and degradation, 
as well as uptake and export (Pegg, 1988).  In addition, polyamines have been implicated 
in protein synthesis (Lenzen et al., 1986), stabilization of nucleic acids (Igarashi and 
Kashiwagi, 2000), gene expression regulation (Celano et al., 1989), free radical 
scavenging (Ha et al., 1998), membrane permeability regulation (Lapidus and Sokolove, 
1992), and programmed cell death (Ha et al., 1997).  Polyamines are also present in the 
mammalian brain at micromolar concentrations (Sarhan and Seiler, 1989), where they 
possess regulatory roles at ion channels (Scott et al., 1993), including many effects on the 
NMDA receptor complexes.  It has been suggested that these polyamines act as 
neurotransmitters, or possibly regulators of synaptic transmission (Harman and Shaw, 
1981; Shaw, 1979). 
 
1.4.2 Polyamine Activity at the NMDAR Complex 
 
 As with most NMDA inhibitors, the subunit composition of the receptor complex 
has a large bearing on the activity of the polyamines, individually and as a group (Hess et 
al., 1998; Zhang et al., 1994).  While at least three separate NMDA receptor polyamine 
binding sites have been identified (Yoneda and Ogita, 1991), the polyamines also display 
effects at other modulatory sites on the NMDAR complex.  These compounds, in 
addition to their inherent properties, also are able to enhance or reduce the modulatory 
properties of glycine and glutamate, as well as reducing the Ca2+-influx inhibitory effects 
mediated by protons. 
 The final two polyamines in the metabolic pathway, spermine and spermidine, 
possess at least four modulatory effects on the complex (denoted in parentheses below as 
1-4), and act as both allosteric agonists and antagonists.  The two inhibitory effects of 
polyamines consist of (1) a voltage-independent inhibition, as they can serve to decrease 
the NMDAR binding affinity of the endogenous excitatory amino acid, L-glutamate 
(Hess et al., 1996); and (2) a voltage-dependent NMDAR inhibition, in which these 
compounds can act directly in the channel pore at the Mg2+ binding site to interrupt the 
cation flux through the channel (Araneda et al., 1999; Rock and MacDonald, 1992).  The 
 15
voltage-dependent inhibition was reported as the low-affinity part of a biphasic nature 
exhibited by spermine and spermidine on [3H]MK-801 binding.  While these compounds 
potentiate binding at lower concentrations, the effect reverses around 300μM, at which 
point the polyamine begins to displace the channel-bound ligand, presumably through the 
previously noted steric hindrance of the pore (Ransom and Stec, 1988).  The lower 
affinity potentiation of [3H]MK-801 binding is an example of the positive modulatory 
effects of polyamines.  These effects, while producing similar outcomes, are markedly 
different, depending on the levels of glycine present.  At saturation concentrations of 
glycine, polyamines (3) increase the channel currents which are induced by L-glutamate, 
independent of glycine; and at lower glycine levels, polyamines (4) increase the receptor 
affinity for glycine, thereby potentiating the channel-opening effects of glycine, relative 
to its concentration. 
 Putrescine itself has no effect on the binding of [3H]MK-801 to NMDA receptors 
in the presence of physiological levels of glutamate and glycine (Reynolds and Miller, 
1989).  Putrescine does, however, inhibit the stimulatory effects of spermine and 
spermidine, regardless of the presence of the excitatory amino acids.  This effect was 
shown to be non-competitive, suggesting that the effects of putrescine may be mediated 
at a separate polyamine recognition site (Sacaan and Johnson, 1990). 
 The polyamine arcaine acts as a displacer of MK-801 in the presence and absence 
of spermine and spermidine (Sacaan and Johnson, 1990).  This compound is structurally 
similar to the endogenous polyamine agmatine, but has a guanidine moiety on both ends.  
As arcaine is able to inhibit the ligand binding to baseline levels, it is believed that this 
compound acts as an antagonist or inverse agonist at one of the polyamine binding sites 
(Reynolds, 1990). 
A long-chain diamine, 1,10-diaminodecane (DA10 or N-10-N), does not replicate 
the effects of similarly-structured spermine and spermidine.  In fact, in the absence of 
other polyamines, this compound inhibits the binding of [3H]MK-801 (Williams et al., 
1989), due to a decrease in the rate of association of the channel-blocker.  Experiments 
performed in a range of glutamate and glycine concentrations have shown that DA10 
does not act at the amino acid sites; in fact, a high concentration of spermidine served to 
attenuate the effects of DA10.  Another study performed with longer-chain diamines 
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possessing 12, 14, and 16 carbon-chains produced similar results, with higher potency 
(Berger et al., 1992).  These data indicate that long diamines may act as inverse agonists, 
producing effects opposite to those of spermine and spermidine, but at the same site 
(Williams et al., 1990).   
Diethylenetriamine (DET), a linear polyamine, has also been identified as an 
NMDA receptor antagonist.  However, it does not directly reduce [3H]MK-801 binding in 
the absence of spermine or spermidine, indicating that it acts as either a competitive 
antagonist at the binding site for longer-chain polyamines, or possibly as an allosteric 
displacer of them (Williams et al., 1989).  Further studies showed that increasing DET 
concentrations resulted in a parallel shift of the concentration-effect curve of spermidine-
potentiation, which confirms the former hypothesis of a direct effect of DET as a 
competitive antagonist at the long-chain polyamine binding site (Williams et al., 1990).  
Interestingly, high concentrations of DET (>100 μM) are able to slightly potentiate MK-
801 binding, indicating that it acts as a weak partial agonist at a polyamine recognition 
site (Williams et al., 1991). 
 A large study undertaken by Yukio Yoneda (Yoneda et al., 1995) examined over 
60 polyamine derivatives for their ability to affect the binding of [3H]MK-801 from 
whole rat brain preparation in the presence and absence of spermidine (1 mM).  These 
screenings of primarily synthetic polyamines demonstrated again that diamines with less 
than eight methylene groups have no effect on NMDARs, whereas those longer acted as 
channel antagonists.  Triamines with between five and ten combined methylene groups 
between the two chains demonstrated the MK-801 binding potentiation of spermidine, 
but the eleven-methylene N-(3-aminopropyl)octanediamine (TA38) appeared to act as a 
competitive antagonist for spermidine by attenuating the spermidine-potentiating effects 
while having no statistical effect on binding in the absence of the endogenous polyamine.  
Tetraamines containing less than a combined fifteen methylene groups had similar 
activity to spermine, while those containing greater than fifteen displaced the MK-801 in 
the presence and absence of spermidine.  The synthetic polyamine bis-(3-
aminopropyl)nonane-diamine (TE393) was the only tetraamine which had no effect on 
the binding in the absence of added spermidine, but significantly inhibited binding in its 
presence (Yoneda et al., 1995).  This structure-activity experiment demonstrated that the 
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chain length and number of amines in a polyamine can significantly impact its effects on 
the NMDAR complex, perhaps at different polyamine recognition sites. 
Another structure-activity study studied the effects of various linear and cyclic 
synthetic tetraamines over a range of concentrations and compared the pKa values of the 
nitrogen atoms in the compounds.  This study again detailed the complex nature of 
polyamine modulation of the NMDAR complex.  While diethylspermine acts as a potent 
inhibitor of [3H]MK-801 binding with an IC50 value of 10μM, a geometric homologue 
with fluorine atoms substituted for each of the terminal methyl hydrogen atoms possesses 
no activity.  This latter compound, N1,N12-bis(2,2,2-trifluoroethyl)spermine, is only 
protonated at the two central nitrogen atoms at physiological pH, thus the compound has 
pKa values similar to putrescine, and maintains putrescine’s lack of NMDAR activity.  
Many other examples in this study belie the importance of charge as opposed to number 
of amines possessed by a given polyamine (Bergeron et al., 1996). 
 Insertion of an aromatic moiety into long-chain diamines has also been shown to 
increase the affinity of these compounds for the polyamine binding domains of the 
NMDAR complex (Berger et al., 1998).  This study showed that introduction of a 
thiophene moiety between the fourth and fifth methylene groups of 1,12-
dodecanediamine (DA12) results in a fifty-fold increase in [3H]MK-801 displacement in 
the presence and absence of 100μM spermine.  Interestingly, shifting the thiophene group 
to a different position in the chain without varying the total number of methylene groups 
resulted in a decrease in potency.  This increase in potency may be due to the 
conformational restraint of such a grouping, or possibly point to an affinity for aromatic 
groupings at one or more of the polyamine recognition sites.  
Many additional series of inhibitors which act at these sites have been synthesized 
and reported, including several novel series in our laboratory (Bence et al., 2000; 
Worthen et al., 2001). 
 
1.4.3 Agmatine: 
  
 Agmatine, 4-(aminobutyl)-guanidine, has been long known as a part of the 
polyamine pathway in plants, bacteria, and invertebrates, as it is converted into putrescine 
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by the enzyme agmatinase (Tabor and Tabor, 1984; see Figure 1.2).  This biosynthetic 
route represents a second method of polyamine synthesis, independent of ornithine and 
ODC levels, which is believed to be favored in the lower life forms mentioned above. 
 A study in the mid-1990’s which was searching in mammalian brain tissue for an 
endogenous ligand at imidazoline binding sites led to the discovery of agmatine in 
mammalian tissue for the first time (Li et al., 1994).  Shortly afterwards, subsequent 
studies discovered ADC and agmatinase in mammalian brain tissue, indicating that 
agmatine is locally synthesized (Li et al., 1995; Sastre et al., 1996).  The heterogeneous 
distribution of agmatine throughout rat brain tissue was characterized 
immunocytochemically (Otake et al., 1998) using a polyclonal antibody developed to 
recognize agmatine but not the other polyamines (Wang et al., 1995).  Based on this 
study, agmatine was proposed to be primarily localized in neurons of the hypothalamus, 
rostral midbrain, laterodorsal nucleus, locus coeruleus nucleus raphe dorsalis, and the 
periaqueductal gray.  Agmatine is also found in neurons of the cerebral cortex, 
hippocampus, subcortical telencephalon, and thalamus.  Interestingly, agmatine was not 
found in astrocytes, although ADC activity has been demonstrated there (Regunathan et 
al., 1995).  The same immunocyctochemical method was used to reveal that agmatine in 
the hippocampus is primarily located in axon terminals that form excitatory synapses on 
pyramidal cells (Reis et al., 1998). 
 The study by Regunathan et al. which first indicated the activity of ADC in the 
mammalian brain has been debated, and the group of Anthony Pegg published a study 
which concluded that there is not enough evidence to prove this alternative pathway of 
agamatine synthesis (Coleman et al., 2004).  However, the group of Soudar Regunathan 
has since then published a study identifying a mammalian cDNA which codes for a 
distinct ADC enzyme (Zhu et al., 2004).  More recent articles have reported the 
decarboxylation of arginine to agmatine in rat liver (Horyn et al., 2005), and analyzed the 
expression of ADC in the regions of rat brains (Iyo et al., 2006).   
Agmatine was also found by HPLC methodology to be well-distributed 
throughout mammalian tissues (Raasch et al., 1995), largely in the lumen of the stomach.  
This high gastrointestinal content is due to several factors: the formation and release of 
agmatine from physiological gut microflora bacteria and pathogens (Molderings et al., 
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1999), the absorption from ingested food, and also to a lesser extent from shed GI 
epithelial cells (Benamouzig et al., 1997).  Studies have shown that radio-labeled 
agmatine is transported into the stomach wall in a temperature-dependent manner by 
means of a specific agmatine transporter (Molderings et al., 2002), and it has been 
postulated that this absorbed agmatine is an important source for function in other organs 
of the body, especially the liver (Molderings et al., 2003).  While agmatine is 
metabolized by two different enzymes, ADC and diamine oxidase (DAO, which converts 
agmatine into guanidinobutyraldehyde) (Lortie et al., 1996), the activity of ADC is 
relatively low compared to that of DAO in rat liver and kidney, while DAO metabolism 
of agmatine is nearly non-existent in brain tissue (Holt and Baker, 1995). 
 Agmatine is known to possess bioactivity, as it causes the release of a number of 
hormones and neurotransmitters including insulin from pancreatic islet cells (Sener et al., 
1989), catecholamines from adrenomedullary chromafin cells (Li et al., 1994), and 
luteinizing hormone from pituitary cells (Kalra et al., 1995).  Agmatine administered 
systematically also impairs specific types of learning and memory as well as behavior 
(McKay et al., 2002). 
It has been proposed by the group of Donald Reis that agmatine may be an 
endogenous neurotransmitter in the mammalian brain (Reis and Regunathan, 2000) based 
on a number of factors: It is synthesized in the CNS (Li et al., 1994), stored in synaptic 
vesicles in axon terminals (Reis et al., 1998), released from synaptosomes by 
depolarization (Reis and Regunathan, 1998), reaccumulated and inactivated by reuptake 
(Sastre et al., 1997), degraded by the specific enzyme agmatinase (Sastre et al., 1996), 
and binds with high affinity to α2-adrenoceptors and imidazoline binding sites as well as 
to the NMDA receptor.   
 The activity of agmatine at NMDA receptors was first demonstrated in an MK-
801 displacement study in rat cerebral cortex membrane (Anis et al., 1990).  
Enhancement of opioid analgesia, a characteristic of known NMDA receptor antagonists 
(Wong et al., 1996), is demonstrated by agmatine in vivo, as well as the prevention of 
opioid tolerance (Kolesnikov et al., 1996). 
Yang and Reis also studied the direct effects of agmatine at varying 
concentrations on the voltage current through the NMDA receptor channel (Yang and 
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Reis, 1999).  The data indicated that agmatine is a concentration- and voltage-dependent 
antagonist of the NMDA receptor channel.  Using whole-cell currents recorded from 
hippocampal neurons, a reversible channel-block was established which was more potent 
at hyperpolarizing membrane potentials than at positive voltages.  This blockage was 
obtained in the presence of currents elicited by N-methyl-D-aspartate, but in the absence 
of NMDA, no current effect was observed, indicating that agmatine has no agonist 
properties.  A competitive antagonist at the NMDA binding site, (±)-2-amino-5-
phosphonopentanoic acid (AP5), inhibited the NMDA current in both directions; 
however, simultaneous administration of agmatine and AP5 yielded an additional current 
blockage, indicating that agmatine is not a competitive antagonist at the same site, but 
acts to allosterically modulate the channel.  This study also investigated the activity of 
agmatine on other glutamate receptor channels activated by AMPA or kainite, and found 
that the concentrations necessary to block the NMDA channel completely yielded current 
reduction in these channel of no more than 20%, indicating a strong selectivity for the 
NMDA receptor channels.  Additionally, the action of arcaine and agmatine were 
observed in the presence of spermine, which is known to potentiate NMDA current.  This 
spermine-induced potentiation still occurred in the presence of these channel inhibitors, 
although it was diminished; these data indicate that the polyamines mostly likely act at 
different binding sites. 
Previous studies have shown that in the absence of the spermidine potentiation, 
agmatine is only a weak channel inhibitor with an IC50 value of approximately 1mM, 
while ifenprodil and arcaine, also polyamine binding site inhibitors, showed significant 
binding reduction at concentrations of 500nM and 5μM, respectively (Gibson et al., 
2002).  However, in the presence of 100μM spermidine, agmatine had a Ki of 14.8μM for 
MK-801 binding, indicating that agmatine is not a direct channel antagonist, nor does it 
bind to the polyamine binding site without a simultaneous binding of spermidine.  Thus, 
agmatine is believed to be the only competitive inhibitor of the polyamine binding site 
amongst these three antagonists. 
While works have been published which have focused on synthesis of polyamine 
analogues and their effects on the NMDA receptor channel, none have been reported on 
agmatine analogues as such.  The intriguing properties of agmatine as a potent and 
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selective allosteric competitive inhibitor of the NMDA receptor complex have led to 
interest in optimizing this molecule for use in drug development.  Thus, this study will 
undertake to synthesize and screen a variety of agmatine analogues, in order to find lead 
compounds for pharmaceutical development. 
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1.5 Hypothesis and Specific Aims 
 
HYPOTHESIS 
 
The hypothesis set forth in this work is that a more potent and therapeutically useful 
agmatine analog can be found which will allosterically modulate the NMDA receptor 
channel from a polyamine binding site, specifically at the site which binds agmatine.  To 
this end, the work will set forth to study the structure-activity relationship of agmatine 
congeners with the NMDAR complex, and attempt to discover new lead compounds for 
pharmaceutical development.  The agents so produced may be therapeutically useful in 
the treatment of such conditions as Epilepsy, Alzheimer’s disease, Huntington disease, 
and the neurodegeneration associated with the use and withdrawal of drugs of abuse, 
specifically ethanol. 
 
SPECIFIC AIMS 
 
Specific Aim 1. Synthesize a library of novel agmatine analogues having selectivity 
for the polyamine binding site of the N-methyl-D-aspartate (NMDA) receptor 
complex.  This study will undertake to develop and synthesize a varied library of novel 
analogs of agmatine, with the goal of achieving selectivity and potent inhibition of the 
NMDA receptor.  Earlier work has shown the effectiveness of agmatine to bind in a 
selective antagonistic manner at the polyamine recognition site, or sites, of the NMDA 
receptor complex.  Design and testing of structural congeners of agmatine will effectuate 
a more defined set of substructural motifs, leading to more potent compounds.  These 
optimization studies will produce molecules with varied chain length and flexibility, as 
well as aromatic and heteroatomic substitution in the chain region and modification of the 
guanidine moiety.   
 
 
Specific Aim 2.  Evaluate the synthesized library for their ability to displace 
[3H]MK-801 from the N-methyl-D-aspartate receptor.  Agmatine has been shown to 
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inhibit the binding of [3H]MK-801 to the ion channel of the NMDA receptor by allosteric 
modulation at one of the polyamine binding sites, thus indicating its potential usefulness 
in modulation of channel opening.  In this study, the synthesized analogs of agmatine will 
be screened for their ability to similarly inhibit the binding of [3H]MK-801 to the NMDA 
receptors of male rat P2 brain tissue preparation using the method of Ransom and Stec, 
which was modified to be amenable to high-throughput screening (Ransom and Stec, 
1988).  Utilizing a programmable liquid handler, compounds can be diluted and 
dispensed into 96-well plates with remarkable speed and precision.  Each compound will 
be initially evaluated at two concentrations, with promising candidates being more 
thoroughly analyzed utilizing a range of concentrations to determine IC50 values for each 
active compound in the presence and absence of pathological levels of the long-chain 
polyamine spermidine. 
 
 
Specific Aim 3.  Construct a pharmacophoric model of the most potent antagonists 
at the binding site in question using a neural network approach to molecular 
modeling.  The polyamine binding site of the NMDA receptor is not very well 
characterized, much less the crystal structure known.  Without knowledge of the 
structural biology, the approach to in silico modeling will be more challenging: after 
screening large libraries of compounds synthesized in this work and elsewhere, a 
program will be used to design a neural network model based on the data yielded.  From 
this model, new compounds will be selectively synthesized based on in silico prediction 
of activity.  These new compounds will then be used to verify and modify the developed 
model, in addition to providing new, more selective inhibitors.   
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CHAPTER 2: SYNTHESIS AND EVALUATION OF AGMATINE ANALOGS 
 
2.1 Introduction 
 
 The primary goal of this study was to synthesize and test agmatine analogs in 
order to seek out a more potent inhibitor of the spermidine/spermine potentiation of 
NMDA channels demonstrated in channel overactivation, while attempting to maintain 
the lower inhibitory potency of agmatine at physiological levels of longer-chain 
polyamines.  A number of spermine and spermidine analogues have been made and 
reported, but a focus on agmatine analogs has been largely overlooked. 
 Agmatine is composed of three specific moieties, labeled as A, B, and C in figure 
X.  Moiety A consists of a terminal amine, which is protonated and carries a formal 
charge of +1 at physiological pH, and may be involved in hydrogen bonding with a 
residue at the site, or sites, at which agmatine acts in the NMDAR complex.  Moiety B is 
a lipophilic n-butyl chain which connects the two terminal groups.  Moiety C is the 
terminal guanidino group, which is also charged at physiological pH, and has a +1 charge 
shared between the two omega-nitrogen atoms through resonance. 
 
H2N
N
H
NH2
NHA. B.
C.
C1
C2
 
Figure 2.1 Modification sites on agmatine molecule 
 
 Modifications of each of these moieties, and combinations of the separate 
modifications, are numerous.  “Moiety A”, the terminal amine, can be replaced by 
heteroatoms including oxygen as well as halogens, or even left off completely to leave a 
terminal methyl group.  “Moiety B”, the butyl bridge, can be lengthened or shortened to 
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n-pentyl and propyl bridges, respectively.  It is also possible to add a heteroatom into this 
chain, as seen in the amino acid canavanine.  As will become apparent, replacing this 
group with a benzyl, phenyl, xylyl, or other aromatic moiety is also quite viable.  The 
modification of “Moiety C” presents a plethora of opportunities.  While the interior 
secondary amine is seldom changed in groupings similar to a guanidine, the two omega 
nitrogen atoms proved to be quite flexible.  Urea and thiourea groups can be obtained by 
the conversion of region C1 to an oxygen or sulfur molecule, respectively.  In addition, 
the C1 and C2 groups can be affixed with a short alkyl group, or they can be joined 
together by either an ethyl or propyl bridge. 
 The first synthetic goal was to find simple and reliable procedures which would 
allow modifications of both the aliphatic chain moiety and the guanidine of the agmatine 
molecule.  The former involved the attachment of a guanidine group to a range of 
primary amines, and it became evident that this synthetic route would need to fulfill 
several requirements: an ability to synthesize several compounds in parallel, a decent 
yield without necessitating purification for preliminary product screening, and also the 
ability to produce a very pure product for further screening of lead compounds.  Much 
time and effort was spent to these ends, but a synthetic route meeting these goals was 
discovered utilizing N,N’-bis(tert-butoxy)-S-methylisothiopseudourea as a guanylation 
reagent (see General Reaction 1 below).  A small parallel synthesizer was purchased 
which can run this reaction on twelve starting materials simultaneously, with yields 
normally in the range of 60 to 80%.  Unlike other guanylating reagents, this di-boc-
protected product is uncharged, yet polar enough to purify by silica gel chromatography 
before deprotection.  Modification of the guanidine moiety has also proved amenable to 
parallel synthesis, as addition of a substituted guanidine group to the primary amine 
starting materials are similarly one-step reactions without the need for lengthy 
purification (see General Reactions 2-3 below). 
 The formation of a Schiff base between arylaldehydes and aminoguanidine 
hydrochloride to form arylidenamino-guanidine compounds (see General Reaction 4) 
also opened up new avenues of facile agmatine analog synthesis.  These reactions 
produced very clean products in high yield, and many of them crystallized from the 
reaction solution upon cooling.  Four series of analogs were created from the same set of 
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aldehydes, which included addition of an aminoguanidine, dimethylhydrazine, 
semicarbazide, and thiosemicarbazide (see General Reactions 4-7, respectively).  Further 
explored in chapter 3, the substituted arylaldehyde chosen dictated the composition of 
moieties A and B of figure 1.  Each of these reactions also replaced the moiety B in 
figure 1 with an aromatic imine.  Moiety C was left unchanged in the case of 
aminoguanidine; the amine of group C1 was replaced with an oxygen molecule in 
semicarbazide, and a sulfur molecule in thiosemicarbazide.  The addition of 
dimethylhydrazine further modified the entire structure of moiety C, switching the 
interior carbon atom for a nitrogen atom, and the terminal amines with methyl groups. 
 
 
2.2 Synthetic Chemistry 
 
Several major synthetic routes were followed in the course of this study in order 
to obtain the agmatine analogs.  From two base starting materials, seven synthetic 
General Reactions were used in order to obtain seven separate products with varying 
moieties similar to a guanidine.  The general procedures utilized in this study are denoted 
as General Reactions 1-7.  General Reactions 1-3 utilized a primary amine as the site of 
addition for an S-methyl guanidine analog, while General Reactions 4-7 relied on the 
Schiff base formation between a starting material aldehyde and an aminoguanidine or 
analog thereof.  These reactions are described below: 
 
General Reaction 1: 
Guanidino-compounds can be prepared by addition of an equimolar amount of the 
primary amine and N,N’-bis(tert-butoxy)-S-methylisothiopseudourea in tetrahydrofuran 
(Verdini et al., 1992).  The boc-protecting groups are then cleaved with excess 
trifluoroacetic acid in dichloromethane followed by rotary evaporation and separation 
with diethyl ether and water (See Scheme 1). The aqueous layer is then reacted with 
hydrochloric acid and lyophilized to form the hydrochloride salt of the guanidine product.  
This method has the distinct advantage of yielding an extremely lipophilic intermediate 
which can easily be separated from unreacted starting materials by silica gel column. 
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Alternatively, a hydrosulfide salt of the guanidine may be prepared by the 
addition of the primary amine (3 equivalents) to S-methylisothiopseudourea hemisulfate 
(1 equivalent).  The solution is refluxed in methanol for six hours, and yields the 
guanylated product as a hemisulfate salt as a crystal solid after cooling to room 
temperature. 
S
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Scheme 2.1 Synthesis of guanidino-compounds from primary amines 
 
General Reaction 2: 
Bridged S-methyl guanidines are prepared in nearly quantitative yield by 
refluxing the corresponding bridged thiourea with methyl iodide in methanol (Kennedy et 
al., 1998).  The crystallized product is amply pure for reaction in the next step with a 
primary amine in methanol at reflux for 2-carbon bridged guanidines (imidazole 
derivatives), and in ethanol at reflux for 3-carbon bridged guanidines (1,4,5,6-
tetrahydropyrimidine derivatives) to yield the corresponding N-substituted product as an 
iodine salt. 
EtOH
H
N
N
H
S
H3C
I HN
N
H
R-NH
I
R-NH2
H
N
N
H
S
MeI
MeOH
HS-CH3
n
n n
or THF
n = 1,2  
Scheme 2.2 Synthesis of Nω-Nω’ bridged guanidino-compounds 
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General Reaction 3: 
Nω-substituted S-methyl guanidines are prepared in nearly quantitative yield by 
refluxing the corresponding substitute thiourea (in this work, ethyl) with methyl iodide in 
methanol.  The crystallized product is amply pure for reaction in the next step with a 
primary amine at reflux in ethanol to yield the corresponding N-substituted product as an 
iodine salt. 
EtOH
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Scheme 2.3 Synthesis of Nω-ethyl guanidino-compounds 
 
General Reaction 4: 
The general method for preparation of arylidenamines proceeds as follows: 
aminoguanidine hydrochloride (1 equivalent) and an aryl aldehyde (1.5-2 equivalents) are 
dissolved in a minimal amount of methanol.  The solution is then heated to reflux and 
stirred for a period of 4-12 hours with TLC monitoring until the aminoguanidine 
hydrochloride is consumed.  Upon cooling to room temperature, the corresponding 
arylidenamino-guanidine is separated from the remaining aryl aldehyde.  In some cases, 
the product crystallizes from the methanol solution during cooling, in which case the 
product is filtered and rinsed with methanol and chloroform.  In most cases, the product 
would remain in solution upon cooling, and the solution is then removed on a rotary 
evaporator.  The resulting solid or semi-solid is then stirred at room temperature in 
chloroform or diethyl ether, into which the remaining aryl aldehyde dissolves, and the 
remaining solid arylidenamino-guanidine is filtered and washed with the corresponding 
rinsing solution.  Products are allowed to dry on filter plates, and then placed on vacuum 
overnight to remove any remaining solvent. 
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Scheme 2.4 Synthesis of arylidenamino-compounds 
 
General Reaction 5: 
Compounds containing an arylaldehyde-dimethylhydrazone moiety can be 
prepared by the formation of a Schiff base between an aryl aldehyde (1 equivalent) and 
dimethylhydrazine (1.25 equivalents).  These compounds are dissolved in a minimal 
amount of methanol, heated to reflux, and stirred for a period of 2-3 hours.  Upon cooling 
to room temperature, the product crystallizes from the methanol solution in some cases; 
otherwise, the product solution is evaporated at a moderate temperature in order to 
remove excess unreacted dimethylhydrazine starting material.  Products are then placed 
on vacuum overnight to remove any remaining solvent. 
Ar MeOH
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Scheme 2.5 Synthesis of arylaldehyde-dimethylhydrazone compounds 
 
General Reaction 6: 
Arylaldehyde semicarbazones can be easily prepared by a Schiff base formation 
between an aryl aldehyde (1.5-2 equivalents) and semicarbazide hydrochloride. These 
compounds are dissolved in a minimal amount of methanol, heated to reflux, and stirred 
for a period of 4-6 hours.  Upon cooling to room temperature, the corresponding 
semicarbazone crystallized from the methanol solution.  The solid precipitate was then 
filtered, rinsed with methanol, and placed on vacuum overnight to remove any remaining 
solvent. 
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Scheme 2.6 Synthesis of arylaldehyde semicarbazone compounds 
 
General Reaction 7: 
The general method for preparation of arylaldehyde thiosemicarbazone 
compounds proceeds as follows: thiosemicarbazide (1 equivalent) and an aryl aldehyde 
(1.5-2 equivalents) are dissolved in a minimal amount of methanol, and the solution is 
heated to reflux and stirred for a period of 4-6 hours.  In most cases, the corresponding 
arylaldehyde thiosemicarbazone crystallizes from the methanol solution during cooling to 
room temperature, in which case the product is filtered and rinsed with methanol and 
chloroform.  In addition, the product may remain in solution upon cooling, at which point 
the solution is removed on a rotary evaporator, and the resulting solid or semi-solid is 
stirred at room temperature in chloroform.  The remaining aryl aldehyde starting material 
is dissolves into this solution, and the solid product is filtered and washed with the 
corresponding rinsing solution.  Products are allowed to dry on filter plates, and then 
placed on vacuum overnight to remove any remaining solvent. 
Ar MeOH
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Scheme 2.7 Synthesis of arylaldehyde thiosemicarbazone compounds 
 
 The following specific compounds were synthesized in our laboratory.  Reaction 
details are noted for deviations from the general procedures described above in General 
Reaction 1-7.  No starting material screened possessed any affinity for polyamine sites, 
which is not surprising in that the diamines used as starting materials for General 
Reactions 1-3 bore the most structural similarity to putrescine, which is inherently 
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inactive in the [3H]MK-801 displacement assay.  Therefore, in order to expedite 
screening of the large number of total compounds, the products were purified to >85%.  
Active compounds were then reevaluated by NMR and in most cases ES+ mass 
spectroscopy for greater purity, and if necessary were further purified by crystallization 
or column chromatography.  Pure products were then used to generate full dose-response 
curves over seven concentrations spanning three orders of magnitude, with n=3. 
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Figure 2.2 Summary of modifications of moiety C (guanidino group) 
 
2.3 Pharmacology 
 
2.3.1 [3H]MK-801 Displacement Screening Assay 
 
 The pharmacological assay utilized P2 brain membrane homogenate from male 
Sprague-Dawley rats (225-250 grams) and radiolabeled MK-801 in order to measure 
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reduction of this bound ligand due to addition of a modulating agent.  The P2 membrane 
was prepared from a homogenized mixture of rat cortex, hippocampus, and cerebellum in 
50 mM Trizma acetate buffer containing 0.32 M sucrose at pH 7.25.  This crude 
homogenate was centrifuged for 10 minutes at 4°C and 2800 rpm in a Sorvall RC 26 Plus 
centrifuge, after which the supernatant was saved and the procedure was repeated with 
the pellet dissolved in cold buffer with sucrose.  The combined supernatants were then 
centrifuged for 20 minutes at 4°C and 20,500 rpm on the same instrument.  The 
supernatant was decanted, and the pellet retained and resuspended in 50 mM Trizma 
acetate buffer at pH 7.25, without sucrose.  Another 20-minute centrifugation was 
performed on the resuspended pellet with the above parameters, and two additional 10-
minute washings, with the pellet retained between each.  After these washings, the 
membrane was again suspended in the above buffer without sucrose, and the protein 
concentration determined using Pierce reagent. Aliquots of 15 mg of the concentrated P2 
membrane preparation were dispensed into cryo-tubes, which were then stored at -80°C.  
With this amount of protein per tube, the final protein concentration could easily be 
brought to 1.5 mg/mL buffer by the addition of sufficient 50 mM Trizma acetate buffer at 
pH 7.25 by bringing the total solution volume to 10 mL. 
The working [3H]MK-801 solution is prepared by the addition of 30 μM [3H]MK-
801 in ethanol (2 μL) to the Trizma buffer (10 mL).  In order to determine the 
concentration of [3H]MK-801 in this working solution, 100 μL was dispensed into 2.5 
mL of Microscint 20 in duplicate, and the counts per minute (CPM) were measured on 
the scintillation counter.  As the stock ethanolic MK-801 solution slowly evaporated and 
became more concentrated, this procedure was necessary in order to calculate further 
buffer dilutions of the working solution required for the desired 6.0 nM final 
concentration. 
High-throughput screens were performed at ambient room temperature in 96-well 
micro-titer plates with a total capacity of 350 μL per well.  To each well was added 100 
μL P2 membrane (thawed on ice and brought to the final concentration of 1.5 mg/mL as 
described above), 100 μL sample and 100 μL [3H]MK-801 ligand (6 nM) for a total of 
300 μL, with a 15-minute incubation period between the additions of the sample and MK-
801.  Three replicates of each of the following were performed per plate: a control with 
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100 μL Tris acetate buffer as the sample, 100 μL spermidine (300 μM) as a spermidine-
potentiated control, and 100 μL dextromethorphan (3 mM) in order to measure non-
specific binding.  The non-specific binding levels were 20-30% of the buffer control, 
indicating that 70-80% of the bound [3H]MK-801 is indeed in the channels of NMDA 
receptors, and is displaced by the rather large final concentration of 1mM 
dextromethorphan.  The spermidine was responsible for a potentiation in [3H]MK-801 
binding of 60-90%, which is consistent with literature values.  This potentiation is 
measured as an increase above buffer control level with the non-specific binding control 
as 0%.  Therefore, with a disintegration count for the buffer control of 750 DPM, non-
specific control of 150 DPM, and spermidine-potentiation control of 1250 DPM, the 
potentiation would be observed as 500DPM.  However, the percent potentiation would be 
measured as:  
 
(DPMpot – DPMcontrol) / (DPMcontrol – DPMnon-specific) x 100% 
 
or 500 DPM / 600 DPM, resulting in a percent potentiation of 80% in this example (see 
Figure 2.3)  It should also be noted that while the counts are expressed as raw DPM 
instead of DPM/mg protein, a constant level of protein was maintained in each well 
across all experiments (0.15 mg/well). 
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Figure 2.3 Calculation of % Potentiation by spermidine 
 
Following the addition of P2 membrane, buffer, dextromethorphan, and 
spermidine, three replicates of each sample at concentrations of 6 mM and 300 μM were 
add, to yielded total well concentrations of 1.0 mM and 50 μM.  The plates were then 
allowed to incubate for 15 minutes in order to establish the equilibrium between the 
spermidine and samples, after which the [3H]MK-801 ligand was added to each well.  All 
micro-titer plates were allowed to incubate for 40 minutes following [3H]MK-801 
addition, and were then harvested into filter plates, which were then dried overnight in 
the hood at ambient temperature.  After 12-16 hours, 35 μL of Microscint 20 was added 
to each membrane on the dried filter plate; each plate was sealed and then incubated for 
two hours before reading on a plate counter. 
 The compounds described below were evaluated for their ability to reduce the 
binding of [3H]MK-801 at concentrations of 1 mM and 50 μM, based on the DPM 
measured by the plate counter.  Percent reduction of MK-801 binding is reported below 
as the reduction in counts from the spermidine-potentiated control (0% reduction) to the 
non-specific dextromethorphan control (100% reduction) (see Figure 2.4 for examples). 
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Figure 2.4 Calculation of % Reduction of [3H]MK-801 binding
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Table 2.1 Reduction of [3H]MK-801 binding in P2 membrane by ligands 
 
Compound Structure % Reduction % Reduction 
Code   at 1mM at 50μM 
JR-3 NH NH2
NH
H2N
H Cl
H Cl  
67.5 11.4 
JR-4 
NH 2
H
N
H2N NH
H Cl
H Cl
 
33.7 4.6 
JR-5 NH NH2
NH
NH2
H Cl
H Cl  
87.8 6.5 
JR-8 
N
H
NH2
NH
HO
H Cl
 
24.5 1.6 
JR-9 
N
H
NH2
NH
Br
H Cl
 
93.6 4.2 
JR-81 
H
N NH2
NH
H2N
H Cl
H Cl
 
-1.9 1.3 
JR-83 
H
N NH2
NH
H2N
1/2 H2SO4  
92.0 20.9 
JR-84 
H
N NH2
NH
H2N
1/2 H2SO4  
94.5 40.0 
JR-89 H2N HN
N
H
N
H I
 
67.8 6.4 
JR-90 HN
N
H
N
H2N
H I
 
31.5 -4.9 
JR-91 HN
N
H
N
H2N
H I
 
50.0 -0.6 
JR-92 HN
N
H
N
H2N
H I
 
19.4 -9.9 
JR-93 HN
N
H
N
NH2
H I
 
61.9 -3.9 
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Table 2.1 (cont.) Reduction of [3H]MK-801 binding in P2 membrane by ligands 
 
Compound Structure % Reduction % Reduction 
Code   at 1mM at 50μM 
JR-102 NH NH2
NH
H Cl
H Cl
H2N
 
99.3 -6.0 
JR-106 
N
H
N
H
N
N
H
H I
N
H
N
H I
 
60.5 -3.5 
JR-107 
H2N
N
H
N
N
H
H I
 
79.9 -6.5 
JR-108 
N
H
N
N
H
H I
H2N  
49.1 -6.0 
JR-109 H2N
N
H
N
N
H
H I
 
24.3 -18.1 
JR-113 
N
H
N
N
H
H I
H2N  
71.8 12.7 
JR-114 
N
H
N
N
H
H I
H2N
 
26.8 4.9 
JR-115 
N
H
N
N
H
H I
H2N  
28.5 3.4 
JR-116 
N
H
N
N
H
H I
HO
 
11.4 7.9 
JR-117 
N
H
N
H
N
N
H
H I
N
N
H
H I
 
82.4 11.0 
JR-119 
H2N
N
H
N
N
H
H I
 
47.0 5.4 
JR-120 
N
H
N
N
H
H I
H2N  
62.4 19.3 
JR-121 N
H
N
H
NH2
NH2 Cl
N
O
O
 
94.2 21.5 
JR-122 N
H
N
H
NH2
NH2 Cl
N
O
O  
98.9 8.4 
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Table 2.1 (cont.) Reduction of [3H]MK-801 binding in P2 membrane by ligands 
 
Compound Structure % Reduction % Reduction 
Code   at 1mM at 50μM 
JR-124 N
H
N
H
NH2
NH2 Cl
C
N  
98.4 -5.9 
JR-125 N
H
N
H
NH2
NH2 Cl
C
N
 
93.1 11.6 
JR-126 
N
H
N
H
NH
CH 3
H2N
H I
 
98.8 40.8 
JR-127 
N
H
N
H
NH
CH3H 2N
H I
 
96.3 27.6 
JR-132 NN
H
N
H
H2N
NH 2
H
H
N NH2
NH2 Cl
Cl
 
90.6 46.7 
JR-138 
N
H
N
F
CH3
CH3
 
-14.1 1.8 
JR-139 
N
H
N
CH3
H3CO
CH3
OCH3
 
-4.2 0.2 
JR-140 
N
H
N
CH3
HO
CH3
OH
 
-16.7 -4.3 
JR-141 
N
H
N
N
H3C
CH3
CH3
CH 3
 
2.8 -3.8 
JR-146 
N
N
H
N
H
NH2
NH2 Cl
 
34.6 -6.3 
JR-147 N N
H
N
H
NH2
NH2 Cl
 
58.1 -6.0 
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Table 2.1 (cont.) Reduction of [3H]MK-801 binding in P2 membrane by ligands 
 
Compound Structure % Reduction % Reduction 
Code   at 1mM at 50μM 
JR-148 
N
N
H
NH
O
NH2
 
-11.1 2.3 
JR-149 
N
N
H
NH NH2
O
 
-12.0 0.3 
JR-150 
N
N
H
N
CH3
CH3
 
-6.7 -0.5 
JR-151 
N
N
H
N
CH3
CH3
 
-6.5 1.6 
JR-157 
N
N
H
NH NH2
O
 
-10.4 0.2 
JR-158 
N
N
H
N
CH3
CH3
 
-7.6 -7.6 
JR-159 
N
H
N
CH3
CH3
H 2N  
-7.9 1.2 
JR-160 N
H
N
H
NH2
NH2 Cl
H2N
 
92.3 -3.6 
JR-185 N
H
NH NH2
S
HO OH  
14.9 -2.6 
JR-187 N
H
NH NH2
S
HO  
-14.3 -0.1 
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Table 2.1 (cont.) Reduction of [3H]MK-801 binding in P2 membrane by ligands 
 
Compound Structure % Reduction % Reduction 
Code   at 1mM at 50μM 
JR-194 
N
H
NH NH2
S
O
H  
-10.5 -2.2 
JR-195 
H2N
N
H
NH
O
NH2
 
-6.1 1.1 
JR-197 N
H
NH2
N
H
NH2
NH2 Cl
 
71.1 -16.6 
JR-199 N
H
NH
H2N
NH2
O
 
23.7 1.9 
JR-200 N
H
NH
H2N
NH 2
S
 
-12.1 4.7 
AH-1 
N
NH NH2
NH
H Cl
 
8.8 7.0 
AH-2 
N
NH NH2
NH
H Cl
 
24.8 7.1 
AH-3 N
H
NH2
NH
H Cl
N  
40.8 12.0 
AH-4 N
H
NH2
NH
H Cl
N  
45.2 19.4 
AH-5 N
H
NH 2
NH
H Cl
N  
24.8 14.2 
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Table 2.1 (cont.) Reduction of [3H]MK-801 binding in P2 membrane by ligands 
 
Compound Structure % Reduction % Reduction 
Code   at 1mM at 50μM 
AH-6 
N
NH NH 2
NH
H Cl
NH
NH
H2N
H Cl
 
23.5 14.4 
AH-7 N
H
NH2
NH
H Cl
O
H3C  
77.0 20.2 
AH-8 
N
H
NHH2N
NH
H Cl
 
91.1 68.3 
AH-9 
N
NH NH2
NH
H Cl
NH
NH
H2N
H Cl
 
12.6 4.8 
AH-10 
NH NH 2
NH
H Cl
N
 
39.9 3.0 
AH-13 NH NH2
NH
H Cl
N
CH3  
38.6 2.4 
AH-14 
N
NH NH2
NH
H Cl
Cl  
14.2 7.7 
AH-15 HNCl
NH
NH2
H Cl
 
27.4 9.4 
AH-16 N
H
N
N
H
H I
N  
52.4 11.3 
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2.3.2 [3H]MK-801 Displacement Dose-Response Study 
 
Further testing to obtain dose-response curves was performed on the most 
promising compounds screened in the above assay.  For each of these compounds, three 
replicates of seven concentrations were tested, spanning an ample region to generate full 
dose-response curves in the absence and presence of spermidine. 
The assay protocol proceeded similarly to the one described above. A blank 
control was measured in triplicate using only freshly-prepared 50 mM Trizma acetate 
buffer at pH 7.25.  The 100 μM spermidine-potentiated MK-801 binding control and 1 
mM dextromethorphan control to measure non-specific binding were each performed in 
triplicate as well.  Samples were dissolved in buffer to make 19 mM stock solutions (for a 
final well concentration of 3.16 mM, or 10-2.5 M), and were diluted serially with 2.16 
equivalents of buffer six times, to give final well concentrations at every 10-0.5 M, down 
to 3.16 μM, or 10-5.5 M.  These seven concentrations were each added to the microtiter 
plate twice, with 50 μL spermidine (600 μM) in one set for a potentiated curve and 50 μL 
buffer in another set to obtain a non-potentiated curve.  In some cases, the compounds 
were not soluble at 19 mM, and stock solutions were prepared at lower concentrations.  
These compounds underwent serial dilutions as stated above.  
 For each compound, the two curves were then plotted, and IC50-values with and 
without spermidine were determined using GraphPad software.  A third value, the IC50pot, 
was derived as the point on the spermidine-potentiated curve which was halfway between 
the spermidine-potentiated control and the buffer control.  This value corresponds to the 
concentration of compound needed to displace half of the [3H]MK-801 bound due to the 
channel-agonist effects of spermidine.  Some of the tested compounds demonstrated IC50-
values which were too low to be accurately gleaned in the previously mentioned 
concentration range; these compounds were prepared in a lower-concentration stock 
solution and re-evaluated at a lower range.  In addition, agmatine, as well as the NMDAR 
antagonists arcaine, memantine, and MK-801 were evaluated by the same methods.   
 43
Table 2.2  IC50-values in the presence and absence of spermidine, 
and IC50 of potentiation 
 
Compound Structure IC50 w/ SPD1 IC50 w/o SPD2 IC50Pot 3
Code  (μM) (μM) (μM) 
JR-3 NH NH2
NH
H2N
H Cl
H Cl  
862.8 767.7 364.8 
JR-5 NH NH2
NH
NH2
H Cl
H Cl  
359.2 221.7 162.0 
JR-83 
H
N NH2
NH
H2N
1/2 H2SO4  
84.7 49.7 27.5 
JR-84 
H
N NH2
NH
H2N
1/2 H2SO4  
68.3 50.8 15.5 
JR-89 H2N HN
N
H
N
H I
 
169.5 105.9 12.4 
JR-93 HN
N
H
N
NH2
H I
 
1069 930.3 389.9 
JR-106 
N
H
N
H
N
N
H
H I
N
H
N
H I
615.5 376.9 254.7 
JR-107 
H 2N
N
H
N
N
H
H I
 
299.4 182.3 52.7 
JR-108 
N
H
N
N
H
H I
H2N  
1145 1348 97.3 
JR-113 
N
H
N
N
H
H I
H2N  
234.1 158.5 20.4 
JR-117 
N
H
N
H
N
N
H
H I
N
N
H
H I
 
207.0 100.0 104.7 
 
1 - IC50 w/ SPD: the measurement of IC50 derived from the data collected in the spermidine-potentiated [3H] MK-801 
displacement assay. 
2 - IC50 w/o SPD: the measurement of IC50 derived from the data collected in the non-spermidine-potentiated [3H] MK-
801 displacement assay, in which the spermidine solution was replaced with buffer. 
3 - IC50 of Pot: from the spermidine-potentiated curve, the concentration corresponding to one-half of the difference in 
DPM between the SPD-potentiated control and the blank control. 
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Table 2.2 (cont.) IC50-values in the presence and absence of spermidine, 
and IC50 of potentiation 
 
Compound Structure IC50 w/ SPD1 IC50 w/o SPD2 IC50Pot 3
Code  (μM) (μM) (μM) 
JR-120 
N
H
N
N
H
H I
H2N  
1304 1136 446.7 
JR-121 N
H
N
H
NH2
NH 2 Cl
N
O
O
 
169.4 218.7 78.0 
JR-122 N
H
N
H
NH2
NH2 Cl
N
O
O  
149.3 325.9 293.8 
JR-124 N
H
N
H
NH2
NH2 Cl
C
N  
 131.3 81.4 43.4 
JR-125 N
H
N
H
NH2
NH2 Cl
C
N
 
442.5 414.4 231.2 
JR-126 
N
H
N
H
NH
CH 3
H2N
H I
 
69.7 16.0 25.8 
JR-127 
N
H
N
H
NH
CH3H 2N
H I
 
232.1 147.2 75.3 
JR-132 NN
H
N
H
H2N
NH 2
H
H
N NH2
NH2 Cl
Cl 67.4 32.1 32.2 
JR-146 
N
N
H
N
H
NH2
NH2 Cl
 
1355 1428 539.5 
JR-147 N N
H
N
H
NH2
NH2 Cl
 
855.0 835.5 464.5 
 
 45
Table 2.2 (cont.) IC50-values in the presence and absence of spermidine, 
and IC50 of potentiation 
 
 
Compound Structure IC50 w/ SPD1 IC50 w/o SPD2 IC50Pot 3
Code  (μM) (μM) (μM) 
JR-160 N
H
N
H
NH2
NH2 Cl
H2N
 
269.4 120.2 104.2 
JR-197 N
H
NH2
N
H
NH2
NH2 Cl
 
654.6 778.9 199.5 
AH-8 
N
H
NHH2N
NH
H Cl
 
32.17 15.29 15.67 
     
Agmatine 
N
H
NH2
NH2
H3N
SO4
 
902.3 1296 274.2 
Arcaine N
H
NH2
NH2
H
NH2N
NH2
SO4
101.1 104.4 33.1 
Memantine 
CH3
H3C
NH3Cl
 
4.77 3.53 0.73 
MK-801 NH
 
5.58 nM 5.92 nM 2.19 nM 
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2.4 Results and Discussion 
 
This structure-activity study was undertaken to examine agmatine mimetics in an 
effort to learn more about the contribution of the different moieties in the molecule (see 
introduction) to potency, as well as selectivity.  This was done by synthesizing a large 
library of over 200 structurally different agmatine analogs and testing their ability to 
displace [3H]MK-801 in the membrane-bound proteins of rat brains, and comparing the 
results of these screens as well as the full dose-response curves of the most interesting 
compounds in the presence and absence of spermidine. 
 
2.4.1 Early Lead Development: 
 
The first set of screenings was performed on JR-1 through JR-91 and AH-1 
through AH-6 and AH-9 through AH-14, evaluating these compounds in the spermidine-
potentiated [3H]MK-801 binding screen in order to determine their ability to modulate the 
NMDA receptor channel. These early assays were performed in the 96-well microtiter 
plates with 8 replicates of each sample at concentrations of 500 μM and 250 μM.  
Modification of the [3H]MK-801 displacement assay utilized a fully automated Packard 
MultiProbe II HT liquid handling system,  which was specifically programmed to 
perform dilutions of samples as well as distribution of samples and reagents into the 96-
well microtiter plates according to the assay specifications.  Data showed that precision 
was increased by utilizing this method, and the assay time was dramatically reduced. 
A primary set of eight compounds was synthesized by addition of the guanidine 
moiety at a terminal amine to form agmatine congeners as in General Reaction 1 above; 
the resulting analogs included replacement of the terminal agmatine amine (moiety A in 
Figure 1) with a hydroxyl group as well as a bromine, and addition of a phenyl group into 
the aliphatic chain region (moiety B).   
Results obtained were very promising for such a small selection of compounds.  
Agmatine analogues bearing terminal hydroxyl groups at the end of an aliphatic chain 
(JR-1 and JR-2, or N-(5-hydroxy-pentyl)-guanidine and N-(4-hydroxy-butyl)-guanidine, 
respectively) showed no activity at the concentrations tested, but several of the 
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compounds with substituted phenyl rings possessed a small amount of activity at both 
concentrations (JR-8 seen above).  N-(2-Aminobenzyl)guanidine (JR-05) reduced 
[3H]MK-801 binding by 59.6% and 36.8% at 500 μM and 250 μM, respectively; N-(4-
Aminobenzyl)guanidine (JR-03) showed reductions of 45.5% and 31.2% at the same 
concentrations.  These aromatic-ring containing compounds were thus viewed as 
promising lead compounds upon proceeding to the next series of compounds, and many 
of the later compounds contained either benzene and pyridine rings.  Another active lead 
compound from this series was N-(4-bromophenyl)guanidine (JR-08), which afforded 
binding inhibition of 84.6% at 500μM and 63.6% at 250μM. 
 
H2N
N
H
NH2
NH
N
H
NH2
NH
NH2
Br N
H
NH2
NH
JR-3 JR-5 JR-9
 
 
The observed inhibition by N-(4-bromophenyl)guanidine led to an attempt to 
optimize this compound by moving the bromo group to the 3-position as well as by 
substitution at the 4-position with chlorine, fluorine, and iodine, and addition of a 
methylene group between the phenyl ring and the guanidine moiety.  Of these 
compounds, only 4-fluoro and 4-chloro analogues afforded even weak inhibition of the 
receptor, with the other compounds slightly potentiated MK-801 binding.  While the 
addition of a halogen at the para-position on a ring provided an interesting early lead, the 
failure of the subsequent compounds to have any significant NMDAR-modifying activity 
combined with the relative lack of possible further modifications of these molecules 
signaled the end of their interest for development.  Interestingly, much later studies 
revisited the usefulness of the halogeno-phenyl group in substitution of moieties A and B 
and produced very active arylidenamines (see Chapter 3). 
With the terminal amines of moiety A intact, synthesized compounds in 
subsequent series focused on modifications of the guanidine moiety (moiety C) by 
substitution of the ω’-amine (moiety C1) with an oxygen to form urea derivatives, 
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substitution of the ω-amine (moiety C2) with a methyl group to form N-1-iminoethyl 
structures and introduction of a 2-carbon Nω-Nω’ bridge to form 4,5-dihydroimidazole 
substituted agmatine and arcaine analogues.  The first of these modifications proved 
unsuccessful, in that the products of the reactions of the amine starting materials with 
urea (JR-41 through JR-53) were very pure, but completely water-insoluble, making 
them impossible to screen in the MK-801 displacement assay.  The second of these 
modifications provided a set of compounds (JR-11 through JR-19) which were mostly 
inactive and also very dark in color, despite column chromatography for further 
purification.  While the color of the compounds tested was taken into consideration by 
the TopCount binding program in order to convert CPM to DPM, the compounds which 
left the final test solution, and thus the wells on the filter plate, mostly opaque would 
always result in a dramatic drop in counts.  Such a strong and consistent false positive 
always rendered the reported activity of dark samples as suspect, especially when the 
demonstrated “activity” closely coincided with the visible color of the filtered sample.  
While this small set of compounds was thus discounted, the problem of activity due to 
dark sample solution color became an important factor in the search for further false 
positives, and ensuring that the active compounds reported indeed possessed inherent 
ability to modify NMDA receptors, and not just the ability to render a solution opaque at 
a low concentration.  
Of the seventeen evaluated 4,5-dihydroimidazole compounds, only N’-(4,5-
dihydro-1H-imidazol-2-yl)propane-1,3-diamine (JR-89) displayed inhibitory properties 
(52.9% at 500 μM).  Of note is the observation that N’-(4,5-dihydro-1H-imidazol-2-
yl)butane-1,4-diamine (JR-90), which is agmatine with a Nω-Nω’ bridge, had slight 
potentiating effects on binding; yet JR-89, with one less methylene group than agmatine, 
acted as a channel antagonist by reducing observed [3H]MK-801 binding in this assay.  
This interesting set of results shows that a modification of one moiety (in this case, the 
guanidino moiety) can affect binding independent of differences at a separate moiety 
(such as the aliphatic chain). 
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N
N
H
R
N
N
H
H
N
N
N
H
H
NH2N
H2N
4,5-Dihydroimidazole
General Structure JR-89 JR-90
 
 
In addition, more structurally diverse linkers at moiety B were used; this set of 
agmatine congeners was a follow-up series based on the lead compounds from the first 
screenings, N-(2-aminobenzyl)guanidine (JR-5) and N-(4-aminobenzyl)guanidine (JR-
3).  The only two active JR-compounds to come out of this series were N-(4-
aminomethyl-benzyl)guanidine (JR-83), and N-(3-aminomethyl-benzyl)guanidine (JR-
84).  The para-compound JR-83 reduced MK-801 binding by 74.4% at 250 μM and 
86.8% at 500 μM, while its meta-isomer JR-84 inhibited binding by 95.4% at 250 μM 
and an astounding 97.2% at 500 μM.  These two compounds immediately became a clear 
focus of further optimization.   
This series also included many interesting pyridine- and pyrrolidine-based 
guanidine compounds, synthesized by Aaron Haubner for use in nicotinic receptor studies 
(AH-1 through AH-6 and AH-9 through AH-14).  The majority of these compounds 
showed no inhibitory activity at either 250 μM or 500 μM, with two exceptions: N-[2-(1-
methyl-pyrrolidin-2-yl)ethyl]guanidine (AH-13) and the di-guanidine N-(3-guanidino-
pyridin-4-yl)guanidine (AH-9).   
 
N
H
NH2
NH
H2N
N
H
NH2
NH
H2N
N
NH HNH2N NH2
NH2NH
N
H
NH2
NH
N
CH3
JR-83 JR-84 AH-9 AH-13
 The first of these compounds, AH-13, was observed to slightly inhibit [3H]MK-
801 binding by 21.5% at 250 μM and 50.2% at 500 μM; while this data is not 
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outstanding, the compound is quite different at its terminal amine from the majority of 
the other screened compounds in that the terminal amine (moiety A) is tertiary and 
attached to three aliphatic groups.  The only other such compound was AH-10 (N-(2-
pyrrolidin-1-yl-ethyl)guanidine), which was not only unable to reduce [3H]MK-801 
binding, but potentiated it by over 40% at both tested concentrations.   
AH-9 inhibited binding by 93.4% at 250 μM and 96.0% at 500 μM, making this 
compound a strong new lead for further development.  However, the inactivity of its 
isomer AH-6 was almost as interesting as the activity of AH-9: both of these compounds 
possessed two ortho-guanidines on their pyridine rings, but differed only in the position 
of the pyridyl amine.  AH-6, which potentiated MK-801 binding in the screening assay, 
had the guanidine groups in the 2,3-position relative to the ring amine, while AH-9, 
which inhibited MK-801 binding by over 95% at 500 μM, had the guanidine groups in 
the 3,4-positions.  Explanations for this remarkable difference in activity could be due to 
two rationales.  1) It is possible that AH-6 formed a six-membered ring by hydrogen 
bonding between the lone pair on the pyridine nitrogen and a hydrogen attached to the ω-
nitrogen of the guanidine in the 2-position.  This would hinder the free rotation of this 
guanidine, and perhaps modify the selectivity of the molecule, and cause it to bind in a 
different way at the same site, or even at a different polyamine site on the NMDA 
receptor complex.  2) Perhaps the ring amine itself is vital to the activity of the compound 
with relation to the binding site, and is only able to interact with a particular local site 
reside when in a certain location (by forming a hydrogen bond with a serine residue, for 
example).  This created a very interesting set of possibilities which was shortly thereafter 
rendered moot by further testing: 
A persistent and nagging issue at this point was the relative lack of spermidine 
potentiation demonstrated by the controls in this assay.  While literature values 
consistently reported potentiation of [3H]MK-801 binding by 100 uM of spermidine to be 
in the range of 60-100%, the controls of these assays were only on the order of 10-20%, a 
significant difference.  In addition, the potentiation of binding demonstrated by certain 
compounds were not necessarily conclusive; while it would be no surprise that some 
polyamine analogs acted as channel agonists due to numerous published instances of such 
events, the possibility existed that spermidine was only demonstrating its full potentiation 
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in certain rows of the microtiter plates, and the compounds therein were merely “innocent 
bystanders”.   
It was by months of filling plates by hand that the problem was revealed: the 
membrane and especially the spermidine solution needed to be kept thoroughly mixed 
during the screening, and it was necessary to vortex these solutions immediately prior 
each of to their additions to the plate.  While the liquid handling system was reducing the 
amount of time required the fill multiple 96-well plates, it lacked the ability to swiftly and 
completely mix a large enough amount of these “reagents” kept in reservoirs on the deck 
of the instrument for quick fills of multiple wells.   
While the above tests provided a good set of potential lead compounds for further 
optimization, and some interesting structure-activity relations between the compounds 
and their activities, it was necessary to re-screen them, especially the active compounds, 
with proper conditions and without the use of the liquid handling system. 
 
2.4.2 Data Verification and Structural Optimization: 
 
 Further screening assays were performed to verify the above data and test more 
compounds based on these collected structure-activity relationship results.  The [3H]MK-
801 binding was repeatedly tested and brought to levels of 60-100%, usually around 
70%.  It was also determined that the screening assay would provide more useful 
information if the concentrations tested were further differentiated to reflect two points 
which would be separated on a dose-response curve.  Therefore, instead of using 250 μM 
and 500 μM, which are separated by a factor of 2, these assays used concentrations of 50 
μM and 1.0 mM, which are separated by a factor of 20.  The full spectra of satisfactory 
compounds which were tested in this assay are divulged with structures in Table 1 above. 
 Of the previously tested compounds from the first series, the activity of JR-3, JR-
5, and JR-9 were confirmed in the re-screening, with [3H]MK-801 binding reductions of 
67.5%, 87.8%, and 93.6%, respectively, at concentrations of 1.0 mM.  None of these 
compounds had significant binding reduction at the lower concentration of 50 μM. 
 The meta- and para-xylene guanidine compounds, JR-83 and JR-84, were again 
the most promising of the JR-series.  Earlier screening tested the chloride salts of each of 
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these compounds, but for this assay and the full dose-response curves that followed, the 
hemisulfate salts were prepared with S-methylisothiopseudourea hemisulfate instead of 
N,N’-bis(tert-butoxy)-S-methylisothiopseudourea, and were recrystallized from methanol 
to give very pure products.  This should not have any bearing on activity, and only 
affected molecular weight.  JR-83 (N-(4-aminomethyl-benzyl)guanidine) reduced 
[3H]MK-801 binding by 92.0% at 1 mM and by 20.9% at 50μM.  JR-84 (N-(3-
aminomethyl-benzyl)guanidine)  was slightly more potent, reducing ligand binding by 
94.5% at 1 mM and by 40.0% at 50 μM.  These two compounds remained strong lead 
compounds for optimization as well as for examination as potential antagonists, and were 
commissioned for evaluation with full dose-response curves, to follow the screening 
assays. 
 The previously-examined imidazole derivatives were the first to show differences 
between the two screening assays.  JR-89, the 4,5-dihydroimidazole compound with an 
aminopropyl chain, was still the most active of those examined, reducing [3H]MK-801 
binding by 67.8% at 1 mM, but by a mere 6.4% at 50 μM.  However, the structurally 
similar compounds JR-90 (N’-(4,5-dihydro-1H-imidazol-2-yl)butane-1,4-diamine) and 
JR-91 (N’-(4,5-dihydro-1H-imidazol-2-yl)pentane-1,5-diamine) possessed markedly 
different activities in this screen.  These two compounds were both observed to cause an 
increase in radioligand binding to the membrane in the previous assay, with JR-90 
causing nearly twice the potentiation at 250 μM than at 500 μM.  In the present assay, 
neither possessed significant activity at 50 μM, but at 1 mM, JR-90 decreased the binding 
of [3H]MK-801 by 31.5%, and JR-91 by 50.0%.  While neither of these compounds is 
noteworthy as an NMDAR inhibitor, they do reflect the necessity for the re-screening of 
the compounds under consistent spermidine potentiation.  In the early screen, if JR-90 
was indeed acting as a channel agonist, it would not likely have shown twice the 
potentiating activity at 250 μM than at 500 μM.  To the contrary, this compound was 
most likely partially attenuating the effects of spermidine, which was demonstrating more 
potentiating activity in these wells than in the controls; thus a higher concentration of JR-
90 was not potentiating less radioligand binding, but instead inhibiting binding by a 
larger amount.  Still, the interesting observation remains that while JR-90 is most 
structurally similar to agmatine itself with their common n-butyl chain, both the 
 53
imidazole derivative with an additional methylene group (JR-91) and one less methylene 
group (JR-89) at moiety B possess greater antagonist activity. 
 The pyridine and pyrrolidine-containing compounds of the AH-series were also 
re-screened for activity at 1 mM and 50 μM.  All of the tested pyridine-containing 
compounds demonstrated a small amount of activity as NMDAR antagonists, none of 
these molecules reduced [3H]MK-801 binding by more than 50% at 1 mM.  This was 
especially disappointing for AH-9 (N-(3-guanidino-pyridin-4-yl)-guanidine), which 
appeared to be so active in the previous screen.  In contrast, this screen yielded a paltry 
12.6% reduction in ligand binding due to AH-9 at 1 mM, and 4.8% at 50 μM.  These 
results were repeated and verified, and the previous screening data for AH-9 must be 
attributable to either an error in solution preparation or perhaps a dispensing error by the 
liquid handling system previously used. 
 There were four additional compounds of the AH-series examined in this new set 
of screens, which included the first indole compound tested in AH-8 (N-(1H-indol-5-
yl)guanidine hydrochloride).  This compound appeared to be very active in the reduction 
of [3H]MK-801 binding, eliciting a response of 91.1% at 1 mM and 68.3% at 50 μM.  
While these results were potentially tremendous, this compound, while 95%+ pure by 
NMR, existed as a pitch black semisolid.  As seen above, very dark compounds tend to 
give false positives, especially when the tested solution is also visibly opaque.  However, 
the results were encouraging in that the solution was too dilute to show color at 300 μM 
(the stock solution used to fill the low-concentration well for a final compound 
concentration of 50 μM), and AH-8 still demonstrated significant activity.  This 
compound was also interesting as it conformationally restricted the entire “moiety B” of 
agmatine in figure 1, and connected a secondary amine to a guanidine with a separation 
of four methylene groups while only allowing rotation of the guanidine.  Additionally, 
AH-7 (N-(4-methoxy-benzyl)-guanidine hydrochloride) was demonstrated to have some 
activity in the assay, reducing the [3H]MK-801 binding by 77.0% at 1 mM and 20.2% at 
50 μM.  This was the first screened compound with a terminal methoxy group at moiety 
A (Figure 2.1), and the previously tested compounds with a hydroxyl group in the same 
location were completely inactive in this screen.  While AH-7 was not tremendously 
active, the terminal methoxy group, as well as the indole group which was involved in the 
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more active AH-8, were revisited in further development of active NMDAR antagonists 
(see Chapter 3).  Additionally, AH-8 was potent enough to evaluate further as an 
antagonist, and was designated for a full dose-response curve. 
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 While the dimethyl pyridine group was used in the synthesis of tested compounds 
in the AH-series, the dimethyl phenyl (or phenyldiamine) group had been altogether 
ignored up to this point.  It was also of interest as 1,4-phenyldiamine could undergo 
addition of a guanidine to form the structural backbone of the active indolyl compound, 
AH-8.  However, phenyldiamines are also very dark compounds which readily 
polymerize, and even filtering with active charcoal was unable to render these solutions 
light enough to yield a clear testing solution.  N-(3-Amino-phenyl)-guanidine 
dihydrochloride (JR-102), which was the only synthetic phenyldiamine derivative to 
yield a non-opaque solution at 6 mM (although it was a very dark, albeit lovely, purple 
solution), was screened at 1 mM and 50 μM final well concentrations.  It did render the 
filter plate entirely too dark to be trusted at 1 mM, and not surprisingly produced a 99.3% 
reduction of counted CPM, but at 50 μM, JR-102 was completely devoid of activity.  
Therefore, this compound could not be judged to have antagonist activity in this assay, 
and even if the 1 mM reading was correct, the lack of any radioligand displacement at 50 
μM indicated that it was not as potent as the structurally similar JR-83 or JR-84. 
 The next series of compounds included another set of imidazole derivatives, 
which incorporated aromatic groups at moiety C (see Figure 2.1), as follow-up 
compounds to JR-3, JR-5, JR-83, and JR-84.  Replacement of the guanidine with an 
imidazole did not reduce the radioligand binding for any of the new compounds (JR-92, 
JR-93, JR-119, and JR-120) over their guanidine counterparts.  All of these compounds 
were somewhat active as NMDA inhibitors at 1 mM, but at the lower concentration of 50 
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μM they each failed to reduce binding more than 20%.  The most promising of these 
compounds was JR-120 (N'-(4,5-dihydro-1H-imidazol-2-yl)-benzylamino-3-
methylamine hydriodide), which reduced [3H]MK-801 binding by 62.4% at 1 mM and 
19.3% at 50 μM, and JR-93 (N'-(4,5-dihydro-1H-imidazol-2-yl)-benzylamino-2-amine 
hydriodide) which reduced ligand binding by 61.9% at 1 mM.  However, the bis-
imidazole arcaine analog, JR-117 (N,N-bis(3,4-dihydro-1H-imidazol-2-yl)-1,4-
bis(aminomethyl)benzene dihydriodide), was a bit more potent than any of the mono-
substituted imidazole compounds at 1 mM, reducing radioligand binding by 82.4%.  
These three described compounds were set aside for further examination of their full 
dose-response curves. 
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 In addition, a set of 1,4,5,6-tetrahydropyrimidine compounds (JR-106 through 
JR- 116) were synthesized and screened according to General Reaction 2 above.  These 
compounds were structurally similar to the previously described imidazole derivatives, 
except that instead of a 2-methylene bridge connecting the ω-nitrogen atoms of the 
guanidine groups, there exists a 3-methylene bridge.  Each of the previously examined 
combinations of moiety A and moiety B from figure 1 which had adjoined imidazole and 
guanidine groups were synthesized with this new moiety C.  The compounds in this 
series with the aliphatic chains at moiety B possessed behavior similar to those with the 
imidazole substituents.  The 1,3-diaminopropane derivative, JR-113, was the most potent 
of the three, reducing [3H]MK-801 binding by 71.8% at 1 mM and 12.7% at 50 μM.  The 
1,4-diaminobutane and 1,5-diaminopentane derivatives, JR-114 and JR-115 respectively, 
carry only slight activity at 1 mM with 26.8% and 28.5% radioligand reduction, and 
negligible reduction at 50 μM.  While none of the ring-containing 1,4,5,6-
tetrahydropyrimidine compounds demonstrated activity at 50 μM, both of the 
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xylenediamine derivatives showed significant inhibitory ability at 1 mM.  JR-107 (4-
aminomethyl-benzyl-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-amine hydriodide), the para-
compound, was able to reduce the binding of [3H]MK-801 by nearly 80% at 1 mM, while 
JR-108 (3-aminomethyl-benzyl-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-amine hydriodide), 
the meta-compound, reduced binding by nearly 50% at the same concentration.  As with 
the previous series, the bis-compound of p-xylenediamine was synthesized, and 
demonstrated decent inhibitory activity at 1 mM.  The compound, N,N-bis(1,4,5,6-
tetrahydro-pyrimidin-2-yl)-1,4-bis(aminomethyl)benzene diiodide (JR-106), reduced 
radioligand binding at the high concentration by 60.5%, and along with JR-113, JR-106, 
and JR-108 was judged to be amply effective to be further examined in the next step. 
 
JR-107 JR-106JR-113
N
H
N
N
H
H I
H2N H2N
N
H
N
N
H
H I
N
H
N
H
N
N
H
H I
N
H
N
H I
 
 
 The next series of compounds is described in synthetic General Reaction 3, the 
N’-ethyl-guanidine compounds.  Two clean compounds were produced with this general 
reaction, using meta- and para-xylenediamine as the groups for moiety A and B of figure 
1.  These two compounds, JR-126 (N-[4-(aminomethyl)-benzyl]-N’-ethyl-guanidine 
hydriodide) and JR-127 (N-[3-(aminomethyl)-benzyl]-N’-ethyl-guanidine hydriodide), 
were quite effective at both concentrations.  The former reduced the amount of 
radioligand bound to the P2 membrane by a hearty 98.8% at 1 mM and 40.8% at 50 μM, 
while the latter was responsible for reducing [3H]MK-801 binding by a 96.3% at 1 mM 
and 27.6% at 50 μM.  These compounds each possess similar activity to their guanylated 
counterparts, JR-83 and JR-84.  Additionally, these two compounds are clear candidates 
for further examination. 
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 The following several series of compounds deviate from the first three synthetic 
general reactions, and involve the formation of Schiff bases from substituted 
benzylamines and aminoguanidine congeners, as seen in General Reactions 4-7 of the 
chemical synthesis section above.  A set of the arylidenamines demonstrated in General 
Reaction 4 were synthesized by Dr. Sundar Neelakantan (unpublished work in the 
laboratory of Dr. Peter Crooks), and were shown to be active in assays performed by 
Robert Holley in the laboratory of Dr. John Littleton.  Such activity opened another door 
in the synthesis of aromatic agmatine analogs, with a facile reaction which was amenable 
to parallel synthesis, and yielded pure products, often crystalline.  These arylidenamino-
guanidino compounds are further examined in Chapter 3 of this work. 
 A primary series of nine compounds were prepared by reaction of various 
nitrogen-containing or nitrogen-substituted arylaldehydes with aminoguanidine 
hydrochloride to form arylidenamines.  These included the para- and meta-nitro 
compounds (JR-121 and JR-122), the meta- and para-cyano compounds (JR-124 and 
JR-125), the 1,4-bis-compound (JR-132), the 4-pyridyl and 3-pyridyl compounds (JR-
146 and JR-147), and the para-amino and meta-amino compounds (JR-160 and JR-
197).  Each of these nine compounds possessed significant antagonist activity at the 
NMDAR channels at 1 mM, substantiating the data previously obtained about the 
arylidenamines.  Each of these compounds was thus appropriated for further examination.  
The most active of these compounds according to this assay were, with % reduction of 
[3H]MK-801 binding at 1 mM and 50 μM: (3-nitrobenzylidenamino)-guanidine 
hydrochloride (JR-122) with 98.9% and 8.4%, (3-cyanobenzylidenamino)-guanidine 
hydrochloride (JR-124) with 98.4% and -5.9%, (4-nitrobenzylidenamino)-guanidine 
hydrochloride (JR-121) with 94.2% and 21.5%, (4-cyanobenzylidenamino)-guanidine 
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hydrochloride (JR-125) with 93.1% and 11.6%, (4-aminobenzylidenamino)-guanidine 
hydrochloride (JR-160) with 92.3% and -3.6%, p-bis-benzylidenamino-guanidine 
hydrochloride (JR-132) with 90.6% and 46.7%, and (3-aminobenzylidenamino)-
guanidine hydrochloride (JR-197) with 71.1% and -16.6%.  While neither of the pyridyl 
compounds appeared to be extremely useful as an NMDA antagonist, they did possess 
some activity and were deemed to be worth further examination due to the promise of 
this group as a whole.  To reiterate, these compounds are discussed further in Chapter 3. 
 The success of the arylidenamino compounds begat the notion that modification 
of the aminoguanidine molecule could bring about an increase in potency of these 
compounds.  The first of these modifications was in fact the biggest deviation from 
aminoguanidine, by using 1,1-dimethylhydrazine in its place in order to produce aromatic 
agmatine analogs without terminal amines in moiety C (see Figure 2.1).  This reaction is 
described in General Reaction 5 above.  Unfortunately, the nature of these compounds is 
such that the guanidine congener group is not charged in water, making them rather water 
insoluble.  Even at the maximal allowed amount of DMSO in the test solution, many of 
the synthesized products in this set were unable to be tested in the P2 membrane MK-801 
displacement assay.  Those compounds that were sufficiently soluble for testing primarily 
included those with hydroxy or methoxy substituents, or nitrogen-containing compounds 
such as amines and pyridines.  However, none of these compounds demonstrated any 
significant activity in the screen, even at 1 mM.  As the para-amino compound (JR-159, 
N’-(4-amino-benzylidene)-N,N-dimethyl-hydrazone) as well as the 4-pyridyl and 3-
pyridyl compounds (JR-150, pyridine-4-carbaldeyde-dimethylhydrazone, and JR-151, 
pyridine-3-carbaldeyde-dimethylhydrazone, respectively) shared the same Moiety A and 
Moiety B as arylidenamines which had been previously prepared and found to be active 
(JR-160, JR-146, and JR-147), it is easily deducible that the dimethylhydrazine analogs 
are not active and there was thus no reason to further pursue them. 
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 A second attempt to examine aminoguanidine derivative mimetics involved the 
replacement of Moiety C1 in order to form semicarbazine compounds, with a terminal 
urea group.  As the pKa of urea is 0.10, these compounds share the same solubility 
problems as the dimethylhydrazine compounds, in that their solubility relies on the 
groups found in Moieties A and B, and is not assisted by a charged group at Moiety C.  
The synthesis of these compounds is detailed in reaction General Reaction 6 above.  
Again, the para-amino compound (JR-195, 4-amino-benzaldehyde semicarbazone) and 
the 4-pyridyl and 3-pyridyl compounds (JR-148, pyridine-4-carbaldehyde 
semicarbazone, and JR-149, pyridine-3-carbaldehyde semicarbazone, respectively) were 
synthesized and thus were able to be directly compared to the corresponding 
arylidenamines; and again they were found wanting.  None of these three compounds 
possessed any activity in the [3H]MK-801 displacement assay, at any concentration.  
However, the meta-amino compound, 3-amino-benzaldehyde semicarbazone (JR-199), 
was able to reduce radioligand binding to the NMDAR complex by 23.7% at 1 mM.  
While this result is hardly indicative of a possible lead compound, it is interesting to note 
that there is a difference between the 3-amino and 4-amino semicarbazine compounds 
(JR-195 and JR-199). 
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 The third and final attempt to improve upon the arylidenamines was a similar 
substitution as the one above, but substituting a sulfur atom at Moiety C1 instead of an 
oxygen atom, in order to form a terminal thiourea, as detailed in General Reaction 7.  As 
could be expected, however, these thiosemicarbazine compounds shared the same 
solubility issues and were, in fact, less water-soluble than the semicabazine compounds.  
Only four of these compounds were able to be tested, and even then, their complete 
solubility was in doubt.  These compounds consisted of hydroxyl-substituted derivatives 
(JR-185 and JR-187), the para-aldehyde (JR-194) which precipitated from the 
methanolic reaction solution before it was able to form the bis-compound, and the meta-
amino compound (JR-200).  None of these compounds demonstrated any significant 
activity, and every compound save JR-185 (2,4-dihydroxy-benzaldehyde 
thiosemicarbazone), which reduced [3H]MK-801 binding by 14.9% at 1 mM, potentiated 
radioligand binding by at least 10%. 
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2.4.3 Full Dose-Response Curve Examination 
 
 The twenty-four compounds which have been indicated so far through this 
discussion as worthy of further examination underwent further screening at seven 
concentrations ranging from 16 mM to 1.0 μM, as described in Section 2.3.2 above.  
These compounds were chosen based primarily on their activity in the screens, but also 
on their structure and structural similarity to other active compounds. 
 A solution of each compound was prepared freshly in order to ensure accurate 
readings.  Each compound was then tested at seven concentrations which were chosen 
based on the screening assay, so that the IC50 was estimated to be as close to the middle 
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of the concentration range as possible.  The compounds were then each screened in the 
presence of 100 μM spermidine in order to closely replicate the commonly-seen 
pathological levels of the long-chain polyamine, and again in the absence of spermidine, 
in order to more accurately represent its physiological levels.  While the actual 
physiological levels of spermidine are closer to 10 μM, the freshly-prepared and frozen 
P2 rat brain membrane should have normal levels of spermidine and spermine still bound 
to the NMDA receptor complex, as is the case for glycine and L-glutamate. 
 These two separate sets of screening data will be used to establish the difference 
in activity mediated by the compound under pathological and physiological conditions, at 
least in the case of conditions which are caused by excessive amounts of long-chain 
polyamines, or those which induce the release of neurotoxic levels of these polyamines.   
 Previous work performed in this laboratory (Gibson et al., 2002) demonstrated 
that agmatine demonstrates the ability to reduce spermidine-potentiated [3H]MK-801 
binding in this assay down to a level which corresponded to the baseline levels of bound 
[3H]MK-801 in the absence of spermidine, and that the further reduction of bound 
radioligand below this non-potentiated level appears to proceed at a similar rate in both 
conditions.  This data indicates that agmatine, while not a potent complete inhibitor of 
NMDAR channel opening (like MK-801 or memantine), acts as a selective inhibitor of 
over-NMDAR complex overactivation. 
 While a goal of this study is to seek out structures, or structural motifs, which 
modulate NMDAR complex activity at one of the polyamine sites instead of directly in 
the channel pore, it is certainly also a goal to attempt to optimize the intriguing effects of 
agmatine: attenuation of the potentiating effects of long-chain polyamines on the 
NMDAR without affinity effects on channel activity at physiological levels of these 
polyamines. 
 When performed in this assay with the same procedure as was followed for the 
tested compounds, agmatine had an IC50-value of 902 μM from the spermidine-
potentiated curve, and greater than 1 mM in the absence of added spermidine (see Figure 
2.5).  It was impossible to obtain an accurate value for the latter value, as the threshold of 
agmatine solubility in the buffer used was met at approximately 6 mM.  These numbers 
are somewhat higher than previously reported values, but all assays differ slightly, and 
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the important factor to note is that the “Agmatine + SPD” curve is essentially on top of 
the “Agmatine” curve at and above 1 mM.  While it is assumed that both curves would 
proceed together to the non-specific control levels, the solubility threshold of agmatine 
was met, as previously mentioned. 
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Figure 2.5 Agmatine dose-response curves in the presence and  
absence of added spermidine (100 μM) 
 
 The focus of this study was to find a more potent compound than agmatine, while 
maintaining the agmatine activity profile, and thus a comparison of the IC50-values 
obtained from neither the spermidine-potentiated dose-response curve nor that without 
spermidine potentiation would accurately indicate the activity which leads to the desired 
response, which is that point at which the curves meet.  Therefore, a value must be 
derived from the spermidine-potentiated curve to attest to the ability of a compound to 
reduce [3H]MK-801 binding from the spermidine-potentiated control to the non-
potentiated control.   
 Thus, in conjunction with the non-potentiated dose-response curve, an “IC50pot” 
value was taken from the spermidine-potentiated curve which corresponds to the 
concentration at which 50% of the [3H]MK-801 bound solely due to spermidine-
 63
potentiation is disallowed.  In other words, the IC50pot value is the point on the 
spermidine-potentiated curve which corresponds to the average of the spermidine-
potentiated and non-potentiated controls.  For example, in the case of agmatine in Figure 
2.4, this would be 274 μM, which is the concentration corresponding to 940 DPM, the 
average of the spermidine-potentiated control (1074 DPM) and non-potentiated control 
(805 DPM).  This value is directly taken from the curve using GraphPad Prism, which 
offers the ability to view the points on the curves in a database format, thereby granting 
the ability to garner an X-value (concentration) from a Y-value (DPM) for any curve. 
 Each of the IC50-values from the two dose-response curves as well as the derived 
IC50pot are divulged in Table 2.2 of Section 2.3.2 above, and the set of curves for each of 
the tested compounds are displayed with the individual compound synthetic details in 
Section 2.6 below. 
 In addition to the potency gleaned from the IC50-values, the derived curves can 
also be utilized together to learn more about the possible binding sites of the compounds 
tested, or at least which sites are not occupied by these molecules. 
 Primarily, a direct channel inhibitor, one binding in the pore itself, should have 
the same IC50-value in the presence and the absence of spermidine.  As the long-chain 
polyamines are known to bind at a site separate from the channel domain, they only serve 
to increase channel opening frequency.  This effect will result in an increase in the 
amount of channel inhibitor which binds, but should not modify either the rate of binding 
or the concentration necessary to inhibit the channel; these parameters are reflected in the 
dose-response curves as the slope and IC50 values.  Therefore, these two values will be 
the same regardless of spermidine concentrating in dose-response curves generated by 
compounds such as non-radiolabeled MK-801 (see Figure 2.6) which bind directly to the 
channel pore.  While it is indeed possible that a compound could have the same slope and 
IC50 values in both situations by binding at a separate allosteric site, a significant 
difference in these values between curves is indicative of binding away from the channel. 
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Figure 2.6 Dose-response curves for cold MK-801 in the presence and absence of 
100 μM spermidine (IC50 = 5.58 ± 0.07 nM with SPD, 5.92 ± 0.11 nM without SPD; 
hill slope = -1.09 ± 0.07 with SPD, -0.96 ± 0.11 without SPD) 
 
 In addition, the ratio of the two IC50-values discloses information about the 
possibility of the tested compounds binding at the same polyamine recognition site at 
which spermidine acts.  If the compound being tested is acting as an antagonist, or 
inverse agonist, at the same position where spermidine is acting as an agonist, these two 
molecules will be competitive.  According to the Cheng-Prusoff equation, the IC50 of a 
competitive inhibitor should increase linearly with the concentration of the competitive 
agonist (Berger et al., 1998; Cheng and Prusoff, 1973): 
 
IC50, [agonist] = x = IC50, [agonist] = 0 * (1 + X/EC50) 
 
The EC50 of spermidine in this assay has been examined at different time points, as the 
equilibrium is slowly achieved between spermidine and its polyamine recognition site.  
At 45 minutes, this value was roughly 6.3 μM.  For the purposes of each assay performed 
in this study, this corresponds to the 40-45 minute incubation time between the addition 
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of the membrane, polyamine, and tested compound, and the addition of [3H]MK-801.  As 
100 μM of spermidine was used in the generation of the SPD-potentiated curve, the two 
IC50-values should follow this equation, if they are indeed competitive at the same site: 
 
IC50, [spermidine] = 100 μM = IC50, [spermdine] = 0 * (1 + 100 μM/6.3 μM) 
IC50, [spermidine] = 100 μM = IC50, [spermdine] = 0 * (16.9) 
 
Therefore, competition of these compounds at the same polyamine recognition site would 
be indicated by a 17-fold increase in the IC50 from the non-potentiated to the potentiated 
curve, which would be accompanied by no change in the slope of the curve, simply a 
shift of the curve to the right. 
 While a number of the tested agmatine analogs had a ratio of IC50 with spermidine 
to IC50 without spermidine of close to 1 (which would not eliminate the possibility of 
channel site binding), none of the ratios were nearly as high as 17, which indicates that 
none of the compounds act competitively at the same site as spermidine.  
 In comparing the values generated for each of these compounds, a number of 
factors are of importance towards dictating their potency as well as their selectivity.  In 
addition to the ratios of the two curve-generated IC50-values, it is also useful to compare 
the IC50pot to the IC50 without spermidine.  This ratio assumes that the compounds bind in 
separate sites, activity that is indicated by the curves displayed by agmatine.  Agmatine 
has a ratio for IC50 without spermidine to IC50 of potentiation (ratio of potentiation, or 
Ratiopot) of nearly 6:1, whereas compounds such as MK-801 have ratios on the range of 
2-3:1.  Higher ratios are therefore indicative of greater separation between polyamine site 
binding and channel binding, or a shallow slope, which also indicates multi-site binding. 
 The five guanidine compounds which were evaluated at the full concentration 
range, as mentioned above, were JR-3, JR-5, JR-83, JR-84, and AH-8.  All of these 
were aromatic compounds, and all contained another amine; a primary amine in the case 
of the first four, and a secondary amine of an indole ring in the latter.  While the two 
earliest leads, JR-3 and JR-5, showed activity in the early screens, they did not prove to 
be extremely potent when tested across the entire range of concentrations.  The former 
possessed an IC50pot of 364.8 μM, with the two other values being roughly equal.  The 
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latter was roughly twice as potent, with a 162.0 μM IC50pot, again with roughly equal 
curve-derived IC50-values.  The two xylenediamine compounds bettered these by a full 
order of magnitude.  The para-compound, JR-83, was observed to have an IC50pot of 27.5 
μM; however, the IC50 value for this compound in the presence of spermidine was nearly 
twice that of the value in its absence, and the Ratiopot was less than 2:1.  The meta-
compound, JR-84, was nearly twice as potent with a 15.5 μM IC50pot.  In addition, the 
Ratiopot was greater than 3:1.  This compound had a shorter inter-atomic distance 
between the amine group and the guanidine group, making it more structurally similar to 
agmatine, which may explain the increase in selectivity over JR-83.  The final guanidine 
compound examined, AH-8, while quite potent with a 15.7 μM IC50pot, did not display 
any of the signs of selectivity expected of an agmatine analog.  The ratio of IC50 values 
for this compound in the presence to absence of spermidine was greater than 2:1, and the 
Ratiopot was less than 1:1.   
 The imidazole derivates, or ethyl-bridged guanidine compounds, were generally 
less potent than their unsubstituted guanidine counterparts.  The two examined 
compounds in this set with the same moiety A and B (see Figure 2.1) as guanylated 
compounds were JR-93 and JR-120, which corresponded to JR-5 and JR-84, 
respectively.  Neither of these compounds had remarkable potency, with JR-93 being less 
than half as potent as JR-5 and JR-120 having an IC50pot nearly 30 times as high as that 
of JR-84.  While the aromatic 1,4,5,6-tetrahydropyrimidine derivatives, or propyl-
bridged guanidine compounds, appeared to be more potent than the similar imidazole 
derivatives, they also displayed less activity than their guanylated counterparts.  JR-107 
and JR-108, the para- and meta-xylenediamine compounds, with IC50pot -values of 52.7 
μM and 97.3 μM, respectively, were less potent than their guanylated isomers, JR-83 and 
JR-84.  Interestingly, it was the para-xylene 1,4,5,6-tetrahydropyrimidine compound 
which was nearly twice as potent as the meta-compound, while the meta-xylene 
guanylated compound was twice as active as the para-compound.  However, the meta-
xylene compound demonstrated more selectivity in both cases; while JR-107 had a 
Ratiopot of nearly 4:1, JR-108 yielded the same ratio at over 13:1.  This observation 
reinforces the hypothesis that the shorter direct chain more closely mimics the selectivity 
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of agmatine, but in this case, the aromatic compound displayed greater selectivity than 
that of agmatine. 
N'-(4,5-Dihydro-1H-imidazol-2-yl)-propane-1,3-diamine hydriodide (JR-89), the 
imidazole derivative of agmatine with a propyl instead of butyl chain, demonstrated very 
good potency and selectivity, with a 12.4 μM IC50pot and a Ratiopot greater than 8.5:1.  
The 1,4,5,6-tetrahydropyrimidyl compound with the same propane bridge, JR-113, was 
also very promising, with its IC50pot of 20.4 μM  and Ratiopot of 7.8:1.   
 Two symmetrical di-substituted bridged-guanylated compounds were tested, both 
with a para-xylene linker, JR-106 and JR-117.  The bis-imidazole compound, JR-117, 
and the bis-1,4,5,6-tetrahydropyrimidyl compound, JR-106, demonstrated 104.7 μM and 
254.7 μM IC50pot -values, respectively.  Neither of these values is remarkable, but these 
bis-compounds yielded very similar sets of dose-response curves: the hill slopes of the 
spermidine-potentiated curves are roughly twice as steep as the hill slopes of the curves 
in the absence of spermidine.  As a result, the Ratiopot for each compound is close to 1:1.  
These data indicate that neither of these compounds binds to the same polyamine site as 
agmatine, although the significance difference in hill slope indicates that neither act as 
inhibitors of the channel site.  It is thus postulated that these bis-compounds bind at 
another polyamine recognition site, and act allosterically as more potent inhibitors in the 
absence of spermidine than in its presence. 
 The final two compounds to be tested with these sets of dose-response curves 
were the Nω-ethyl guanylated para- and meta-xylene-diamines, JR-126 and JR-127.  The 
latter compound was unremarkable, with an IC50pot of 75.3 μM and a Ratiopot of 2:1.  The 
former compound, N-[4-(aminomethyl)-benzyl]-N’-ethyl-guanidine hydriodide, had an 
IC50pot of 25.8 μM, but acted much like the bis-compounds in terms of selectivity.  The 
ratio of hill slopes for the spermidine-potentiated curve to the non-potentiated curve was 
2.3:1, and the Ratiopot was 1:1.6.  It is interesting that these compounds act in such 
different manners, while being very similar structurally.  However, each of the mono-
substituted meta-xylene compounds demonstrated greater selectivity for the polyamine 
site recognizing agmatine than their corresponding mono-substituted para-xylene 
compounds, an observation which holds true in this case as well. 
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 The remaining compounds, the arylidenamino-guanidines, will be discussed in 
chapter 3 of this work, as they are part of a larger set of very similar compounds, both in 
structure and activity. 
 
 
2.5 Conclusions 
 
 This study was undertaken to develop and evaluate agmatine analogs as inhibitors 
of the NMDA receptor complex polyamine recognition sites in order to develop leads and 
better understand the structure-activity relationship associated with the selectivity 
demonstrated by agmatine. 
 A library of nearly 200 compounds were designed and synthesized, and those 
amenable to the P2 membrane protein [3H]MK-801 displacement assay were screened for 
their ability to allosterically or directly modulate the opening of the NMDA receptor 
channel.  The most active compounds were then re-examined at a comprehensive range 
of concentrations in the presence and absence of a pathological level of the polyamine 
spermidine, in order to evaluate their potency as well as selectivity for the NMDAR site 
which recognizes agmatine. 
 A majority of the potent compounds contained aromatic rings between a primary 
amine and a terminal guanidine congener.  It was observed that the most potent connector 
groups were the xylenediamine moieties, with the meta-diamine demonstrating more 
selectivity than the para-diamine.  These included N-(3-amino-methyl-benzyl)-guanidine 
dihydrochloride (JR-84), which had a 12.4 μM IC50pot and greater than 3:1 Ratiopot.  
Other aromatic groups also showed promise as linkers, such as N-(1H-indol-5-
yl)guanidine hydrochloride (AH-8), which possessed a 15.7 μM IC50pot, but apparently 
little selectivity for the agmatine site. 
 There was also a pair of agmatine analogs with shorter aliphatic chains connecting 
the terminal amine to an ethyl- or propyl-bridged guanidine group that demonstrated both 
potency and selectivity for the agmatine site.  N'-(4,5-dihydro-1H-imidazol-2-yl)-
propane-1,3-diamine hydriodide (JR-89) and N'-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-
aminopropyl-3-amine hydriodide (JR-113) had IC50pot values of 12.4 μM and 20.4 μM, 
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respectively, with ratios of potentiation of roughly 8:1 for each.  These compounds 
demonstrate potency of a full order of magnitude better than agmatine, and demonstrate 
slightly greater selectivity. 
 A set of arylidenamino-guanidine compounds were all active in the [3H]MK-801 
displacement screenings, and these inhibitors are further examined for structure-activity 
relationship to potency and selectivity of NMDA receptor inhibition in the following 
chapter. 
 A number of compounds and structural motifs were examined in this study, and 
several leads were developed for further in vivo testing, as well as others which will be 
further optimized for therapeutic value as inhibitory modulators of the NMDA receptor 
complex. 
  
2.6 Experimental Protocol 
 
 The following includes the reaction details of each of the screened compounds 
mentioned above in Table 1.1, including structures and analytical data.  Each description 
refers to one of the seven general reactions from Section 2.2.  In addition, the full dose-
response curves are given for those compounds which were determined to be hits, and 
which were then subjected to this further pharmacological analysis.  Again, it should also 
be noted that while the counts are reported as raw DPM instead of DPM/mg protein on 
the graphs below, a constant level of protein was maintained in each well across all 
experiments (0.15 mg/well). 
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JR-03 
N
H
NH2
NH
H2N
H Cl
H Cl  
N-(4-Amino-benzyl)-guanidine Dihydrochloride 
 
p-Aminobenzylamine (567 μL, 611 mg, 5.0 mmol) and N,N’-bis(tert-butoxy)-S-
methylisothiopseudourea (1.45 g, 5.0 mmol) were dissolved in tetrahydrofuran (10 mL) 
and reacted according to the above General Reaction 1.  The final product was dissolved 
in water and lyophilized to yield a yellow solid product (998 mg, 4.21 mmol, 84% yield).  
Mp: 207-209°C; 1H NMR (300MHz, d-D2O) δ 7.44 (4H, m), 4.48 (2H, s); 13C NMR 
(300MHz, d-DMSO) δ 157.0, 131.6, 130.2, 128.3, 122.9, 43.3; ES+ m/z 165. 
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JR-04 
NH 2
H
N
H2N NH
H Cl
H Cl
 
N-(4-Aminomethyl-phenyl)-guanidine Dihydrochloride 
 
p-Aminobenzylamine was reacted with di-tert-butyl dicarbonate in a 1:1 
stoichiometric ratio in order to obtain (4-amino-benzyl)-carbamic acid tert-butyl ester in 
nearly quantitative yield.  This ester product (1.11 g, 5.0 mmol) and N,N’-bis(tert-
butoxy)-S-methylisothiopseudourea (1.45 g, 5.0 mmol) were dissolved in tetrahydrofuran 
(10 mL) and reacted according to the above General Reaction 1.  The final product was 
dissolved in water and lyophilized to yield an off-white solid product (713 mg, 3.01 
mmol, 60% yield).  1H NMR (300MHz, d-D2O) δ 7.5 (4H, m), 4.22 (2H, s). 
 
JR-05 
N
H
NH2
NH
NH2
H Cl
H Cl  
N-(2-Amino-benzyl)-guanidine Dihydrochloride 
 
o-Aminobenzylamine (611 mg, 5.0 mmol) and N,N’-bis(tert-butoxy)-S-
methylisothiopseudourea (1.45 g, 5.0 mmol) were dissolved in tetrahydrofuran (10 mL) 
and reacted according to the above General Reaction 1.  The final product was dissolved 
in water and lyophilized to yield a dark yellow solid product (566 mg, 2.39 mmol, 48% 
yield).  Mp: 207-209°C; 1H NMR (300MHz, d- D2O) δ 7.51 (4H, m), 4.53 (2H, s); 13C 
NMR (300MHz, d-DMSO) δ 156.9, 133.0, 129.3, 128.4, 127.4, 125.8, 122.1, 40.3; ES+ 
m/z 165. 
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JR-08 
N
H
NH2
NH
HO
H Cl
 
N-[4-(2-Hydroxy-ethyl)-phenyl]-guanidine Hydrochloride 
 
4-Aminophenethyl alcohol (686 mg, 5.0 mmol) and N,N’-bis(tert-butoxy)-S-
methylisothiopseudourea (1.45 g, 5.0 mmol) were dissolved in tetrahydrofuran (10 mL) 
and reacted according to the above General Reaction 1.  The final product was dissolved 
in water and lyophilized to yield a tan-yellow solid powder product (388 mg, 1.80 mmol, 
36% yield).  1H NMR (300MHz, d-D2O) δ 7.36 (2H, d, J = 9Hz), 7.21 (2H, d, J = 9Hz), 
3.83 (2H, t, J = 6.6Hz), 2.86 (2H, t, J = 6.6Hz) 
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JR-09 
N
H
NH2
NH
Br
H Cl
 
N-(4-Bromo-phenyl)-guanidine Hydrochloride 
 
4-Bromoaniline (860 mg, 5.0 mmol) and N,N’-bis(tert-butoxy)-S-
methylisothiopseudourea (1.45 g, 5.0 mmol) were dissolved in tetrahydrofuran (10 mL) 
and reacted according to the above General Reaction 1.  The final product was dissolved 
in water and lyophilized to yield a yellow solid product (210 mg, 0.84 mmol, 17% yield).  
1H NMR (300MHz, d-D2O) δ 7.63 (2H, d, J = 9Hz), 7.21 (2H, d, J = 9Hz) 
 
JR-81 
H
N NH2
NH
H2N
H Cl
H Cl
 
N-(5-Amino-pentyl)-guanidine Dihydrochloride 
 
1,5-Diaminopentane was reacted with di-tert-butyl dicarbonate in a 1:1 
stoichiometric ratio in order to obtain (5-amino-pentyl)-carbamic acid tert-butyl ester in 
nearly quantitative yield.  This ester product (303 mg, 1.5 mmol) and N,N’-bis(tert-
butoxy)-S-methylisothiopseudourea (480 mg, 1.75 mmol) were dissolved in 
tetrahydrofuran (5 mL) and reacted according to the above General Reaction 1.  The final 
product was dissolved in water and lyophilized to yield a yellow semi-solid product (241 
mg, 1.11 mmol, 74% yield). 1H NMR (300MHz, d-D2O) δ 3.21 (2H, t), 3.02 (2H, t), 1.71 
(4H, m), 1.46 (2H, m) 
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JR-83 
H
N NH2
NH
H2N
1/2 H2SO4  
N-(4-Aminomethyl-benzyl)-guanidine Hemisulfate 
 
p-Xylenediamine (163 mg, 1.2 mmol) and 2-methyl-2-thiopseudourea sulfate 
(111 mg, 0.4 mmol) were dissolved in methanol (5 mL) and reacted according to the 
alternate General Reaction 1 described above.  Upon cooling to room temperature, the 
final product slowly crashed from solution as a white crystal product (82 mg, 0.36 mmol, 
90% yield).  Mp: > 300°C; 1H NMR (300MHz, d-D2O and d-DMSO) δ 7.50 (2H, d, J = 
8.4 Hz), 7.44 (2H, d, J = 8.4 Hz), 4.47 (2H, s), 4.17 (2H, s); ES+ m/z 179. 
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JR-84 
H
N NH2
NH
H2N
1/2 H2SO4  
N-(3-Amino-methyl-benzyl)-guanidine Dihydrochloride 
 
m-Xylenediamine (158 μL, 163 mg, 1.2 mmol) and 2-methyl-2-thiopseudourea 
sulfate (111 mg, 0.4 mmol) were dissolved in methanol (5 mL) and reacted according to 
the alternate General Reaction 1 described above.  Upon cooling to room temperature, the 
final product slowly crashed from solution as an off-white crystal product (59 mg, 0.26 
mmol, 65% yield).  Mp: > 300°C; 1H NMR (300MHz, d-D2O) δ 7.44 (4H, m), 4.45 (2H, 
s), 4.19 (2H, s); 13C NMR δ 158.2, 138.6, 125.0, 131.1, 129.7, 129.1, 128.6, 127.9, 45.7, 
44.4; ES+ m/z 179. 
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JR-89 
H2N
H
N
N
H
N
H I
 
N'-(4,5-Dihydro-1H-imidazol-2-yl)-propane-1,3-diamine Hydriodide 
 
1,3-Diaminopropane (250 μL, 3.0 mmol) and 2-methylsulfanyl-4,5-dihydro-1H-
imidazole hydriodide (610 mg, 2.5 mmol) were dissolved in methanol (15 mL) and 
reacted according to the above General Reaction 2.  The product was evaporated to 
dryness on a rotary evaporator and then recrystallized from chloroform to yield white 
plate crystals (188 mg, 0.70 mmol, 29% yield).  Mp: 136-138°C; 1H NMR (300MHz, d-
DMSO) δ 3.23 (4H, m), 3.03 (2H, t, J = 6Hz), 2.64 (2H, t, J = 6Hz), 1.79 (2H, p, J = 
6Hz); 13C NMR δ 153.0, 43.7, 40.8, 38.0, 19.8; ES+ m/z 143. 
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JR-90 
H
N
N
H
N
H2N
H I
 
N'-(4,5-Dihydro-1H-imidazol-2-yl)-butane-1,4-diamine Hydriodide 
 
1,4-Diaminobutane (302 μL, 3.0 mmol) and 2-methylsulfanyl-4,5-dihydro-1H-
imidazole hydriodide (610 mg, 2.5 mmol) were dissolved in methanol (15 mL) and 
reacted according to the above General Reaction 2.  The product did not crystallize upon 
cooling, but was evaporated to dryness on a rotary evaporator and rinsed with chloroform 
to remove excess diamine starting material, yielding an off-white semi-solid (322 mg, 
1.13 mmol, 45% yield).  1H NMR (300MHz, d-DMSO) δ 3.68 (4H, s), 3.22 (2H, m), 2.79 
(2H, m), 1.60 (4H, m) 
 
JR-91 
H
N
N
H
N
H2N
H I
 
N'-(4,5-Dihydro-1H-imidazol-2-yl)-pentane-1,5-diamine Hydriodide 
 
1,5-Diaminopentane (351 μL, 3.0 mmol) and 2-methylsulfanyl-4,5-dihydro-1H-
imidazole hydriodide (610 mg, 2.5 mmol) were dissolved in methanol (15 mL) and 
reacted according to the above General Reaction 2.  The product did not crystallize upon 
cooling, but was evaporated to dryness on a rotary evaporator and rinsed with chloroform 
to remove excess diamine starting material, yielding a dark orange liquid product (362 
mg, 1.21 mmol, 49% yield).  1H NMR (300MHz, d-DMSO) δ 3.57 (4H, s), 3.10 (2H, m), 
2.62 (2H, m), 1.4 (6H, m) 
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JR-92 
H
N
N
H
N
H2N
H I
 
N'-(4,5-Dihydro-1H-imidazol-2-yl)-benzylamino-4-amine Hydriodide 
 
4-Aminobenzylamine (340 μL, 3.0 mmol) and 2-methylsulfanyl-4,5-dihydro-1H-
imidazole hydriodide (610 mg, 2.5 mmol) were dissolved in methanol (15 mL) and 
reacted according to the above General Reaction 2.  Upon cooling to room temperature, 
the product precipitated as orange crystals (335 mg, 1.05 mmol, 42% yield).  Mp: 201-
203°C; 1H NMR (300MHz, d-DMSO) δ 8.45 (1H, broad t), 6.97 (2H, d, J = 9Hz), 6.56 
(2H, d, J = 9Hz), 5.12 (2H, broad s), 4.14 (2H, d, J = 6Hz), 3.59 (4H, s); 13C NMR δ 
147.6, 127.9, 126.t5, 113.6, 112.0, 46.4, 38.1. 
 
JR-93 
H
N
N
H
N
NH2
H I
 
N'-(4,5-Dihydro-1H-imidazol-2-yl)-benzylamino-2-amine Hydriodide 
 
4-Aminobenzylamine (366 mg, 3.0 mmol) and 2-methylsulfanyl-4,5-dihydro-1H-
imidazole hydriodide (610 mg, 2.5 mmol) were dissolved in methanol (15 mL) and 
reacted according to the above General Reaction 2.  Upon cooling to room temperature, 
the product precipitated as dull orange crystals (196 mg, 0.616 mmol, 25% yield).  Mp: 
195-197°C; 1H NMR (300MHz, d-DMSO) δ 8.37 (1H, broad t), 7.03 (1H, t, J = 7.2Hz), 
7.01 (1H, d, J = 7.2Hz), 6.68 (1H, dt, J = 7.2, 1.5Hz), 6.56 (1H, td, J = 7.2Hz, 1.5Hz), 
5.11 (2H, broad s), 4.18 (2H, d, J = 6Hz), 3.60 (4H, s); 13C NMR δ 159.2, 146.0, 128.4, 
128.2, 119.2, 115.9, 115.0, 42.62, 42.56; ES+ m/z 191. 
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JR-102 
NH NH2
NH
H Cl
H Cl
H2N
 
N-(3-Amino-phenyl)-guanidine Dihydrochloride 
 
1,3-Phenyldiamine (324 mg, 3.0 mmol) and N,N’-bis(tert-butoxy)-S-
methylisothiopseudourea (1.45 g, 5.0 mmol) were dissolved in tetrahydrofuran (10 mL) 
and reacted according to the above General Reaction 1.  The final product was dried on a 
rotary evaporator to yield a clear orange liquid product (88 mg, 0.39 mmol, 13% yield).  
1H NMR (300MHz, d-DMSO) δ 9.11 (2H, broad s), 7.2-7.7 (4H, m). 
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JR-106 
N
H
N
H
N
N
H
H I
N
H
N
H I
 
N,N-bis(1,4,5,6-tetrahydro-pyrimidin-2-yl)-1,4-bis(aminomethyl)benzene Diiodide 
 
p-Xylenediamine (272 mg, 2.0 mmol) and 2-methylsulfanyl-1,4,5,6-tetrahydro-
pyrimidine hydriodide (1.29 g, 5.0 mmol) were dissolved in ethanol and reacted 
according to the above General Reaction 2.  The product was evaporated to dryness on a 
rotary evaporator and then recrystallized from chloroform to yield white needle crystals 
(112 mg, 0.20 mmol, 10% yield).  Mp: 266-267°C; 1H NMR (300MHz, d-DMSO) δ 7.79 
(4H, broad s), 7.66 (2H, broad s), 7.41 (1H, t, J = 1.5Hz), 7.25 (2H, d, J = 1.5Hz), 7.23 
(1H, s), 4.34 (4H, d, J = 2.4Hz), 3.26 (8H, t, J = 3Hz), 1.82 (4H, p, J = 3Hz); 13C NMR δ 
152.3, 137.5, 128.8, 126.2, 125.8, 43.5, 40.3, 19.7; ES+ m/z 151 (MW 302, 2 charges). 
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JR-107 
H 2N
N
H
N
N
H
H I
 
4-Aminomethyl-benzyl-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-amine Hydriodide 
 
p-Xylenediamine (681 mg, 5.0 mmol) and 2-methylsulfanyl-1,4,5,6-tetrahydro-
pyrimidine hydriodide (1.29 g, 5.0 mmol) were dissolved in ethanol and reacted 
according to the above General Reaction 2.  The resulting solution was evaporated to 
dryness on a rotary evaporator followed by a vacuum pump to yield a light yellow solid 
product (208 mg, 0.60 mmol, 12% yield).  1H NMR (300MHz, d-D2O) δ 7.42 (4H, m), 
4.41 (2H, d), 4.04 (2H, d), 3.33 (4H, t), 1.92 (2H, p) 
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JR-108 
N
H
N
N
H
H I
H2N  
3-Aminomethyl-benzyl-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-amine Hydriodide 
 
m-Xylenediamine (660 μL, 5.0 mmol) and 2-methylsulfanyl-1,4,5,6-tetrahydro-
pyrimidine hydriodide (1.29 g, 5.0 mmol) were dissolved in ethanol and reacted 
according to the above General Reaction 2.  The resulting solution was evaporated to 
dryness on a rotary evaporator followed by a vacuum pump to yield a dark orange semi-
solid (314 mg, 0.91 mmol, 18% yield).  1H NMR (300MHz, d-DMSO) δ 7.24 (4H, m), 
4.32 (2H, m), 3.74 (2H, d), 3.24 (4H, t), 1.83 (2H, p); 13C NMR δ 155.1, 148.2, 128.5, 
123.5, 113.8, 44.3, 39.9, 36.1, 14.4. 
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JR-109 
H2N
N
H
N
N
H
H I
 
N'-(1,4,5,6-Tetrahydro-pyrimidin-2-yl)-benzylamino-4-amine Hydriodide 
 
4-Aminobenzylamine (567 μL, 5.0 mmol) and 2-methylsulfanyl-1,4,5,6-
tetrahydro-pyrimidine hydriodide (1.29 g, 5.0 mmol) were dissolved in ethanol and 
reacted according to the above General Reaction 2.  The resulting solution was 
evaporated to dryness on a rotary evaporator followed by a vacuum pump to yield a 
bright orange solid powder product (528 mg, 1.59 mmol, 32% yield).  1H NMR 
(300MHz, d-DMSO) δ 7.63 (2H, broad s), 7.40 (1H, broad t), 6.96 (2H, d, J = 9 Hz), 6.47 
(2H, d, J = 9 Hz), 5.09 (2H, s), 4.07 (2H, d), 3.22 (4H, t), 1.82 (2H, p). 
 
JR-113 
N
H
N
N
H
H I
H2N
 
N'-(1,4,5,6-Tetrahydro-pyrimidin-2-yl)-aminopropyl-3-amine Hydriodide 
 
1,3-Diaminopropane (416 μL, 5.0 mmol) and 2-methylsulfanyl-1,4,5,6-
tetrahydro-pyrimidine hydriodide (1.29 g, 5.0 mmol) were dissolved in ethanol and 
reacted according to the above General Reaction 2.  The resulting solution was 
evaporated to dryness on a rotary evaporator followed by a vacuum pump to yield a clear, 
colorless liquid product (597 mg, 2.1 mmol, 42% yield).  1H NMR (300MHz, d-DMSO) 
δ 3.22 (4H, t, J = 5.7 Hz), 3.11 (2H, t, J = 6.3 Hz), 2.67 (2H, t, J = 6.9 Hz), 1.79 (2H, p, J 
= 5.7 Hz), 1.60 (2H, t, J = 6.7 Hz). 
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JR-114 
N
H
N
N
H
H I
H2N
 
N'-(1,4,5,6-Tetrahydro-pyrimidin-2-yl)-aminobutyl-4-amine Hydriodide 
 
 1,4-Diaminobutane (502 μL, 5.0 mmol) and 2-methylsulfanyl-1,4,5,6-tetrahydro-
pyrimidine hydriodide (1.29 g, 5.0 mmol) were dissolved in ethanol and reacted 
according to the above General Reaction 2.  The resulting solution was evaporated to 
dryness on a rotary evaporator followed by a vacuum pump to yield an orange liquid, 
from which crashed light orange needle crystals (270 mg, 0.91 mmol, 18% yield).  1H 
NMR (300MHz, d-DMSO) δ 3.23 (4H, t, J = 5.7 Hz), 3.11 (2H, t), 2.69 (2H, t), 1.80 (2H, 
p, J = 5.7 Hz), 1.47 (4H, broad m). 
 
 85
JR-115 
N
H
N
N
H
H I
H2N
 
N'-(1,4,5,6-Tetrahydro-pyrimidin-2-yl)-aminopentyl-5-amine Hydriodide 
 
 1,5-Diaminopentane (587 μL, 5.0 mmol) and 2-methylsulfanyl-1,4,5,6-tetrahydro-
pyrimidine hydriodide (1.29 g, 5.0 mmol) were dissolved in ethanol and reacted 
according to the above General Reaction 2.  The resulting solution was evaporated to 
dryness on a rotary evaporator followed by a vacuum pump to yield a dark orange 
viscous liquid, from which crashed orange needle crystals (620 mg, 1.99 mmol, 40% 
yield).  1H NMR (300MHz, d-DMSO) δ 3.23 (2H, t), 3.07 (4H, t, J = 5.7 Hz), 2.70 (2H, 
t), 1.67 (2H, p, J = 5.7 Hz), 1.46 (4H, broad m) 1.32 (2H, broad m). 
 
JR-116 
N
H
N
N
H
H I
HO
 
N'-(1,4,5,6-Tetrahydro-pyrimidin-2-yl)-aminobutan-4-ol Hydriodide 
 
 4-Amino-1-butanol (461 μL, 5.0 mmol) and 2-methylsulfanyl-1,4,5,6-tetrahydro-
pyrimidine hydriodide (1.29 g, 5.0 mmol) were dissolved in ethanol and reacted 
according to the above General Reaction 2.  The resulting solution was evaporated to 
dryness on a rotary evaporator followed by a vacuum pump to yield a light orange semi-
solid (320 mg, 1.07 mmol, 21% yield).  1H NMR (300MHz, d-DMSO) δ 3.40 (2H, t, J = 
6.3 Hz), 3.11 (4H, t, J = 5.7 Hz), 2.77 (2H, t, J = 7.5 Hz), 1.67 (2H, p, J = 5.7 Hz), 1.45 
(2H, t). 
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JR-117 
N
H
N
H
N
N
H
H I
N
N
H
H I
 
N,N-bis(3,4-Dihydro-1H-imidazol-2-yl)-1,4-bis(aminomethyl)benzene Dihydriodide 
 
p-Xylenediamine (341 mg, 2.5 mmol) and 2-methylsulfanyl-4,5-dihydro-1H-
imidazole hydriodide (2.0 g, 8.2 mmol) were dissolved in methanol (15 mL) and reacted 
according to the above General Reaction 2.  The product was evaporated to dryness on a 
rotary evaporator to yield a tan solid product (296 mg, 0.89 mmol, 36% yield).  1H NMR 
(300MHz, d-DMSO) δ 7.31 (4H, s), 4.36 (4H, s), 3.60 (8H, s);  13C NMR δ 43.3, 45.8, 
128.2, 137.1, 159.9; ES+ m/z 137 (MW 274, 2 charges). 
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JR-119 
H2N
N
H
N
N
H
H I
 
N'-(4,5-Dihydro-1H-imidazol-2-yl)-benzylamino-4-methylamine Hydriodide 
 
p-Xylenediamine (341 mg, 2.5 mmol) and 2-methylsulfanyl-4,5-dihydro-1H-
imidazole hydriodide (610 mg, 2.5 mmol) were dissolved in methanol (15 mL) and 
reacted according to the above General Reaction 2.  The product was evaporated to 
dryness on a rotary evaporator to yield a yellow semi-solid (236 mg, 0.71 mmol, 28% 
yield).   
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JR-120 
N
H
N
N
H
H I
H2N  
N'-(4,5-Dihydro-1H-imidazol-2-yl)-benzylamino-3-methylamine Hydriodide 
 
m-Xylenediamine (330 μL, 2.5 mmol) and 2-methylsulfanyl-4,5-dihydro-1H-
imidazole hydriodide (610 mg, 2.5 mmol) were dissolved in methanol (15 mL) and 
reacted according to the above General Reaction 2.  The product was evaporated to 
dryness on a rotary evaporator to yield a tan semi-solid (292 mg, 0.88 mmol, 35% yield).  
1H NMR (300MHz, d-DMSO) δ 9.98 (2H, broad s), 8.66 (1H, s), 7.2-7.5 (4H, m), 4.40 
(2H, d), 3.86 (2H, s), 3.61 (4H, s). 
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(4-Nitrobenzylidenamino)-guanidine Hydrochloride 
 
4-Nitrobenzaldehyde (1.13 g, 7.5 mmol) and aminoguanidine hydrochloride (553 
mg, 5.0 mmol) were dissolved in methanol (50 mL) and reacted according to the above 
General Reaction 4.  The product solution was dissolved on the rotary evaporator, and the 
residue was stirred in chloroform and filtered to remove the remaining starting material.  
The filtered product was dried on vacuum overnight to afford a light-yellow powdery 
solid (768 mg, 3.15 mmol, 63% yield).  Mp: 252-254ºC; 1H NMR (300MHz, d- D2O) δ 
8.23 (2H, m), 8.0 (1H, m), 7.81 (2H, m); 13C NMR δ 155.4, 147.9, 144.2, 139.6, 128.4, 
123.7; ES+ m/z 208. 
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(3-Nitrobenzylidenamino)-guanidine Hydrochloride 
 
3-Nitrobenzaldehyde (1.13 g, 7.5 mmol) and aminoguanidine hydrochloride (553 
mg, 5.0 mmol) were dissolved in methanol (50 mL) and reacted according to General 
Reaction 4 above.  The product solution was dissolved on the rotary evaporator, and the 
residue was stirred in chloroform and filtered to remove the remaining starting material.  
The filtered product was dried on vacuum overnight to afford a pale yellow powdery 
solid (1109 mg, 4.55 mmol, 91% yield).  Mp: 267-268ºC; 1H NMR (300MHz, d-D2O) δ 
8.53 (1H, t, J = 2.0Hz), 8.28 (1H, ddd, J = 9.0, 2.0, 1.3Hz), 8.09 (1H, s), 8.03 (1H, td, J = 
9.0, 1.3Hz), 7.66 (1H, t, J = 9.0Hz); 13C NMR δ 155.5, 148.2, 146.1, 134.7, 133.7, 130.1, 
125.1, 121.8; ES+ m/z 208. 
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(3-Cyanobenzylidenamino)-guanidine Hydrochloride 
 
3-Cyanobenzaldehyde (491 mg, 3.75 mmol) and aminoguanidine hydrochloride (276.4 
mg, 2.5 mmol) were dissolved in methanol (50 mL) and reacted according to the above 
General Reaction 4.  The product solution was dissolved on the rotary evaporator, and the 
residue was stirred in chloroform and filtered to remove the remaining starting material.  
The filtered product was dried on vacuum overnight to afford an off-white powdery solid 
(257 mg, 1.15 mmol, 46% yield).  Mp: 235-239ºC; 1H NMR (300MHz, d- D2O) δ 12.18 
(1H, s), 8.48 (1H, t, J = 1.5Hz), 8.19 (1H, s), 8.12 (1H, dt, J = 8.3, 1.5Hz), 7.87 (1H, dt, J 
= 8.3, 1.5Hz), 7.64 (1H, t, J = 8.3Hz); 13C NMR δ 155.4, 144.2, 134.7, 133.2, 132.3, 
130.3, 129.8, 118.4, 111.8; ES+ m/z 188. 
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(4-Cyanobenzylidenamino)-guanidine Hydrochloride 
 
4-Cyanobenzaldehyde (983 mg, 7.5 mmol) and aminoguanidine hydrochloride 
(553 mg, 5.0 mmol) were dissolved in methanol (50 mL) and reacted according to the 
above General Reaction 4.  The product solution was dissolved on the rotary evaporator, 
and the residue was stirred in chloroform and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford a white powdery 
solid (944 mg, 4.22 mmol, 84% yield).  Mp: 264-267ºC; 1H NMR (300MHz, d- DMSO) 
δ 12.22 (1H, s), 8.22 (1H, s), 8.07 (2H, d, J = 9.0Hz), 7.91 (2H, d, J = 9.0Hz); 13C NMR δ 
155.4, 144.6, 137.7, 132.4, 128.0, 118.5, 112.1; ES+ m/z 188. 
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N-[4-(Aminomethyl)-benzyl]-N’-ethyl-guanidine Hydriodide 
 
p-Xylenediamine (340 mg, 2.5 mmol) and N-ethyl-S-methyl-isothiourea 
hydriodide (615 mg, 2.5 mmol) were dissolved in ethanol (10 mL) and reacted according 
to the above General Reaction 3.  The product was evaporated to dryness on a rotary 
evaporator to a colorless liquid product (324 mg, 0.97 mmol, 39% yield).  1H NMR 
(300MHz, d-DMSO) δ 7.32 (2H, m), 7.24 (2H, m), 4.40 (2H, d, J = 12Hz), 3.69 (2H, d), 
3.18 (2H, q, J = 8Hz), 1.08 (3H, t, J = 8Hz); ES+ m/z 206. 
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N-[3-(Aminomethyl)-benzyl]-N’-ethyl-guanidine Hydriodide 
 
m-Xylenediamine (330 μL, 2.5 mmol) and N-ethyl-S-methyl-isothiourea 
hydriodide (615 mg, 2.5 mmol) were dissolved in ethanol (10 mL) and reacted according 
to the above General Reaction 3.  The product was evaporated to dryness on a rotary 
evaporator to yield a colorless liquid product (478 mg, 1.43 mmol, 57% yield).  .  1H 
NMR (300MHz, d-D2O) δ 7.31 (4H, m), 4.43 (2H, d, J = 5Hz), 3.81 (2H, d, J = 5Hz), 
3.22 (2H, q, J = 7.5Hz), 1.18 (3H, t, J = 7.5Hz); 13C NMR δ 155.3, 143.7, 136.8, 128.2, 
126.1, 125.9, 124.9, 45.3, 44.1, 36.0, 14.3; ES+ m/z 207. 
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p-Bis-benzylidenamino-guanidine Dihydrochloride 
 
p-Terephthalaldehyde (402 mg, 3.0 mmol) and aminoguanidine hydrochloride 
(553 mg, 5.0 mmol) were dissolved in methanol (50 mL) and reacted according to the 
above General Reaction 4.  The product solution was dissolved on the rotary evaporator, 
and the residue was stirred in chloroform and filtered to remove the remaining starting 
material.  Two separate solid samples were collected as part of the solid product floated 
above the chloroform, and the remainder sunk to the bottom.  The two solid fractions 
were then finely powdered and stirred again with chloroform to ensure separation.  The 
light-yellow powder top product was characterized as a mixture of benzylidino-
guanidine-4-carboxaldehyde and the bis product.  The bottom product was isolated and 
characterized as p-terephthalaldehyde-bis-guanylhydrazone, a fine off-white powder (365 
mg, 1.14 mmol, 38% yield).  Mp: >300ºC; 1H NMR (300MHz, d-DMSO) δ 12.24 (2H, 
s), 8.21 (2H, s), 7.94 (4H, s); 13C NMR δ 155.3, 145.8, 135.0, 127.7; ES+ m/z 124. 
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N’-(4-Fluoro-benzylidene)-N,N-dimethyl-hydrazone 
 
4-Fluorobenzaldehyde (408 μL, 3.8 mmol) and 1,1-dimethylhydrazine (360 μL, 
4.74 mmol, 1.25 equiv) were dissolved in methanol (10mL) and reacted according to the 
above General Reaction 5.  The product solution was dissolved on the rotary evaporator, 
and the residue was stirred in chloroform and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford a light orange 
plate-like crystal solid (528 mg, 3.18 mmol, 84% yield).  1H NMR (300MHz, d-DMSO) δ 
7.57 (2H, m), 7.30 (1H, s), 7.16 (2H, m), 2.88 (6H, s); GC/MS: 5.140 min, m/z 166. 
 
JR-139 
N
H
N
CH3
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CH3
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N’-(2,4-Dimethoxy-benzylidene)-N,N-dimethyl-hydrazone 
 
2,4-Dimethoxybenzaldehyde (632 mg, 3.8 mmol) and 1,1-dimethylhydrazine (360 
μL, 4.74 mmol, 1.25 equiv) were dissolved in methanol (10mL) and reacted according to 
the above General Reaction 5.  The off-white product solution was dissolved on the 
rotary evaporator to remove the solvent and remaining 1,1-dimethylhydrazine (bp 62-
64ºC), and the residue dried on vacuum overnight to afford a light yellow liquid product 
(594 mg, 2.85 mmol, 75% yield).  1H NMR (300MHz, d-DMSO) δ 7.59 (1H, d, J = 8.7 
Hz), 7.42 (1H, s), 6.55 (1H, d, J = 2.4Hz), 6.50 (1H, dd, J = 8.7, 2.4Hz), 3.80 (3H, s), 
3.77 (3H, s), 2.83 (6H, s).   
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N’-(2,4-Dihydroxy-benzylidene)-N,N-dimethyl-hydrazone 
 
2,4-Dihydroxybenzaldehyde (525 mg, 3.8 mmol) and 1,1-dimethylhydrazine (360 
μL, 4.74 mmol, 1.25 equiv) were dissolved in methanol (10mL) and reacted according to 
the above General Reaction 5.  The orange product solution was dissolved on the rotary 
evaporator to remove the solvent and remaining 1,1-dimethylhydrazine (bp 62-64ºC), and 
the residue dried on vacuum overnight to afford a dark orange solid product (363 mg, 
2.00 mmol, 53% yield).  1H NMR (300MHz, d-DMSO) δ 7.57 (1H, s), 7.11 (1H, d, J = 
8.1 Hz), 6.29 (1H, dd, J = 8.1, 2.7Hz), 6.21 (1H, d, J = 2.7Hz), 2.79 (6H, s). 
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N’-(4-Dimethylamino-benzylidene)-N,N-dimethyl-hydrazone 
 
p-Dimethylamino-benzaldehyde (567 mg, 3.8 mmol) and 1,1-dimethylhydrazine 
(360 μL, 4.74 mmol, 1.25 equiv) were dissolved in methanol (10mL) and reacted 
according to the above General Reaction 5.  The yellow product solution was dissolved 
on the rotary evaporator to remove the solvent and remaining 1,1-dimethylhydrazine (bp 
62-64ºC), and the residue dried on vacuum overnight to afford a yellow solid product 
(662 mg, 3.46 mmol, 91% yield).  1H NMR (300MHz, d-DMSO) δ 7.36 (2H, d, J = 
8.7Hz), 7.27 (1H, s), 6.68 (2H, d, J = 8.7Hz), 2.90 (6H, s), 2.79 (6H, s) 
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(4-Pyridylmethylenamino)-guanidine Hydrochloride 
 
4-Pyridinecarboxaldehyde (160 mg, 1.5 mmol) and aminoguanidine 
hydrochloride (110 mg, 1.0 mmol) were dissolved in methanol (15 mL) and reacted 
according to the above General Reaction 4.  The product solution was dissolved on the 
rotary evaporator, and the residue was stirred in chloroform and filtered to remove the 
remaining starting material.  The filtered product was dried on vacuum overnight to 
afford an off-white powdery solid (171 mg, 0.86 mmol, 86 % yield).  Mp: 227-228ºC; 1H 
NMR (300MHz, DMSO-d6) δ 12.4 (1H, broad singlet), 8.65 (2H, m), 8.20 (1H, s), 8.0 
(NH, broad s), 7.85 (2H, m); 13CNMR (DMSO-d6) δ 155.4, 149.8, 144.1, 140.6, 121.2 . 
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(3-Pyridylmethylenamino)-guanidine Hydrochloride 
 
3-Pyridinecarboxaldehyde (160 mg, 1.5 mmol) and aminoguanidine 
hydrochloride (110 mg, 1.0 mmol) were dissolved in methanol (15 mL) and reacted 
according to General Reaction 4.  The product solution was dissolved on the rotary 
evaporator, and the residue was stirred in chloroform and filtered to remove the 
remaining starting material.  The filtered product was dried on vacuum overnight to 
afford an off white powdery solid (175 mg, 0.88 mmol, 88% yield).  Mp: 228-229ºC; 1H 
NMR (300MHz, D2O) δ 8.70 (1H, s), 8.54 (1H, d), 8.15 (1H, d), 8.0 (1H, s), 7.45 (1H, 
m).; 13C NMR δ 157.4, 152.6, 150.2, 147.6, 137.7, 132.0, 127. 
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Pyridine-4-carbaldehyde Semicarbazone 
 
4-Pyridinecarboxaldehyde (282.6 μL, 3.0 mmol) and semicabazide hydrochloride 
(223 mg, 2.0 mmol) were dissolved in methanol (10 mL) and reacted according to the 
above General Reaction 6.  Upon cooling, the product crashed out as a white precipitate 
(297 mg, 1.81 mmol, 91% yield).  1H NMR (300MHz, d-DMSO) δ 11.15 (1H, s), 8.80 
(2H, d, J = 8Hz), 8.32 (2H, d, J = 8Hz), 7.93 (1H, s), 6.94 (2H, broad s) 
 
JR-149 
N
N
H
NH NH2
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Pyridine-3-carbaldehyde Semicarbazone 
 
3-Pyridinecarboxaldehyde (282 μL, 3.0 mmol) and semicabazide hydrochloride 
(223 mg, 2.0 mmol) were dissolved in methanol (10 mL) and reacted according to the 
above General Reaction 6.  Upon cooling, the product crashed out as a white precipitate 
(274 mg, 1.67 mmol, 84% yield).  1H NMR (300MHz, d-DMSO) δ 10.73 (1H, s), 9.19 
(1H, s), 8.70 (2H, m), 7.92 (1H, s), 7.83 (1H, dd), 6.8 (2H, broad s) 
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Pyridine-4-carbaldeyde-dimethylhydrazone 
 
4-Pyridinecarboxaldehyde (283 μL, 3.0 mmol) and 1,1-dimethylhydrazine (274 
μL, 3.6 mmol) were dissolved in methanol (10 mL) and reacted according to the above 
General Reaction 5.  The yellow product solution was dissolved on the rotary evaporator 
to remove the solvent and remaining 1,1-dimethylhydrazine (bp 62-64ºC), and the residue 
dried on vacuum overnight to afford a light-orange solid product (371 mg, 2.49 mmol, 
83% yield). 1H NMR (300MHz, d-DMSO) δ 8.41 (2H, d, J = 8Hz), 7.40 (2H, d, J = 8Hz), 
7.13 (1H, s), 3.01 (6H, s) 
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Pyridine-3-carbaldeyde-dimethylhydrazone 
 
3-Pyridinecarboxaldehyde (282 μL, 3.0 mmol) and 1,1-dimethylhydrazine (274 
μL, 3.6 mmol) were dissolved in methanol (10 mL) and reacted according to the above 
General Reaction 5.  The light yellow product solution was dissolved on the rotary 
evaporator to remove the solvent and remaining 1,1-dimethylhydrazine (bp 62-64ºC), and 
the residue dried on vacuum overnight to afford a yellow liquid product (413 mg, 2.77 
mmol, 92% yield).  1H NMR (300MHz, d-DMSO) δ 8.64 (1H, s), 8.39 (1H, d, J = 5Hz), 
7.86 (1H, d, J = 6Hz), 7.35 (1H, dd, J = 5Hz, 6Hz), 7.27 (1H, s), 2.96 (6H, s) 
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Pyridine-2-carbaldehyde Semicarbazone 
 
2-Pyridinecarboxaldehyde (287 μL, 3.0 mmol) and semicabazide hydrochloride 
(223 mg, 2.0 mmol) were dissolved in methanol (10 mL) and reacted according to the 
above General Reaction 6.  Upon cooling the lime green solution, the product crashed out 
as a tan precipitate (284 mg, 1.73 mmol, 87% yield).  1H NMR (300MHz, d-DMSO) δ 
11.18 (1H, s), 8.86 (1H, d, J = 6Hz), 8.41 (1H, t J = 7Hz), 8.29 (1H, d, J = 7Hz), 7.98 
(1H, s), 7.80 (1H, t, J = 6Hz) 
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Pyridine-2-carbaldeyde-dimethylhydrazone 
 
2-Pyridinecarboxaldehyde (287 μL, 3.0 mmol) and 1,1-dimethylhydrazine (274 
μL, 3.6 mmol) were dissolved in methanol (10 mL) and reacted according to the above 
General Reaction 5.  The off-white product solution was dissolved on the rotary 
evaporator to remove the solvent and remaining 1,1-dimethylhydrazine (bp 62-64ºC), and 
the residue dried on vacuum overnight to afford a yellow liquid product (397 mg, 2.66 
mmol, 89% yield).  1H NMR (300MHz, d-DMSO) δ 8.43 (1H, d, J = 6Hz), 7.67 (2H, m), 
7.19 (1H, s), 7.16 (1H, m), 3.00 (6H, s) 
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N’-(4-Amino-benzylidene)-N,N-dimethyl-hydrazone 
 
4-Aminobenzaldehyde was prepared by the method of Bellamy and Ou 
(Tetrahedron Letters, Vol. 25 No. 8, 1984, pp. 839-842).  p-Nitrobenzaldehyde (755 mg, 
5 mmol) and tin(II) chloride dihydrate (5.64 g, 25 mmol) were refluxed at 70-75°C in 
ethanol (15 mL).  The solution turned dark red and opaque, and a TLC taken at 20 
minutes revealed that all aldehyde starting material had been consumed, and the solution 
was allowed to cool to ambient temperature.  The reaction mixture was then poured over 
30 mL of ice in a 50 mL beaker.  An aqueous solution of 5% sodium bicarbonate (30 mL) 
was added, which brought the effervescing reaction mixture to pH 3-5.  Extraction with 
ethyl acetate was impossible due to a lack of clear H2O/EtAc separation; an additional 
200 mL of the sodium bicarbonate solution was added until the effervescence deceased 
and the solution became yellow.  The ethyl acetate was removed, and the aqueous layer 
was again extracted with additional ethyl acetate.  The yellow organic layers were 
combined and rinsed twice with brine.  The ethyl acetate was boiled with charcoal, and 
filtered to yield a clear pale yellow liquid, which was then dried with sodium sulfate.  The 
ethyl acetate was removed on a rotary evaporator, then overnight on a vacuum pump to 
yield an orange solid which was identified as 4-aminobenzaldehyde.  This product (60 
mg, 0.5 mmol) and 1,1-dimethylhydrazine (48 μL, 0.63 mmol, 1.25 equiv) were 
dissolved in methanol (5 mL) and reacted according to the above General Reaction 5.  
The off-yellow product solution was dissolved on the rotary evaporator to remove the 
solvent and remaining 1,1-dimethylhydrazine (bp 62-64ºC), and the residue dried on 
vacuum overnight to afford a solid orange product (69 mg, 0.42 mmol, 85% yield).  1H 
NMR (300MHz, d-DMSO) δ 7.23 (1H, s), 7.21 (2H, d, J = 9Hz), 6.51 (2H, d, J = 9Hz), 
5.21 (2H, s), 2.77 (6H, s).  GC/MS: 14.997 min, 100.0%, m/z 163. 
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(4-Aminobenzylidenamino)-guanidine Hydrochloride 
 
4-Aminobenzaldehyde (60 mg, 0.5 mmol, prepared by the method of Bellamy and 
Ou, Tetrahedron Letters, Vol. 25 No. 8, 1984, pp. 839-842) and aminoguanidine 
hydrochloride (44mg, 0.4 mmol) were dissolved in methanol (10 mL) and reacted 
according to General Reaction 4.  The product solution was dissolved on the rotary 
evaporator, and the residue was stirred in chloroform and filtered to remove the 
remaining starting material.  The filtered product was dried on vacuum overnight to 
afford a light brown powdery solid (46 mg, 0.22 mmol, 55% yield).  Mp: 169-173ºC; 1H 
NMR (300MHz, d-DMSO) δ 11.42 (1H, s), 7.93 (1H, s), 7.50 (2H, d, J = 9Hz), 6.58 (2H, 
d, J = 9Hz), 5.74 (2H, s); 13C NMR (300MHz, d-D2O) δ 187.7, 152.3, 152.2, 131.9, 
126.0, 118.6; ES+ m/z 178. 
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N
H
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S
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2,4-Dihydroxy-benzaldehyde Thiosemicarbazone 
 
2,4-Dihydroxybenzaldehyde (414 mg, 3.0 mmol) and thiosemicabazide (182 mg, 
2.0 mmol) were dissolved in methanol (10mL) and reacted according to the above 
General Reaction 7.  Upon cooling, the product crashed out as a fine light-orange crystal 
precipitate (309 mg, 1.46 mmol, 73% yield).  1H NMR (300MHz, d-DMSO) δ 11.18 (1H, 
s), 8.22 (1H, s), 7.93 (1H, s), 7.75 (1H, s), 7.64 (1H, d, J = 8Hz), 6.26 (2H, m) 
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H
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4-Hydroxy-benzaldehyde Thiosemicarbazone 
 
4-Hydroxybenzaldehyde (366 mg, 3.0 mmol) and thiosemicabazide (182 mg, 2.0 
mmol) were dissolved in methanol (10 mL) and reacted according to the above General 
Reaction 7.  The product did not precipitate upon cooling to ambient temperature, and 
thus the solution was evaporated on a rotary evaporator, the resulting semi-solid stirred 
with chloroform to dissolve unreacted starting material, and the product filtered to yield a 
light yellow solid (322 mg, 1.64 mmol, 82% yield).  1H NMR (300MHz, d-DMSO) δ 
11.23 (1H, s), 8.03 (1H, broad s), 7.94 (1H, s), 7.81 (1H, broad s), 7.60 (2H, d, J = 8Hz), 
6.78 (2H, d, J = 8Hz) 
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4-Terephthalaldehyde Mono Thiosemicarbazone 
 
p-Terephthalaldehyde (489 mg, 3.0 mmol) and thiosemicabazide (182 mg, 2.0 
mmol) were dissolved in methanol (10 mL) and reacted according to the above General 
Reaction 7.  Upon cooling, the product crashed out as a light yellow solid precipitate (390 
mg, 1.83 mmol, 92% yield).1H NMR (300MHz, d-DMSO) δ 11.60 (1H, s), 9.98 (1H, s), 
8.32 (1H, broad s), 8.15 (1H, broad s), 8.08 (1H, s), 8.00 (2H, d, J = 9Hz), 7.89 (2H, d, J 
= 9Hz) 
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4-Amino-benzaldehyde Semicarbazone 
 
 4-Aminobenzaldehyde (60 mg, 0.5 mmol, prepared by the method of 
Bellamy and Ou, Tetrahedron Letters, Vol. 25 No. 8, 1984, pp. 839-842) and 
semicarbazide hydrochloride (45 mg, 0.4 mmol) were dissolved in methanol (10 mL) and 
reacted according to General Reaction 6.  Upon cooling the solution, the product crashed 
out as an orange powder precipitate (57 mg, 0.32 mmol, 80% yield). ).  1H NMR 
(300MHz, d-DMSO) δ 7.86 (2H, d, J = 9Hz), 7.74 (1H, s), 7.58 (2H, d, J = 9Hz), 6.94 
(2H, d), 6.79 (2H, d), 6.62 (1H, d). 
 
 
 107
 
JR-197 
N
H
NH2
N
H
NH2
NH2 Cl
 
(3-Aminobenzylidenamino)-guanidine Hydrochloride 
 
3-Aminobenzaldehyde was prepared by the dropwise addition of 2.0 M HCl in 
ethanol (6.0 mL) to the corresponding 3-aminobenzaldehyde ethylene acetal (902 mg, 
5.97) in methanol (34 mL).  The reaction solution darkened with the acid addition, from 
very pale orange to dark yellow, and during stirring at room temperature for 30 minutes, 
the color returned to a light orange, and TLC revealed a completed reaction.  
Aminoguanidine hydrochloride (111 mg, 1.0 mmol) was added to a 15-mL sample of the 
methanolic reaction solution (0.176 M, 2.64 mmol aldehyde), and the mixture refluxed 
for 3 hours.  The reaction was then cooled to room temperature, and fine tan crystals 
(35.5 mg, 0.16 mmol, 16% yield) crashed out of solution, which were collected and 
rinsed with cold methanol.  Mp: 240-246ºC; 1H NMR (300MHz, d-DMSO) δ 12.14 (1H, 
s), 8.20 (1H, s), 7.84 (1H, d, J = 7.8Hz), 7.63 (1H, s), 7.49 (1H, t, J = 7.8Hz), 7.36 (1H, d, 
J = 7.8Hz); 13C NMR δ 155.2, 145.8, 134.6, 129.8, 124.7, 123.5, 120.9; ES+ m/z 178. 
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JR-199 
N
H
NH
H2N
NH2
O
 
3-Amino-benzaldehyde Semicarbazone 
 
3-Aminobenzaldehyde was prepared by the dropwise addition of 2.0M HCl in 
ethanol (6.0 mL) to the corresponding 3-aminobenzaldehyde ethylene acetal (902 mg, 
5.97 mmol) in methanol (34 mL).  The reaction solution darkened with the acid addition, 
from very pale orange to dark yellow, and during stirring at room temperature for 30 
minutes, the color returned to a light orange, and TLC revealed a completed reaction.  
Semicarbazide hydrochloride (112 mg, 1.0 mmol) was added to a 9-mL sample of the 
methanolic reaction solution (0.176 M, 1.58 mmol aldehyde), and the mixture refluxed 
for 3 hours.  Upon cooling the solution, the product crashed out as an off-white powder 
precipitate (65 mg, 0.37 mmol, 37% yield).  1H NMR (300MHz, d-DMSO) δ 10.38 (1H, 
s), 7.83 (1H, s), 7.65 (1H, d, J = 7.8 Hz), 7.52 (1H, s), 7.42 (1H, t, J = 7.8Hz), 7.23 (1H, 
d, J = 7.8Hz), 6.51 (2H, broad s). 
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JR-200 
N
H
NH
H2N
NH2
S
 
3-Amino-benzaldehyde Thiosemicarbazone 
 
3-Aminobenzaldehyde was prepared by the dropwise addition of 2.0M HCl in 
ethanol (6.0 mL) to the corresponding 3-aminobenzaldehyde ethylene acetal (902 mg, 
5.97 mmol) in methanol (34 mL).  The reaction solution darkened with the acid addition, 
from very pale orange to dark yellow, and during stirring at room temperature for 30 
minutes, the color returned to a light orange, and TLC revealed a completed reaction.  
Thiosemicarbazide (112 mg, 1.0 mmol) was added to a 9-mL sample of the methanolic 
reaction solution (0.176 M, 1.58 mmol aldehyde), and the mixture refluxed for 3 hours.  
Upon cooling, the product crashed out as a light brown powder solid precipitate (61 mg, 
0.31 mmol, 31% yield).  1H NMR (300MHz, d-DMSO) δ 9.96 (1H, s),7.3-7.7 (5H, m), 
6.18 (2H, s). 
 
AH-1 
N
NH NH2
NH
H Cl
 
Pyridin-2-yl-guanidine Hydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR (300MHz, 
d-DMSO) δ 9.50 (1H, s, broad), 8.05 (1H, s), 7.85 (1H, m,), 7.75 (1H, m), 7.62 (1H, d, J 
= 0.03Hz). 
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AH-2 
N
NH NH2
NH
H Cl
 
Pyridin-3-yl-guanidine Hydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR (300MHz, 
d-DMSO) δ 9.036 (1H, d, J=0.008), 7.961 (1H, d, J=0.002Hz), 7.759 (1H, m, J = 
0.005Hz), 7.73 (1H, m, J=0.01Hz), 6.69 (2H, s, broad). 
 
AH-3 
N
H
NH2
NH
H Cl
N
 
N-Pyridin-2-ylmethyl-guanidine Hydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR (300MHz, 
d-DMSO) δ 11.50 (2H, s, broad), 8.80 (1H, d, J=0.018Hz), 8.425 (1H, t, J = 
0.021Hz), 8.356 (1H, t, J=0.025), 7.781 (1H, t, J = 0.021Hz), 7.70 (2H, s, broad),  4.811 
(2H, d, J=0.02Hz). 
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AH-4 
N
H
NH2
NH
H Cl
N  
N-Pyridin-3-ylmethyl-guanidine Hydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR (300MHz, 
d-DMSO) δ 8.91 (1H, s), 8.88 (1H, d, J=0.018Hz), 8.688 (1H, t, J = 0.02Hz), 8.516 (1H, 
d, J=0.015Hz), 8.084 (1H, t, J = 0.021Hz), 7.68 (2H, s, broad), 4.711 (2H, 
d, J=0.021Hz).  
 
AH-5 
N
H
NH 2
NH
H Cl
N
 
N-Pyridin-4-ylmethyl-guanidine Hydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR (300MHz, 
d-DMSO) δ 8.92 (1H, d, J=0.021Hz), 8.758 (1H, t, J=0.02Hz), 7.91 (1H, d, J =0.021Hz), 
7.727 (2H, s, broad), 4.842 (2H, d, J = 0.021Hz). 
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AH-6 
N
NH NH 2
NH
H Cl
NH
NH
H2N
H Cl
 
2,3-Di-N-guanidyl-pyridine Dihydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR (300MHz, 
d-DMSO) δ 9.62 (1H, s), 8.262 (1H, s, broad), 8.031 (1H, d, J = 0.02Hz), 7.92 (1H, d, 
J=0.014Hz), 7.685 (3H, s), 6.894 (1H, t, J = 0.022Hz), 3.84 (2H, s, broad). 
 
AH-7 
N
H
NH2
NH
H Cl
O
H3C
 
N-(4-Methoxy-benzyl)-guanidine Hydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR (300MHz, 
d-DMSO) δ 9.07(1H, s, broad), 8.20 (1H, s, broad), 7.077 (2H, s, broad), 6.918 (2H, 
m), 6.808 (2H, m), 3.691 (3H, s). 
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AH-8 
N
H
NHH2N
NH
H Cl
 
N-(1H-Indol-5-yl)guanidine Hydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR (300MHz, 
d-DMSO) δ 9.90 (1H, s, broad), 8.10 (2H, s, broad), 8.026 (1H, s) 8.00 (1H, d, 
J=0.044Hz),  7.50 (1H, m, J=0.04Hz), 7.256 (1H, s), 6.928 (1H, m) 
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AH-9 
N
NH NH2
NH
H Cl
NH
NH
H2N
H Cl
 
3,4-Di-N-guanidyl-pyridine Dihydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR (300MHz, 
d-DMSO) δ 11.07 (1H, s), 8.398 (1H, s), 8.138 (1H, s), 6.964 (1H, d, J=0.02), 6.10 (3H, 
s, broad). 
 
AH-10 
NH NH2
NH
H Cl
N
 
N-(2-pyrrolidin-1-yl-ethyl)-guanidine Hydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR 
(300MHz, d-DMSO) δ 10.25 (1H, s, broad), 7.12 (2H, s, broad), 4.13 (1H, s, broad), 
3.475 (2H, m, J=0.02Hz), 3.23 (2H, d, J = 0.02Hz), 2.750 (2H, d, J = 0.014Hz)  2.21 (2H, 
m),  1.908 (2H, m). 
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AH-13 
NH NH2
NH
H Cl
N
CH3  
N-[2-(1-methyl-pyrrolidin-2-yl)-ethyl)-guanidine Hydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR 
(300MHz, d-DMSO) δ 11.02 (1H, s), 7.12 (2H, s, broad), 4.13 (1H, s, broad), 3.475 (2H, 
m, J=0.02Hz), 3.23 (2H, d, J = 0.02Hz), 2.75 (2H, d, J = 0.014Hz),  2.21 (2H, m), 1.908 
(2H, m).   
 
AH-14 
N
NH NH2
NH
H Cl
Cl  
5-Chloro-pyridin-2-yl-guanidine Hydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR 
(300MHz, d-DMSO) δ  9.20 (1H, d, J=0.08), 8.331 (1H, s), 7.99 (1H, d, J = 0.02Hz), 
7.045 (1H, d, J=0.03), 6.45 (2H, s, broad). 
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AH-15 
HNCl
NH
NH2
H Cl
 
N-(7-Bromo-fluoren-2-yl)guanidine Hydrochloride 
 
 Prepared using General Reaction 1 above by Aaron Haubner.  1H NMR (300MHz, 
d-DMSO) δ 11.43 (1H, s), 10.14 (1H, s),  7.907 (2H, s), 7.88 (2H, s), 7.84 (2H, s)  7.818 
(2H,m),  7.772 (2H,m),  7.579 (2H,m). 
 
AH-16 
N
H
N
N
H
H I
N  
N-(Pyridin-3-yl)-methyl-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-amine Hydriodide 
 
 Prepared using General Reaction 2 above by Aaron Haubner.  1H NMR 
(300MHz, d-DMSO) δ 8.55 (1H, s), 8.521 (1H, d, J=0.02Hz), 7.71 (1H, d, J = 0.035Hz), 
7.43 (1H, m), 6.02 (2H,s,broad),  4.370 (2H,s),  3.255 (4H, t, J=0.025 Hz),  3.074 (2H, m, 
J=0.02). 
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Arcaine sulfate 
N
H
NH2
NH2
H
NH2N
NH2
SO4
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Memantine hydrochloride 
CH3
H3C
NH3Cl
 
 Purchased from commerial sources 
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MK-801 (Dizocilpine) 
NH
 
 Purchased from commercial sources 
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CHAPTER 3:  LEAD OPTIMIZATION: SYNTHESIS AND EVALUATION OF 
ARYLIDENAMINO-GUANIDINES 
 
3.1 Introduction 
 
 After the synthesis of a library of several hundred agmatine analogs, and their 
subsequent screening and analysis, it became clear that the most consistently active series 
of compounds was the arylidenamino-guanidines.  The nine compounds in the JR-series 
(JR-121, JR-122, JR-124, JR-125, JR-132, JR-146, JR-147, JR-160, and JR-197) were 
examined in the assays reported in chapter 2, and in addition, twenty arylidenamino-
guanidines were synthesized by Dr. Sundar Neelakantan and screened using the same 
procedure as the others (the two pyridyl compounds were synthesized in each series, but 
each were screened to give significantly similar data).  All 27 of the unique compounds 
were active in this assay, an impressive 100% hit rate.  These data suggested the 
importance of further examination of this class of compounds, which began with a close 
look at the structural motif from which each of these molecules were derived, i.e. 
aminoguanidine. 
Aminoguanidine hydrochloride, an agmatine analog which is devoid of the n-
butyl chain, has been shown to be quite active in several aspects of neurobiology, which 
are closely related to polyamines.  The activity of this compound was first shown in the 
inhibition of diamine oxidase, or histaminase, which is responsible for the deamination of 
histamine as well as the polyamine putrescine (Sculer, 1952).  More recently, 
aminoguanidine has been demonstrated in the alleviation of several of the effects of 
diabetes, due to inhibition of advanced glycosylation end products (Brownlee et al., 
1986).  It has also been shown to inhibit nitric oxide synthase in vivo and in vitro (Corbett 
et al., 1992), the enzyme which catalyzes the biosynthesis of the neurotransmitter nitric 
oxide (NO) from L-arginine (also the amino acid at the top of the polyamine pathway).   
 Aminoguanidine also directly impacts the levels of the polyamines spermidine 
and spermine by affecting the activity of S-adenosylmethionine decarboxylase 
(SAMDC).  SAMDC is the enzyme responsible for the conversion of S-
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adenosylmethionine to decarboxylated S-adenosylmethionine, which acts as the donor of 
the aminopropyl group that is joined to putrescine to form spermidine, and thence to 
spermidine to form putrescine.  Aminoguanidine at concentrations of ~1mM has been 
shown to stabilize SAMDC, and increase its levels and activity in mouse cell lines 
(Stjernborg and Persson, 1993). 
Aminoguanidine has also been examined as a possible antagonist of the NMDA 
receptor complex, and has been shown to have no activity in the [3H]MK-801 
displacement assay in P2 membrane (see Figure 3.1).  However, conjugates of 
aminoguanidine and an array of arylaldehydes were synthesized and screened in the 
above assay, and of the 45 compounds tested, all have demonstrated to be NMDA 
receptor inhibitory modulators.  The lack of aminoguanidine activity in this assay is 
important for two reasons: 
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Figure 3.1 [3H]MK-801-displacement activity of aminoguanidine hydrochloride 
 
 Firstly, the activity seen by the arylidenamino-guanidines is indeed due to the 
products, and not the aminoguanidine hydrochloride starting material.  The proportions of 
starting materials used in the synthesis are chosen in such a way that aminoguanidine is 
the limiting reagent, as it is difficult to separate from the final product by 
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chromatography.  While the products are mostly crystalline and appear to be very pure 
under scrutiny of 1H and 13C NMR, these analytical methodologies do little to display 
such a small compound without C-H bonds.  In D2O, deuterium exchange will render this 
molecule invisible to proton NMR, and even d-DMSO, the N-H peaks are hardly 
discernable as usually broader peaks which overlap the corresponding product peaks.  In 
carbon NMR spectra, the peak for the lone quaternary carbon in this molecule is quite 
small even at a high concentration; even in the product which constitutes the vast 
majority of the compound in solution, the corresponding peak is very small, thus at a 5% 
starting material impurity, aminoguanidine would also be virtually invisible.   
Secondly, the lack of activity of aminoguanidine is interesting in that it 
demonstrates that while it has been demonstrated to be a required moiety for the activity 
of the arylidenamino-guanidines (while semicarbazine, thiosemicarbazine, and 
dimethylhydrazine failed in the same position), this molecule itself does not possess any 
inhibitory activity.  Indeed, this structure is the only entirely conserved moiety in a set of 
45 active compounds, thus this observation may reveal much about the structure-activity 
of at least one of the polyamine binding sites of the NMDA receptor complex. 
 In order to further evaluate the usefulness of these compounds towards the 
specific goals of creating and optimizing agmatine analogs for use in NMDAR 
modulation, it was determined that a larger amount of similar compounds should be 
synthesized and tested.  For the existing set of 27 arylidenamino-guanidines, full dose-
response curves were obtained from the P2 membrane [3H]MK-801 displacement assay, 
as described below.  Using these data and 12 molecular descriptors, a partial least squares 
(PLS) model was developed, with an R-value for correlation of predicted vs. observed 
pIC50-values of 0.902.  This PLS model along with the subsequent full neural network 
model are described in detail in Chapter 5 of this work. 
 A set of an additional 22 arylidenamino-guanidine compounds were designed, 
each with predicted IC50 values of less than 100 μM according to the above model.  These 
compounds were then synthesized using the same synthetic schemes laid forth in Chapter 
2, and yielded a set of 18 new molecules.  These molecules were then tested as possible 
NMDAR inhibitory modulators, as well as being utilized in an effort to verify the 
developed PLS model, and provide a sufficient amount of data to produce a neural 
 124
network model.  The synthesis of these molecules and the evaluation of the entire final 
set of 45 arylidenamino-guanidines are described below. 
 
 
3.2 Synthetic Chemistry 
 
 The general method for preparation of arylidenamino-guanidines proceeds as 
follows: Aminoguanidine hydrochloride (1 equivalent) and an aryl aldehyde (1.5-2 
equivalents) are dissolved in a minimal amount of methanol.  The solution is then heated 
to reflux and stirred for a period of 4-12 hours with TLC monitoring until the 
aminoguanidine hydrochloride is consumed.  Upon cooling to room temperature, the 
corresponding arylidenamino-guanidine is separated from the remaining aryl aldehyde.  
In some cases, the product crystallizes from the methanol solution during cooling, in 
which case the product is filtered and rinsed with methanol and chloroform.  In most 
cases, the product would remain in solution upon cooling, and the solution is then 
removed on a rotary evaporator.  The resulting solid or semi-solid is then stirred at room 
temperature in chloroform or diethyl ether, into which the remaining aryl aldehyde 
dissolves, and the remaining solid arylidenamino-guanidine is filtered and washed with 
the corresponding rinsing solution.  Products are allowed to dry on filter plates, and then 
placed until vacuum overnight to remove any remaining solvent. 
 
Ar MeOH
N
H
NH2
NH2
N
H
NH2
NH2
Cl
O
H
H2N
Cl
NR
H  
Scheme 3.1 One-step synthesis of arylidenamino-guanidines from aldehydes 
 
 The structures of all of the following compounds were verified using 1H NMR 
and 13C NMR, and in some cases mass spectroscopy; melting points were also obtained 
for each product. 
 125
 
 
3.3 Pharmacology 
 
Each of these compounds were screened for their ability to reduce the binding of 
[3H]MK-801 in a P2 membrane preparation, comprised of membrane-bound proteins 
including the NMDA receptor complex.  The range of concentrations tested spanned an 
ample region to generate full dose-response curves in the absence and presence of 
spermidine. 
The pharmacological assay utilized P2 brain membrane homogenate from male 
Sprague-Dawley rats (225-250 grams) and radiolabeled MK-801 in order to measure 
reduction of this bound ligand due to addition of a modulating agent.  The P2 membrane 
was prepared from a homogenized mixture of rat cortex, hippocampus, and cerebellum in 
50 mM Trizma acetate buffer containing 0.32 M sucrose at pH 7.25.  This crude 
homogenate was centrifuged for 10 minutes at 4°C and 2800 rpm in a Sorvall RC 26 Plus 
centrifuge, after which the supernatant was saved and the procedure was repeated with 
the pellet dissolved into cold buffer with sucrose.  The combined supernatants were then 
centrifuged for 20 minutes at 4°C and 20,500 rpm on the same instrument.  The 
supernatant was decanted, and the pellet retained and resuspended in 50 mM Trizma 
acetate buffer at pH 7.25, without sucrose.  Another 20-minute centrifugation was 
performed on the resuspended pellet with the above parameters, and two additional 10-
minute washings, with the pellet retained between each.  After these washings, the 
membrane was again suspended in the above buffer without sucrose, and the protein 
concentration determined using Pierce reagent. Aliquots of 15 mg of the concentrated P2 
membrane preparation were dispensed into cryo-tubes, which were then stored at -80°C.  
With this amount of protein per tube, the final protein concentration could easily be 
brought to 1.5 mg/mL buffer by the addition of sufficient 50 mM Trizma acetate buffer at 
pH 7.25 to bring the total solution volume to 10 mL. 
The working [3H]MK-801 solution is prepared by the addition of 30 μM [3H]MK-
801 in ethanol (2 μL) to the Trizma buffer (10 mL).  In order to determine the 
concentration of [3H]MK-801 in this working solution, 100μL was dispensed into 2.5 mL 
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of Microscint 20 in duplicate, and the counts per minute (CPM) were measured on the 
scintillation counter.  As the stock ethanolic MK-801 solution slowly evaporated and 
became more concentrated, this procedure was necessary in order to calculate further 
buffer dilutions of the working solution necessary to obtain the desired 6.0nM 
concentration. 
Samples were dissolved in buffer to make 19 mM stock solutions (for a final well 
concentration of 3.16 mM, or 10-2.5 M), and were diluted serially with 2.16 equivalents of 
buffer six times, to give final well concentrations at every 10-0.5 M decrement, down to 
3.16 μM, or 10-5.5 M.  In some cases, the compounds were not soluble at 19 mM, and 
stock solutions were prepared at lower concentrations.   
The assay was performed at ambient room temperature in 96-well micro-titer 
plates with a total capacity of 350 μL per well.  To each well was added 100μL P2 
membrane, thawed on ice and brought to the final concentration of 1.5mg/mL as 
described above.  A blank control was measured in triplicate using only freshly-prepared 
50 mM Trizma acetate buffer at pH 7.25.  A 100 μM spermidine-potentiated control and 
1 mM dextromethorphan control to measure non-specific binding were each performed in 
triplicate as well.  The seven prepared concentrations of the compound being tested 
(50μL, n = 3) were added to the plate, with each sample being added in two separate sets: 
spermidine (50μL, 600μM) was added to one set for a potentiated curve and buffer 
(50μL) to the other set to obtain a non-potentiated curve.  The plates were then allowed to 
incubate for 15 minutes in order to establish the equilibrium between the spermidine and 
samples, after which 100μL [3H]MK-801 ligand (6nM) was added to each well for a total 
of 300μL.  All micro-titer plates were allowed to incubate for 40 minutes following 
[3H]MK-801 addition, and were then harvested into filter plates, which were then dried 
overnight in the hood at ambient temperature.  After 12-16 hours, 35μL of Microscint 20 
was added to each membrane on the dried filter plate; each plate was sealed and then 
incubated for two hours before reading on a plate counter. 
 For each compound, the potentiated and non-potentiated curves were plotted, and 
IC50-values with and without spermidine were determined using GraphPad software.  A 
third value, the IC50pot, was derived as the point on the spermidine-potentiated curve 
which was halfway between the spermidine-potentiated control and the buffer control.  
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This value corresponds to the concentration of compound needed to displace half of the 
[3H]MK-801 bound due to the channel-agonist effects of spermidine.  Some of the tested 
compounds demonstrated IC50-values which were too low to be accurately gleaned in the 
previously mentioned concentration range; these compounds were prepared in a lower-
concentration stock solution and re-evaluated at a lower range.  In addition, agmatine and 
NMDAR antagonists arcaine, memantine, and MK-801 were evaluated by the same 
methods.   
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Table 3.1 IC50-values in the presence and absence of spermidine, 
and IC50 of potentiation 
Compound Structure IC50 w/  SPD1
IC50 w/o  
SPD2 IC50
Pot 3 RatioPot
# (Code)  (μM) (μM) (μM)  
1 
(AG-17) 
N
H
N
H
NH2
NH2 Cl
 
232.1 339.4 73.1 4.6 : 1 
2 
(AG-6) 
N
H
N
H
NH2
NH2 Cl
H3C
 
156.4 149.6 80.7 1.9 : 1 
3 
(JR-202) N
H
N
H
NH2
NH2 Cl
 
30.7 27.8 6.0 4.6 : 1 
4 
(JR-212) 
N
H
N
H
NH2
NH2 Cl
 
97.5 105.8 42.5 2.5 : 1 
5 
(JR-211) N
H
N
H
NH2
NH2 Cl
 
65.0 71.9 22.8 3.2 : 1 
6 
(JR-124) N
H
N
H
NH2
NH2 Cl
C
N
 
131.3 81.4 43.4 1.9 : 1 
7 
(JR-125) N
H
N
H
NH2
NH2 Cl
C
N
 
442.5 414.4 231.2 1.8 : 1 
8 
(JR-226) N
H
N
H
NH2
NH2 Cl
O O
H3C
 
280.2 327.5 71.1 4.6 : 1 
9 
(JR-227) N
H
N
H
NH2
NH2 ClO
O
H3C
 
138.5 143.2 72.4 2.0 : 1 
10 
(AG-20) 
N
H
N
H
NH2
NH2 Cl
CF3  
67.2 71.1 25.1 2.8 : 1 
 
1 - IC50 w/ SPD: the measurement of IC50 derived from the data collected in the spermidine-potentiated [3H] MK-801 
displacement assay. 
2 - IC50 w/o SPD: the measurement of IC50 derived from the data collected in the non-spermidine-potentiated [3H] MK-
801 displacement assay, in which the spermidine solution was replaced with buffer. 
3 - IC50 of Pot: from the spermidine-potentiated curve, the concentration corresponding to one-half of the difference in 
DPM between the SPD-potentiated control and the blank control. 
* - This measurement is the IC50 of the lower phase, as these SPD-potentiated curves were clearly biphasic in nature. 
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Table 3.1 (cont.) IC50-values in the presence and absence of spermidine, 
and IC50 of potentiation 
 
Compound Structure IC50 w/  SPD1
IC50 w/o  
SPD2 IC50
Pot 3 RatioPot
# (Code)  (μM) (μM) (μM)  
11 
(AG-13) 
N
H
N
H
NH2
NH2 Cl
OHHO
 
311.2 289.9 167.5 1.7 : 1 
12 
(AG-12) 
N
H
N
H
NH2
NH2 Cl
O
H3C  
61.9 62.3 12.8 4.9 : 1 
13 
(AG-8) 
N
H
N
H
NH2
NH2 Cl
O
H3C
 
150.9 118.6 34.7 3.4 : 1 
14 
(AG-10) 
N
H
N
H
NH2
NH2 Cl
O
O
H3C
H3C
 
64.9 69.2 28.8 2.4 : 1 
15 
(JR-197) N
H
NH2
N
H
NH2
NH2 Cl
 
654.6 778.9 199.5 3.9 : 1 
16 
(JR-160) 
N
H
N
H
NH2
NH2 Cl
H2N
 
269.4 120.2 104.2 1.2 : 1 
17 
(JR-219) N
H
N
H
NH2
NH2 Cl
N
CH 3
H3C
 
71.7 94.4 7.9 11.9 : 1 
18 
(JR-122) N
H
N
H
NH 2
NH2 Cl
N
OO
 
325.9 293.8 149.3 2.0 : 1 
19 
(JR-121) N
H
N
H
NH2
NH 2 Cl
N
O
O
 
169.4 218.7 78.0 2.8 : 1 
20 
(JR-228) N
H
N
H
NH2
NH2 Cl
O
H3C
OH
 
157.9 161.7 63.1 2.6 : 1 
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Table 3.1 (cont.) IC50-values in the presence and absence of spermidine, 
and IC50 of potentiation 
 
 
Compound Structure IC50 w/  SPD1
IC50 w/o  
SPD2 IC50
Pot 3 RatioPot
# (Code)  (μM) (μM) (μM)  
21 
(JR-223) N
H
N
H
NH2
NH2 Cl
N
OO
O
H3C
 
259.4* 219.8 7.8 28.2 : 1 
22 
(JR-218) 
N
H
N
H
NH2
NH2 Cl
Cl
 
41.2 52.6 7.1 7.4 : 1 
23 
(JR-217) N
H
N
H
NH2
NH2 Cl
Cl
 
78.7 117.6 18.4 6.4 : 1 
24 
(JR-220) 
N
H
N
H
NH2
NH2 Cl
Cl
 
124.5* 124.5 3.6 34.6 : 1 
25 
(AG-9) 
N
H
N
H
NH2
NH2 Cl
Cl Cl
 
49.7 42.3 10.2 4.1 : 1 
26 
(AG-23) 
N
H
N
H
NH2
NH2 Cl
F
 
206.5 225.5 74.9 3.0 : 1 
27 
(AG-18) 
N
H
N
H
NH2
NH2 Cl
F
 
177.8 265.4 66.1 4.0 : 1 
28 
(AG-24) 
N
H
N
H
NH2
NH2 Cl
FF
 
125.6 109.4 55.2 2.0 : 1 
29 
(JR-209) 
N
H
N
H
NH2
NH2 Cl
 
25.7 13.6 8.5 1.6 : 1 
30 
(AG-4) N
H
N
H
NH2
NH2 Cl
 
46.4 46.6 21.4 2.2 : 1 
 
 
 131
Table 3.1 (cont.) IC50-values in the presence and absence of spermidine, 
and IC50 of potentiation 
 
 
Compound Structure IC50 w/  SPD1
IC50 w/o  
SPD2 IC50
Pot 3 RatioPot
# (Code)  (μM) (μM) (μM)  
31 
(JR-213) N
H
N
H
NH2
NH2 Cl
 
117.8* 77.2 8.7 8.9 : 1 
32 
(JR-203) N
H
N
H
NH2
NH2 Cl
CH3  
47.6 38.6 26.5 1.5 : 1 
33 
(JR-204) N
H
N
H
NH2
NH2 Cl
H 3C
 
48.9 80.3 11.5 7.0 : 1 
34 
(AG-19) N
H
N
H
NH2
NH2 Cl
O
O
 
91.3 118.4 38.5 3.1 : 1 
35 
(AG-15) 
N
H
N
H
NH2
NH2 Cl
ON
O
O
154.9 226.5 109.4 2.1 : 1 
36 
(AG-2) 
N
H
N
H
NH2
NH2 ClN
H
 
279.6 443.7 59.3 7.5 : 1 
37 
(AG-1,  
JR-147) 
N N
H
N
H
NH2
NH2 Cl
 
855.0 835.5 464.5 1.8 : 1 
38 
(AG-11, 
JR-146) 
N
N
H
N
H
NH2
NH2 Cl
 
1355 1428 539.5 2.6 : 1 
39 
(AG-3) N
H
N
H
NH2
NH2 ClN
H
 
115.1 173.0 36.9 4.7 : 1 
40 
(JR-207) N
H
N
H
NH2
NH2 Cl
HN
 
102.6 64.6 50.6 1.3 : 1 
 
 
 132
Table 3.1 (cont.) IC50-values in the presence and absence of spermidine, 
and IC50 of potentiation 
 
 
Compound Structure IC50 w/ SPD1
IC50 w/o 
SPD2 IC50
Pot 3 RatioPot
# (Code)  (μM) (μM) (μM)  
41 
(JR-214) N
H
N
H
NH2
NH2 ClN
CH3
 
121.5 175.4 48.8 3.6 : 1 
42 
(JR-215) N
H
N
H
NH2
N H2 ClN
H
H3C
 
101.9 75.5 32.9 2.3 : 1 
43 
(AG-5) 
N
H
N
H
NH2
NH2 Cl
S
 
334.8 290.1 117.2 2.5 : 1 
44 
(AG-14) 
N
H
N
H
NH2
NH2 Cl
 
149.6 162.9 58.3 2.8 : 1 
45 
(JR-132) 
N
N
H
N
H
H2N
NH 2
H
H
N NH2
NH2 Cl
Cl 67.4 32.1 32.2 1.0 : 1 
      
Agmatine 
N
H
NH2
NH2
H3N
SO4
 
902.3 1296 274.2 4.7 : 1 
Arcaine N
H
NH2
NH2
H
NH2N
NH2
SO4
101.1 104.4 33.1 3.2 : 1 
Memantine 
CH3
H3C
NH3Cl
 
4.77 3.53 0.73 4.8 : 1 
MK-801 NH
 
5.58 nM 5.92 nM 2.19 nM 2.7 : 1 
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3.4 Results and Discussion 
 
3.4.1 Synthesis of the Optimized Set of Arylidenamino-Guanidines 
 
 Following the success of the previously prepared and screened arylidenamino-
guanidines, an additional 22 compounds were designed based on additional structural 
diversity and the IC50-values predicted for them from the PLS model.  As with so many 
of the best-laid plans of Sprague-Dawley rats and men, the finalized set of 18 compounds 
which were tested in the radioligand displacement assay were not the same as these 22 
originally designed, but they introduced many new structural entities to this set of 
arylidenamino-guanidines nonetheless. 
 The synthesis of a meta-vinyl substituted benzylidenamine (JR-201, (3-vinyl-
benzylidenamino)-guanidine hydrochloride) was unsuccessful, possibly due to 
polymerization of the reactive vinyl substituent.  In addition, the use of 2- and 4-
imidazole groups as the aromatic moiety of the arylaldehyde did not proceed via the 
facile Schiff base formation.  These starting materials, 2-imidazolecarboxaldehyde and 
4(5)-imidazolecarboxaldehyde, may exist in resonance forms which leave the aldehyde 
less reactive to the Schiff base formation with aminoguanidine. 
 While (2-biphenyl-carboxylidenamino)-guanidine hydrochloride (JR-209) was 
prepared and evaluated in this assay without impediment, the 4-isomer (JR-208, (4-
biphenyl-carboxylidenamino)-guanidine hydrochloride) was prepared and identified as 
the desired product, but was completely water-insoluble.  This was an unforeseen 
conundrum which did not manifest itself in any of the other arylidenamino-guanidines.  
While biphenyl is understandably not highly hydrophilic, it was indeed curious that the 
addition of the idenamino-guanidine moiety at the 2-position would render the biphenyl 
analog water-soluble, but that addition at the 4-position would not. 
 The solubility problem was also seen with the three carboxy-substituted 
compounds in this series.  (2-Carboxybenzylidenamino)-guanidine hydrochloride (JR-
221), (3-carboxybenzylidenamino)-guanidine hydrochloride (JR-210), and (4-
carboxybenzylidenamino)-guanidine hydrochloride (JR-222) were all prepared as clean 
products.  Each of these compounds would be predicted to form water-soluble 
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zwitterions; however, none of these three products proved to be even sparingly soluble in 
the prepared buffer.  Thus, while these three compounds were not testable, the conversion 
of the carboxyl groups of the meta- and para-compounds into the corresponding methyl 
esters via treatment with thionyl chloride in methanol resulted in 
benzylidenaminoguanidine-3-methyl ester hydrochloride (JR-226, compound 8) and 
benzylidenaminoguanidine-4-methyl ester hydrochloride (JR-227, compound 9), 
respectively, which were readily soluble in buffer.  The conversion of JR-221 to the 
corresponding ortho-methyl ester compound did not proceed, possibly due to steric 
hindrance around the carboxyl group. 
 In addition to the two methyl ester compounds, a third unplanned addition to this 
series was (4-methoxy-3-hydroxybenzylidenamino)-guanidine hydrochloride (JR-228, 
compound 20).  This compound was synthesized after the preparation and testing of JR-
201 through JR-223, because of the structural similarity to (4-methoxy-2-
nitrobenzylidenamino)-guanidine hydrochloride (JR-223, compound 21), which 
displayed interesting activity in the [3H[MK-801 displacement assay, as described in 
Section 3.4.2. 
 
3.4.2 Evaluation of the Full Set of Arylidenamino-Guanidines as Modulatory Inhibitors 
 
 The set of forty-five arylidenamino-guanidino compounds were each evaluated at 
seven concentrations ranging from 16 mM to 1.0 μM, as described in Section 3.3 above.  
Further details of their analysis are prefaced in Section 2.4.3 of Chapter 2.  Each of the 
arylidenamino-guanidines were renumbered in order to compare them in a more natural 
progression, roughly corresponding to electronegativity of substitutions.  Therefore, 
similar groups of compounds are numbered together, in order to ease comparison of the 
effects of similar ring substituents on NMDAR inhibitory activity. 
 There were twenty-eight substituted benzylidenamine-guanidine compounds that 
incorporated only one aromatic moiety (compounds 1-28), with a wide range of attached 
groups.  These compounds were synthesized and examined in the comparative dose-
response curve assay.  The compounds were either mono- or di-substituted at different 
positions around the benzene ring; structure-activity relationship information can be 
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gained by comparing and contrasting the IC50pot and Ratiopot values of these substituted 
benzyl compounds with those of the unsubstituted benzylidenamino-guanidine. 
Compound 1, (benzylidenamino)-guanidine hydrochloride, incorporated an 
unsubstituted benzene ring.  This compound had a 73.1 μM IC50pot, and a 4.6:1 Ratiopot.  
While the potency is not exceptional, the selectivity garnered from the Ratiopot is close to 
that of agmatine, which is surprising, considering that there are no attached groups which 
could interact in the same way as the terminal amino group.  This compound serves as a 
good basis from which to compare the effects of additional groups on their potency and 
selectivity. 
 
N
H
N
H
NH2
NH2 Cl
 
Compound 1 
IC50pot = 73.1 μM 
Ratiopot = 4.6 : 1 
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Figure 3.2 Dose-response curves generated by compound 21, in 
the presence and absence of 100 μM spermidine 
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 Four aliphatic-substituted benzylidenamino-guanidines were prepared, all with 
substitutions at the para-position.  These compounds should not contribute in any way to 
direct interaction with binding site residues, but these groups should contribute to the 
hydrophobicity of the Moiety A (see Figure 2.1), and to some degree, to the molecule as 
a whole.  In addition, steric effects may alter the position of the molecules in the 
recognition domain, or the bulkier groups may even keep them from binding in certain 
sites.  The curve-derived IC50-values indicated that the 4-methyl compound was more 
potent than the unsubstituted compound, but the IC50pot was slightly higher, and it was 
significantly less selective based on the Ratiopot.  The most potent and selective of these 
compounds was the 4-isopropyl benzylidenamine guanidine (Compound 3), which had 
the same 4.6:1 Ratiopot, but was a full order of magnitude more potent than the 
unsubstituted compound, with an IC50pot of 6.0 μM.  The 4-n-butyl and 4-tert-butyl 
compounds laid between the previous two in terms of potency and selectivity (see Table 
3.1).  It would thus appear that the addition of a certain amount of lipophilicity 
contributes to the potency of these compounds (or perhaps this is due to simply steric 
effects), but these small aliphatic substituents only serve to decrease their selectivity. 
 
N
H
N
H
NH2
NH2 Cl
H3C
 
N
H
N
H
NH2
NH2 Cl
 
N
H
N
H
NH2
NH2 Cl
 
N
H
N
H
NH2
NH2 Cl
 
Compound 2 
IC50pot = 80.7 μM 
Ratiopot = 1.9 : 1 
Compound 3 
IC50pot = 6.0 μM 
Ratiopot = 4.6 : 1 
Compound 4 
IC50pot = 42.5 μM 
Ratiopot = 2.5 : 1 
Compound 5 
IC50pot = 22.8 μM 
Ratiopot = 3.2 : 1 
 
 A set of five more mono-substituted benzylidenamine-guanidines contained 
substituents which included heteroatoms directly connected to the phenyl ring.  
Compounds 6 and 7 were defined by 3- and 4-cyano groups; while these compounds did 
possess terminal nitrogen-containing functionalities, the tertiary nitrile nitrogen atom 
contributes to any hydrogen bonding as an acceptor of hydrogen bonds, while most 
primary amines act as hydrogen bond donors at physiological pH.  These compounds 
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seemed to suffer from the decrease in selectivity seen with small aliphatic groups, both 
having Ratiopot values lower than 2:1, with the meta-substituted nitrile compound 
showing five times the potency of the para-compound.  Compound 10 possessed an 
ortho-trifluoromethyl group.  This molecule demonstrated good potency with a 25.1 μM 
IC50pot, but only a 2.8:1 Ratiopot.  The two methyl-ester compounds described in Section 
3.4.1 above (the meta-substituted compound 8 and para-substituted compound 9) have 
more intrinsic ability to interact with protein residues, with the C=O electron pairs being 
very likely to form hydrogen bonds with protons from any number of amino acid groups.  
However, neither of these molecules displayed greater potency than the unsubstituted 
compound 1, and they appeared to be significantly less selective for the agmatine 
recognition site. 
 
N
H
N
H
NH2
NH2 Cl
C
N
 
N
H
N
H
NH2
NH2 Cl
C
N
N
H
N
H
NH2
NH2 Cl
O O
H3C
Compound 6 
IC50pot = 43.4 μM 
Ratiopot = 1.9 : 1 
Compound 7 
IC50pot = 231.2 μM 
Ratiopot = 1.8 : 1 
Compound 8 
IC50pot = 71.1 μM 
Ratiopot = 4.6 : 1 
N
H
N
H
NH2
NH2 ClO
O
H3C
 
N
H
N
H
NH2
NH2 Cl
CF3  
Compound 9 
IC50pot = 72.4 μM 
Ratiopot = 2.0 : 1 
Compound 10 
IC50pot = 25.1 μM 
Ratiopot = 2.8 : 1 
 
 Four benzylidenamine-guanidines with exclusively mono- or di-substituted 
hydroxy or methoxy groups were originally prepared and evaluated.  Each of these 
molecules should possess greater hydrophilicity than the unsubstituted compound 1.  
Compound 11, with 2,4-dihydroxy substitution, was significantly less potent and 
selective than the unsubstituted compound, but each of the methoxy compounds had 
more promising activity.  Of these three, the 2-methoxy substituted compound 12, (2-
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methoxybenzylidenamino)-guanidine hydrochloride, was most potent and selective with 
a 12.8 μM IC50pot and a 4.9:1 Ratiopot.  Compound 13, a mono-methoxy compound 
substituted at the para-position, displayed slightly decreased selectivity and potency.  
Compound 14, 2,4-methoxybenzylidenamine-guanindine, was even less selective than 
either of the mono-substituted compounds.  Nevertheless, each of these compounds was 
at least twice as potent as compound 1, indicating that the methoxy group is beneficial in 
an inhibitory molecule of this type, perhaps by simple steric effects, as is seen with 
compound 3. 
 
N
H
N
H
NH2
NH2 Cl
OHHO
 
N
H
N
H
NH2
NH2 Cl
O
H3C
 
N
H
N
H
NH2
NH2 Cl
O
H3C
 
N
H
N
H
NH2
NH2 Cl
O
O
H3C
H3C
 
Compound 11 
IC50pot = 167.5 μM 
Ratiopot = 1.7 : 1 
Compound 12 
IC50pot = 12.8 μM 
Ratiopot = 4.9 : 1 
Compound 13 
IC50pot = 34.7 μM 
Ratiopot = 3.4 : 1 
Compound 14 
IC50pot = 28.8 μM 
Ratiopot = 2.4 : 1 
 
  A set of five compounds with mono-substituted nitrogen-containing groups were 
also prepared, including primary amine, dimethylamine, and nitro groups.  The primary 
amines, being structurally more similar to agmatine, as well as JR-83 and JR-84, were 
expected to afford inhibition similar to these polyamines, but the results were 
disappointing.  Compound 15, containing a meta-amino substituent, had a 200 μM 
IC50pot accompanied by a solid 3.9:1 Ratiopot; compound 16, with a para-amino 
substituent, was twice as potent as compound 15, but had a lower Ratiopot of 1.2:1.  None 
of these data were as promising as the previously examined xylenediamines from Chapter 
2, nor the unsubstituted benzylidenamine-guanidine (compound 1).  It is apparent that 
the terminal amino group needs to be more sterically flexible, since it is attached to a 
methylene group in the cases of JR-83 and JR-84, and in agmatine itself.  This would 
also explain the reduced activity seen in JR-3 and JR-5, both of which have amino 
groups directly attached to the benzene ring.  Another difference in the comparison of a 
methyl-amino group and a phenyl-amino group is that of pKa: the former would be 
protonated at physiological pH, while the latter is mostly unprotonated.  The para-
 139
dimethylaminobenzyl compound 17 was observed to have the most potential as a 
therapeutic entity thus far: with a 7.9 μM IC50pot and an excellent 12:1 Ratiopot, this 
compound was the most selective of any drug tested, due to a very shallow spermidine-
potentiated curve slope.  The lack of activity in compound 16 would indicate that the 
presence of a para-amino group itself is not enough to contribute to agmatine site 
binding; however, this compound sterically resembles the isopropyl compound 3, which 
had nearly the same IC50pot.  The pKa of N,N-dimethylaniline is 5.15, thus in pH 7.25 
buffer, the amine will not be significantly protonated; therefore the nitrogen in the 
dimethylamino substituent will have a lone pair which can act as a hydrogen bond 
acceptor, unlike the isopropyl group of compound 3. It is indeed possible that the steric 
effects of these two similar compounds contribute to their potency, while the hydrogen 
bond accepting ability of compound 17 increases its selectivity for the agmatine binding 
site over the low-affinity NMDAR site, at which both of these compounds act to 
completely displace [3H]MK-801 at high concentrations.  As can be seen in Section 3.6, 
the two curves generated by compound 17 are similar to those of agmatine, but shifted to 
lower concentrations in the case of the former.  The spermidine-potentiated and non-
potentiated dose-response curves generated by compound 17 nearly overlap at 
concentrations greater than 10 μM.  However, at concentrations lower than 10 μM, 
compound 17 inhibits [3H]MK-801 binding in the presence of spermidine, but has no 
effect in its absence.  These activity data are consistent with the hypothesis that two 
binding sites for agmatine and its structural analogs exist.  The activity of the two 
compounds with nitro-substituents, compounds 18 and 19, closely resemble those with 
the methyl ester substituents: these nitro-compounds are less potent and selective than the 
unsubstituted benzylidenamino-guanidine. 
 
N
H
NH2
N
H
NH2
NH2 Cl
 
N
H
N
H
NH2
NH2 Cl
H2N
N
H
N
H
NH2
NH2 Cl
N
CH 3
H3C
Compound 15 
IC50pot = 199.5 μM 
Ratiopot = 3.9 : 1 
Compound 16 
IC50pot = 104.2 μM 
Ratiopot = 1.2 : 1 
Compound 17 
IC50pot = 7.9 μM 
Ratiopot = 11.9 : 1 
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N
H
N
H
NH2
NH2 Cl
N
OO
 
N
H
N
H
NH2
NH 2 Cl
N
O
O
 
Compound 18 
IC50pot = 149.3 μM 
Ratiopot = 2.0 : 1 
Compound 19 
IC50pot = 78.0 μM 
Ratiopot = 2.8 : 1 
 
 A single compound with a nitro- and methoxy-substituent, (4-methoxy-3-
nitrobenzylidenamino)-guanidine hydrochloride, compound 21, was serendipitously 
chosen and synthesized based on availability of starting material in the lab.  This 
compound was the first to show a clear separation between effects at the two postulated 
binding sites, and produced a biphasic curve in the presence of spermidine (Figure 3.3).   
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Figure 3.3 Biphasic dose-response curve generated by compound 21 
 
Therefore, measurement of an IC50pot was unnecessary, as this theoretical value was 
replaced by the IC50 of the top phase of the curve, which was 7.8 μM.  The midpoints of 
the two phases on the spermidine-potentiated curve were separated by 1.5 orders of 
magnitude; the bottom phase of the spermidine potentiated curve had an IC50 of 259.4 
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μM, which was very close to the 219.8 μM IC50 value of the non-spermdine potentiated 
curve.  Structurally, this compound does little to explain its activity based on the 
previously examined benzylidenamine-guanidines.  Neither the 3-nitro nor the 4-methoxy 
compounds (compounds 18 and 13, respectively) were as selective as the unsubstituted 
compound 1, much less this present compound 21.  When attached to the same ring, 
however, these groups act harmoniously to produce a very selective NMDAR antagonist 
for the high affinity “agmatine” binding site.  It is thus proposed that these substituents 
are each separately necessary for recognition at the agmatine binding site, and exclusion 
at the low-affinity site.  An effort to distinguish the need for the 3-nitro group was 
undertaken in the synthesis of compound 20, (4-methoxy-3-hydroxybenzylidenamino)-
guanidine hydrochloride, in which the nitro group was replaced with a hydroxyl moiety.  
This compound was nearly an order of magnitude less potent than compound 21, and 
more than an order of magnitude less selective for the high-affinity agmatine binding site.  
The 4-methoxy-3-hydroxybenzyl moiety of compound 20 is structurally very similar to 
the second ring attached to compound 34, the only difference being that the terminal 
methyl group in compound 20 may rotate around the adjoining oxygen group, whereas in 
compound 34, it is replaced by a methylene group bridging both oxygen atoms.  
Compound 34, benzo[1,3]dioxol-5-ylmethyleneamino-guanidine hydrochloride, is a 
slightly better selective NMDA inhibitor than compound 20, but is again much less 
potent and selective than compound 21, again indicating the importance of the specific 
groups attached to the phenyl ring of compound 21, as opposed to simply steric effects. 
 
N
H
N
H
NH2
NH2 Cl
O
H3C
OH
 
N
H
N
H
NH2
NH2 Cl
N
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O
H3C
 
N
H
N
H
NH2
NH2 Cl
O
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Compound 20 
IC50pot = 199.5 μM 
Ratiopot = 3.9 : 1 
Compound 21 
IC50pot = 7.8 μM 
Ratiopot = 28.2 : 1 
Compound 34 
IC50pot = 7.9 μM 
Ratiopot = 11.9 : 1 
 
 
 Seven mono- and di-halogeno benzylidenamino-guanidines were examined in this 
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work, with mixed but interesting results.  Of the three chloro-substituted compounds, the 
least potent and selective was the meta-substituted compound, at 18.4 μM IC50pot and 
6.4:1 Ratiopot.  While these values were certainly an improvement over than the 
unsubstituted compound 1, the ortho-chloro analog possessed an IC50pot of 7.1 μM and a 
7.4:1 Ratiopot, and the para-chloro analog, compound 24, afforded  the second example 
of a biphasic spermidine-potentiation curve.  The latter compound, (4-
chlorobenzylidenamino)-guanidine hydrochloride, exhibited a 3.6 μM IC50 for the top 
spermidine-potentiated phase of the curve.  The IC50 of the bottom phase of the 
potentiated curve and the 1C50 of the non-potentiated phase curve were identical at 124.5 
μM.  As with compound 21, there was a 1.5 order of magnitude difference between the 
two phases of the spermidine-potentiated curve, which corresponds in this case to a 
Ratiopot of nearly 35:1.  The difference in activity between these three chloro analogs may 
be attributable to cavity accommodation of the large chloride molecule at the 4-position; 
however, the relative volumes of chloride and methyl groups are similar, and there was a 
vast difference in potency and selectivity between the para-chloro analog, compound 24, 
and the para-methyl analog, compound 2.  Still, the fact that the ortho- and para-
compounds were better on both counts than the meta-compound may be in part due to 
steric hindrance, but may also have to do with the electromeric and inductive effects of 
the highly electronegative chloro substituent.  Electron-withdrawing groups at the ortho- 
and para-positions of a phenyl ring will result in a polarized bond with their adjoining 
ring carbon, rendering the 2- and 4-positions of the ring with partial positive charges, and 
a relatively negatively charged carbon at the 1- and 3-positions; the 1-position is the 
imine and the only other position of importance to activity.  Conversely, electron-
withdrawing groups at the meta-position of a phenyl ring will likewise create a partial-
positive charge, but at the 3- and 1-positions of the phenyl ring.  These electronic effects 
may partially explain the similarities between the ortho- and para-
chlorobenzylidenamino-guanidine, and their difference to the meta-compound.  However, 
if this were the only effect contributing to the activity, then compound 25, with chlorine 
substituents at both the 2- and 4-positions, would possess similar potency and selectivity.  
While its potency is still excellent with a 10.2 μM IC50pot, the 4.1:1 Ratiopot is far less 
remarkable than the ortho- or para-chloro mono-substituted compounds.  In addition, 2-
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fluoro-, 4-fluoro-, and 2,4-difluorobenzylidenamino-guanidine (compounds 26-28, 
respectively) are nearly an order of magnitude less potent than their chloro counterparts, 
with each possessing ratios of potentiation lower than compound 1.  Fluorine is more 
electronegative than chlorine, although the size of carbon is more similar to that of 
fluorine than of chlorine, whose nonbonding electron pairs do not overlap very well with 
carbon’s 2p orbital.  It is therefore deduced that while the electronegativity and position 
of the chlorine group may contribute to the inhibitory activity of compound 24, the size 
and molecular orbitals also appear to play important roles. 
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Compound 22 
IC50pot = 7.1 μM 
Ratiopot = 7.4 : 1 
Compound 23 
IC50pot = 18.4 μM 
Ratiopot = 6.4 : 1 
Compound 24 
IC50pot = 3.6 μM 
Ratiopot = 34.6 : 1 
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Compound 26 
IC50pot = 74.9 μM 
Ratiopot = 3.0 : 1 
Compound 27 
IC50pot = 66.1 μM 
Ratiopot = 4.0 : 1 
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N
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Compound 25 
IC50pot = 10.2 μM 
Ratiopot = 4.1 : 1 
Compound 28 
IC50pot = 55.2 μM 
Ratiopot = 2.0 : 1 
 
 
 A single biphenyl compound was tested, with the guanidino-imine moiety in the 
2-position.  As discussed in section 4.1, the isomer with the 4-position substitution was 
water-insoluble and unable to be screened in this assay.  Compound 29, the first of 
several screened with multiple aromatic rings, was among the most potent in this assay, 
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with an 8.5 μM IC50pot, but yielded a Ratiopot of a mere 1.6:1.  These data indicate that 
this compound is not a good “agmatine binding site” antagonist, but is instead a very 
potent “low-affinity site” antagonist.  It is apparent that this larger compound suffers 
from the same drawback as a number of the more bulky molecules screened in the study 
of chapter 2, in that these compounds appeared to be quite potent at the low-affinity 
binding site for agmatine and its analogs, which rendered them less therapeutically useful 
than compounds with a lower affinity for this site. 
 
N
H
N
H
NH2
NH2 Cl
 
Compound 29 
IC50pot = 8.5 μM 
Ratiopot = 1.6 : 1 
 
 A series of four naphthylidenamino-guanidines were prepared, two of which were 
methylated, and all four possessed IC50pot values lower than 30 μM.  Compounds 30, (1-
naphthylidenamino)-guanidine hydrochloride, and 32, (2-methyl-1-naphthylidenamino)-
guanidine hydrochloride, possessed very low selectivity for the agmatine binding site, 
with ratios of potentiation o 2.2:1 and 1.5:1, respectively.  However, this series also 
yielded the third, albeit least definitive, biphasic curve in the study, from compound 31.  
This 2-naphthyl derivative possessed an 8.7 μM IC50 for the top phase of the spermidine-
potentiated curve (corresponding to the agmatine binding site), and a 117.8 μM IC50 for 
the steeper bottom phase (corresponding to the low-affinity site).  However, the non-
potentiated curve and the lower phase of the spermidine-potentiated curve were not as 
closely overlapped as they were in the previous two biphasic compounds (see section 6), 
and the top-phase and bottom-phase IC50 values were separated by barely one order of 
magnitude.  Compound 33 was also quite potent with an 11.5 IC50pot, and selective with 
a 7.0:1 Ratiopot.  This compound, (4-methyl-1-naphthylidenamino)-guanidine 
hydrochloride, is unexpectedly selective in that compounds 30 and 32 were the only other 
1-naphthyl derivatives, and both demonstrated negligible selectivity.  The only 
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explanation structurally is the movement of the methyl group from the 2-position to the 
4-position on the naphthalene ring, which corresponds to a para-position on a phenyl 
group.  The sterics in the case of compound 33 are slightly more aligned than those of 
compounds 30 or 32, as this molecule can be viewed as a benzylidenamino-guanidine 
with substituents at the meta- and para-positions.  These two positions have adjoining 
groups in several of the most selective compounds, and the inclusion of the para-
substituent (which is absent in compounds 30 and 32) appears to be vital in each of them 
(see Figure 3.4). 
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Compound 30 
IC50pot = 21.4 μM 
Ratiopot = 2.2 : 1 
Compound 31 
IC50pot = 8.7 μM 
Ratiopot = 8.9 : 1 
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Compound 32 
IC50pot = 26.5 μM 
Ratiopot = 1.5 : 1 
Compound 33 
IC50pot = 11.5 μM 
Ratiopot = 7.0 : 1 
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Compound 21 Compound 31
Compound 33 Structurally Conserved Moiety  
Figure 3.4 Structurally-conserved Areas of Several Selective Arylidenamino-
guanidines 
 
 Nine compounds with heteroatom-containing aromatic rings were prepared and 
examined in this study, and while they were, as a whole, unable to improve on the 
previously-described arylidenamino-guanidines, they did contribute to the structural 
diversity of this library as well as that of the modeling study described in Chapter 5.  
Compound 35, 5-(p-nitrophenyl)-2-furan carboxylidenamino)-guanidine hydrochloride, 
was synthesized due to the availability of the starting material, and its structural similarity 
to the biphenyl compound 29.  While the compound did possess some activity with a 
109.4 μM IC50pot, as with so many previously examined bulky compounds, the selectivity 
was ineffectual with a mere 2.1:1 Ratiopot.  Compound 36, pyrrole with the imine 
substituent at the 2-position, proved to be the most selective of the compounds in this set. 
It yielded a meager 59.3 μM IC50pot, but the selectivity was on par with agmatine.  
However, the 3- and 4-pyridino analogs (compounds 37 and 38, respectively), were the 
least potent of the entire arylidenamino-guanidine series, each with IC50’s of potentiation 
near 0.5 mM.  Including a 1.8:1 and 2.6:1 Ratiopot for the two compounds, these data 
were interesting, considering the structural similarity to compound 1.  It is 
understandable that the pyridine nitrogen may interact with some resides in the low-
affinity site to lower the selectivity of these compounds, but it is difficult to explain their 
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low potency at the high-affinity polyamine recognition site (the agmatine binding site) 
solely based on the substitution of a phenyl ring with a pyridyl ring.  Even the 3-
thiophenyl derivative (compound 43) was five times more potent than the pyridine 
derivatives, although it did not demonstrate any selectivity for the polyamine site with a 
2.5:1 Ratiopot.  The remaining four heteroaromatic molecules screened in this study were 
substituted indole derivatives.  The previous data obtained from compound AH-8, N-(1H-
indol-5-yl)guanidine hydrochloride, showed this compound to be possess a high degree 
of potency, but a very low Ratiopot; these observations held true in the case of the 
indolecarboxylidenamino-guanidines.  The 5-methyl analog, compound 40, was 3 times 
less potent than its guanylated counterpart, but possessed a very similar 1.3:1 Ratiopot.  
None of the remaining 3-indolyl analogs synthesized were as potent as AH-8 in the MK-
801 displacement assay.  The unsubstituted 3-indolyl analog, compound 39, 
demonstrated similar selectivity to compound 1, with a 4.7:1 Ratiopot, but was less potent 
than agmatine; the 1- and 6-methyl compounds (41 and 42, respectively), lacked both the 
potency and selectivity of agmatine for the agmatine binding site. 
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Compound 35 
IC50pot = 109.4 μM 
Ratiopot = 2.1 : 1 
Compound 36 
IC50pot = 59.3 μM 
Ratiopot = 7.5 : 1 
Compound 37 
IC50pot = 464.5 μM 
Ratiopot = 1.8 : 1 
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Compound 38 
IC50pot = 539.5 μM 
Ratiopot = 2.6 : 1 
Compound 39 
IC50pot = 36.9 μM 
Ratiopot = 4.7 : 1 
Compound 40 
IC50pot = 50.6 μM 
Ratiopot = 1.3 : 1 
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Compound 41 
IC50pot = 48.8 μM 
Ratiopot = 3.6 : 1 
Compound 42 
IC50pot = 32.9 μM 
Ratiopot = 2.3 : 1 
Compound 43 
IC50pot = 117.2 μM 
Ratiopot = 2.5 : 1 
 
 The final two compounds examined in this study were trans-cinnamylidenamino-
guanidine hydrochloride, an analog of compound 1 with an additional trans-double bond 
between the imine and the phenyl ring, and para-bis-benzylidenamino-guanidine 
hydrochloride, the only arylidenamino-guanidine screened containing two identical 
imine-guanidine groups, attached to the phenyl ring at the 1,4-positions.  Neither of these 
compounds generated particularly interesting data.  The former, compound 44, was 
slightly more potent than compound 1, with a decreased degree of selectivity for the 
agmatine binding site, and it is thus concluded that the addition of an extra conjugated 
double bond is not helpful towards developing a therapeutically useful molecule.  The 
latter, compound 45, displayed the same lack of agmatine-site selectivity as the two di-
guanidine compounds examined in chapter 2, JR-106 and JR-117, with all three 
possessing roughly 2:1:1 relative values for the IC50 in the presence of spermidine, IC50 
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in the absence of added spermidine, and IC50pot.  These data reinforce the hypothesis that 
a single guanidine moiety is optimal for selectivity for the polyamine binding domain 
which recognizes agmatine. 
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Compound 44 
IC50pot = 58.3 μM 
Ratiopot = 2.8 : 1 
Compound 45 
IC50pot = 32.2 μM 
Ratiopot = 1.0 : 1 
 
 
3.5 Conclusions 
 
 A small library of forty-five arylidenamino-guanidine compounds were designed 
and synthesized in the pursuit of a more potent and selective NMDAR receptor inhibitor 
which would mimic the selective antagonist activity of agmatine.  Previous studies 
performed in our laboratory generated a 100% hit rate for this class of compounds as 
NMDAR antagonists, which rendered this class worthy of further investigation.  The 
earlier compounds with this structural motif, as well as new compounds which were 
based structurally on the success of the earlier compounds, were each evaluated in a P2 
membrane assay for their ability to displace [3H]MK-801 in the absence and presence of 
pathological levels of spermidine, and across a sufficient range of concentrations to 
obtain two full dose-response curves. 
 Each of these compounds were evaluated for NMDAR polyamine recognition site 
potency by examining their ability to reduce [3H]MK-801 binding from spermidine-
potentiated control levels to those in the absence of added spermidine.  The term to 
indicate the MK-801 displacement potency of these compounds is “IC50 of potentiation”, 
or IC50pot, which is measured by the concentration of substrate needed to displace MK-
801 halfway from the spermidine-potentiated control level to the control level in the 
absence of added spermidine.  A measure of selectivity of the “high-affinity” agmatine 
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site was obtained by comparing this potency to that derived from the non-spermidine 
potentiated curve, which corresponds to the “low-affinity” site, presumably the ion 
channel.  This measure of selectivity is termed the “ratio of potentiation”, or Ratiopot. 
 Three of these candidate molecules, (4-methoxy-3-nitrobenzylidenamino)-
guanidine hydrochloride (compound 21), (4-chlorobenzylidenamino)-guanidine 
hydrochloride (compound 24), and (2-naphthylidenamino)-guanidine hydrochloride 
(compound 31), generated biphasic spermidine-potentiated curves, which clearly 
separated the inhibitory activity at the two binding sites, in the former two cases, by over 
1.5 orders of magnitude.  Each of these compounds was also quite potent at the agmatine 
binding site, with IC50 values for the corresponding high-affinity phase of the curve being 
measured at less than 10 μM. 
 Important structure-activity data was interpreted by scrutiny of each compound in 
this set, and several observations have been made which postulate the importance of 
steric and electronic effects on both the agmatine-site affinity and selectivity of these 
molecules.   
 While several promising lead compounds have resulted from this study, the 
activity of this group of arylidenamino-guanidines as a whole attests to the importance of 
further examination of the structural descriptors of each molecule as they relate to 
inhibitory activity.  Molecular modeling with a neural network approach will thus be 
undertaken with this set of structurally similar molecules in an effort to facilitate further 
development of this intriguing set of compounds (Chapter 5).  Thereafter, an attempt will 
be made to postulate a pharmacophore which will be developed based on the results 
generated in the whole of this work (Chapter 6). 
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3.6 Experimental Protocol  
(see notes in section 2.6 for further details) 
 
COMPOUND 1 (AG17) 
N
H
N
H
NH2
NH2 Cl
 
(Benzylidenamino)-guanidine Hydrochloride 
 
Benzaldehyde (159 mg, 1.5mmol) and aminoguanidine hydrochloride (110 mg, 1 
mmol) were dissolved in methanol (15 mL) and reacted according to the above general 
method.  The product solution was dissolved on the rotary evaporator, and the residue 
was stirred in chloroform and filtered to remove the remaining starting material.  The 
filtered product was dried on vacuum overnight to afford an off white powdery solid (158 
mg, 0.8 mmol, 80 % yield, 140-141 ºC melting point).  1H NMR (300MHz,D2O) δ 8.0 
(1H s), 7.76-7.63 (2H,m), 7.50-7.48 (3H,m); 13C NMR (DMSO-d6) δ 155.2, 146.5, 133.2, 
130.3, 128.5, 127.4 . 
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COMPOUND 2 (AG6) 
N
H
N
H
NH2
NH2 Cl
H3C
 
(4-Methylbenzylidenamino)-guanidine Hydrochloride 
 
p-Tolualdehyde (180mg, 1.5mmol) and aminoguanidine hydrochloride (110 mg, 
1mmol) were dissolved in methanol (15mL) and reacted according to the above general 
method.  The product solution was dissolved on the rotary evaporator, and the residue 
was stirred in chloroform and filtered to remove the remaining starting material.  The 
filtered product was dried on vacuum overnight to afford a colorless crystalline solid (174 
mg, 0.82 mmol, 82 % yield, 170-171ºC melting point).  1H NMR (300MHz, D2O) δ 7.88 
(1H,s), 7.56 (2H,d, J=8.2 Hz), 7.30 (2H,d, J=8.2 Hz), 2.38 (3H,s); 13C NMR (DMSO-d6) 
δ 155.3, 146.5, 140.1, 130.5, 129.1, 127.4, 21.1 . 
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COMPOUND 3 (JR-202) 
N
H
N
H
NH2
NH2 Cl
 
(4-Isopropyl-benzylidenamino)-guanidine Hydrochloride 
 
4-Isopropylbenzaldehyde (222mg, 1.5mmol) and aminoguanidine hydrochloride 
(110mg, 1.0 mmol) were dissolved in methanol (15mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the yellow residue was stirred in diethyl ether and filtered to remove the remaining 
starting material.  The filtered product was recrystallized from ethyl acetate to yield 
hygroscopic yellow needle crystals, which immediately became amorphous upon 
exposure to atmospheric water (65mg, 0.27mmol, 27% yield).  1H NMR (400MHz, d-
DMSO) δ 12.02 (1H, s), 8.14 (1H, s), 7.78 (2H, d, J = 8.0Hz), 7.31 (2H, d, J = 8.4Hz), 
2.92 (1H, m), 1.21 (6H, d, J = 6.8Hz); 13C NMR δ 155.4, 151.2, 146.8, 131.2, 127.7, 
126.7, 33.4, 23.7; ES+ m/z 205. 
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COMPOUND 4 (JR-212) 
N
H
N
H
NH2
NH2 Cl
 
(4-n-Butylbenzylidenamino)-guanidine Hydrochloride 
 
4-Butylbenzaldehyde (243mg, 1.5 mmol) and aminoguanidine hydrochloride (110mg, 
1.0 mmol) were dissolved in methanol (15mL) and reacted according to the above 
general method.  The product solution was dissolved on the rotary evaporator, and the 
light yellow liquid residue was stirred in ethyl ether and filtered to remove the remaining 
starting material.  The filtered product was dried on vacuum overnight to afford a coarse 
off-white powdery solid (231mg, 0.91 mmol, 91% yield, 134-135ºC melting point).  1H 
NMR (400MHz, d-DMSO) δ 12.02 (1H, s), 8.14 (1H, s), 7.76 (2H, d, J = 8 Hz), 7.26 
(2H, d, J = 8Hz), 2.60 (2H, t, J = 7.6 Hz), 1.55 (2H, p, J = 7.6 Hz), 1.29, (2H, sextet, J = 
7.7Hz), 0.89 (3H, t, J = 7.8Hz); 13C NMR δ 155.4, 146.8, 145.2, 131.0, 128.6, 127.6, 
34.7, 32.9, 21.8, 13.8; ES+ m/z 219. 
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COMPOUND 5 (JR-211) 
N
H
N
H
NH2
NH2 Cl
 
(4-tert-Butylbenzylidenamino)-guanidine Hydrochloride 
 
4-tert-Butylbenzaldehyde (243mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110mg, 1.0 mmol) were dissolved in methanol (15mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the residue was stirred in ethyl ether and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford an off-white 
powdery solid (203mg, 0.80mmol, 80% yield, 214-215ºC melting point).  1H NMR 
(400MHz, d-DMSO) δ 12.12 (1H, s), 8.15, (1H, s), 7.77 (2H, dd, J = 8.0Hz), 7.45 (2H, 
m), 1.28 (9H, t, J = 2.8Hz); 13C NMR δ 155.4, 153.3, 146.6, 130.8, 127.4, 125.5, 34.6, 
30.9; ES+ m/z 219. 
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COMPOUND 6 (JR-124) 
N
H
N
H
NH2
NH2 Cl
C
N
 
(3-Cyanobenzylidenamino)-guanidine Hydrochloride 
 
3-Cyanobenzaldehyde (491mg, 3.75 mmol) and aminoguanidine hydrochloride 
(276.4mg, 2.5 mmol) were dissolved in methanol (50mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the residue was stirred in chloroform and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford an off-white 
powdery solid (257 mg, 1.15 mmol, 46% yield, 235-239ºC melting point).  1H NMR 
(300MHz, d- D2O) δ 12.18 (1H, s), 8.48 (1H, t, J = 1.5Hz), 8.19 (1H, s), 8.12 (1H, dt, J = 
8.3, 1.5Hz), 7.87 (1H, dt, J = 8.3, 1.5Hz), 7.64 (1H, t, J = 8.3Hz); 13C NMR δ 155.4, 
144.2, 134.7, 133.2, 132.3, 130.3, 129.8, 118.4, 111.8; ES+ m/z 188. 
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COMPOUND 7 (JR-125) 
N
H
N
H
NH2
NH2 Cl
C
N
 
(4-Cyanobenzylidenamino)-guanidine Hydrochloride 
 
4-Cyanobenzaldehyde (983mg, 7.5 mmol) and aminoguanidine hydrochloride 
(553mg, 5.0 mmol) were dissolved in methanol (50mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the residue was stirred in chloroform and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford a white powdery 
solid (944 mg, 4.22 mmol, 84% yield, 264-267ºC melting point).  1H NMR (300MHz, d- 
DMSO) δ 12.22 (1H, s), 8.22 (1H, s), 8.07 (2H, d, J = 9.0Hz), 7.91 (2H, d, J = 9.0Hz); 
13C NMR δ 155.4, 144.6, 137.7, 132.4, 128.0, 118.5, 112.1; ES+ m/z 188. 
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COMPOUND 8 (JR-226) 
N
H
N
H
NH2
NH2 Cl
O O
H3C
 
Benzylidenaminoguanidine-3-methyl ester Hydrochloride 
 
3-Carboxybenzaldehyde (223mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110mg, 1.0 mmol) were dissolved in methanol (15mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the white solid residue was stirred in chloroform and filtered to remove the remaining 
starting material.  The filtered product was dried on vacuum overnight to afford a (3-
carboxylbenzylidenamino)-guanidine hydrochloride as a white powdery solid (226mg, 
0.93mmol, 93% yield, 276-278ºC melting point).  This intermediate (100 mg, 0.4 mmol) 
was dissolved in methanol (5mL), and thionyl chloride (2.0 mmol, 238 mg, 146uL) was 
added dropwise.  The solution was stirred at room temperature for 18 hours, then the 
solvent removed by rotary evaporation and the resulting solid left on the vacuum pump 
overnight to yield the light yellow solid product (72mg, 0.28 mmol, 70% yield, 213-
215ºC melting point).  1H NMR (300MHz, d-DMSO) δ 12.18 (1H, s), 8.36 (1H, slight 
triplet), 8.28 (1H, s), 8.19 (1H, d, J = 7.9Hz), 8.00 (1H, d, J = 7.9Hz), 7.6 (1H, t, J = 
8Hz), 3.88 (3H, s); 13C NMR δ 165.6, 155.3, 145.7, 133.9, 131.7, 130.6, 130.1, 129.0, 
128.2, 52.3; ES+ m/z 221. 
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COMPOUND 9 (JR-227) 
N
H
N
H
NH2
NH2 ClO
O
H3C
 
Benzylidenaminoguanidine-4-methyl ester Hydrochloride 
 
4-Carboxybenzaldehyde (300mg, 2.0 mmol) and aminoguanidine hydrochloride 
(143mg, 1.3 mmol) were dissolved in methanol (15mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the white solid residue was stirred in chloroform and filtered to remove the remaining 
starting material.  The filtered product was dried on vacuum overnight to afford a (3-
carboxylbenzylidenamino)-guanidine hydrochloride as a cream-colored powdery solid 
(223mg, 0.92 mmol, 71% yield, 276-281ºC melting point).  This intermediate (50 mg, 0.2 
mmol) was dissolved in methanol (5mL), and thionyl chloride (1.0 mmol, 119 mg, 73uL) 
was added dropwise.  The solution was stirred at room temperature for 18 hours, then the 
solvent removed by rotary evaporation and the resulting solid left on the vacuum pump 
overnight to yield the off-white solid product (36mg, 0.14 mmol, 70% yield, 251-253ºC 
melting point).  1H NMR (300MHz, d-DMSO) δ 8.26 (1H, s), 8.005 (2H, m), 7.999 (2H, 
m), 3.86 (3H, s); 13C NMR δ 165.6, 155.4, 145.2, 137.7, 130.6, 129.2, 127.6, 52.3; ES+ 
m/z 221. 
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COMPOUND 10 (AG-20) 
N
H
N
H
NH2
NH2 Cl
CF3  
(2-Trifluoromethylbenzylidenamino)-guanidine Hydrochloride 
 
2-(Trifluoromethyl)benzaldehyde (260 mg, 1.5 mmol) and aminoguanidine 
hydrochloride ( 110 mg, 1 mmol) were dissolved in methanol (15 mL) and reacted 
according to the above general method.  The product solution was dissolved on the rotary 
evaporator, and the residue was stirred in chloroform and filtered to remove the 
remaining starting material.  The filtered product was dried on vacuum overnight to 
afford an off white powdery solid (226mg, 0.89mmol, 89 % yield, 172-173ºC melting 
point). 1H NMR (300MHz,D2O) δ 8.2 (1H,s), 8.1(1H,d, J=8.1Hz), 7.6 (1H,d, J=7.5 Hz), 
7.63 (2H, m);13C NMR (DMSO- d6) δ 155.2, 141.5, 132.5, 130.9, 130.4, 127.5, 126.4, 
125.7, 109.1. 
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COMPOUND 11 (AG-13) 
N
H
N
H
NH2
NH2 Cl
OHHO
 
(2,4-Dihydroxybenzylidenamino)-guanidine Hydrochloride 
 
2,4-Dihydroxybenzaldehyde (207 mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110 mg, 1 mmol) were dissolved in methanol (15 mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the residue was stirred in chloroform and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford a light brown 
powdery solid (182 mg, 0.79 mmol, 79 % yield, 231-232 ºC melting point).  1H NMR 
(300MHz, D2O) δ 7.86(1H,s), 7.23 (1H,d, J=8.5 Hz, 6.4 (1H,dd, J= 2.7 Hz, J= 8.5Hz), 
6.3 (1H,d,J=2.7Hz) ; 13C NMR (DMSO-d6) δ 160.9, 158.0, 154.8, 143.9, 128.0, 110.9, 
107.7, 102.2. 
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COMPOUND 12 (AG-12) 
N
H
N
H
NH2
NH2 Cl
O
H3C  
(2-Methoxybenzylidenamino)-guanidine Hydrochloride 
 
o-Anisaldehyde (204mg, 1.5mmol) and aminoguanidine hydrochloride (110 mg, 1 
mmol) were dissolved in methanol (15 mL) and reacted according to the above general 
method.  The product solution was dissolved on the rotary evaporator, and the residue 
was stirred in chloroform and filtered to remove the remaining starting material.  The 
filtered product was dried on vacuum overnight to afford an off white powdery solid (169 
mg, 0.74 mmol, 74 % yield, 232-233ºC melting point).  1H NMR (300MHz, DMSO-d6) δ 
12.3 (1H, broad), 8.45 (1H, s), 8.1 (1H,m) 7.8 (NH, broad) 7.45 (1H,m), 7.1 (1H,d), 7.0 
(1H,m) ; 13C NMR δ 157.5, 155.1, 141.8, 132.0, 126.1, 121.1, 120.4, 111.7, 55.7 
 
SUN-AG12
-5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
SUN-AG12+SPD
SUN-AG12
log [M] Concentration
D
PM
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COMPOUND 13 (AG-8) 
N
H
N
H
NH2
NH2 Cl
O
H3C
 
(4-Methoxybenzylidenamino)-guanidine Hydrochloride 
 
p-Anisaldehyde (204 mg, 1.5 mmol) and aminoguanidine hydrochloride ( 110 mg, 1 
mmol) were dissolved in methanol (15 mL) and reacted according to the above general 
method.  The product solution was dissolved on the rotary evaporator, and the residue 
was stirred in chloroform and filtered to remove the remaining starting material.  The 
filtered product was dried on vacuum overnight to afford a light brown powdery solid 
(157 mg, 0.69 mmol, 69 % yield, 110-111ºC melting point).  1H NMR (300MHz, D2O) δ 
7.70 (1H,s), 7.55 (2H,d, J=8.0 Hz), 6.95 (2H,d, J=8.0Hz), 3.85 (3H,s);13C NMR (DMSO- 
d6) δ 160.9, 155.2, 146.3, 129.1, 125.9, 114.0, 55.3. 
 
SUN-AG8
-5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
SUN-AG8+SPD
SUN-AG8
log [M] Concentration
D
PM
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COMPOUND 14 (AG-10) 
N
H
N
H
NH2
NH2 Cl
O
O
H3C
H3C
 
(2,4-Dimethoxybenzylidenamino)-guanidine Hydrochloride 
 
2,4-Dimethoxybenzaldehyde (174 mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110 mg, 1 mmol) were dissolved in methanol (15mL) and reacted according to the above 
general method.  The product solution was dissolved on the rotary evaporator, and the 
residue was stirred in chloroform and filtered to remove the remaining starting material.  
The filtered product was dried on vacuum overnight to afford an off white powdery solid 
(157 mg, 0.61 mmol, 61 % yield, 203-204 ºC melting point).  1H NMR (300MHz, 
DMSO- d6) δ 12.0 (1H,broad), 8.35 (1H,s), 8.0 (1H,d), 7.7 (NH, broad) 6.64 (1H,s), 6.60 
(2H,m); 13C NMR δ 162.7, 159.1,154.9, 127.4, 113.9, 106.5, 97.9, 55.9, 55.5. 
 
SUN-AG10
-5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
SUN-AG10+SPD
SUN-AG10
log [M] Concentration
D
PM
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COMPOUND 15 (JR-197) 
N
H
NH2
N
H
NH2
NH2 Cl
 
(3-Aminobenzylidenamino)-guanidine Hydrochloride 
 
3-Aminobenzaldehyde was prepared by the dropwise addition of 2.0M HCl in ethanol 
(6.0 mL) to the corresponding 3-aminobenzaldehyde ethylene acetal (902 mg, 5.97) in 
methanol (34 mL).  The reaction solution darkened with the acid addition, from very pale 
orange to dark yellow, and during stirring at room temperature for 30 minutes, the color 
returned to a light orange, and TLC revealed a completed reaction.  Aminoguanidine 
hydrochloride (111mg, 1.0 mmol) was added to a 15-mL sample of the methanolic 
reaction solution (0.176 M, 2.64 mmol aldehyde), and the mixture refluxed for 3 hours.  
The reaction was then cooled to room temperature, and fine tan crystals (35.5 mg, 0.16 
mmol, 16% yield, 240-246ºC melting point) crashed out of solution, which were 
collected and rinsed with cold methanol.  1H NMR (300MHz, d-DMSO) δ 12.14 (1H, s), 
8.20 (1H, s), 7.84 (1H, d, J = 7.8Hz), 7.63 (1H, s), 7.49 (1H, t, J = 7.8Hz), 7.36 (1H, d, J 
= 7.8Hz); 13C NMR δ 155.2, 145.8, 134.6, 129.8, 124.7, 123.5, 120.9; ES+ m/z 178. 
 
JR-197
-5 -4 -3 -2Control NonSpec
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
JR-197+SPD
JR-197
log [M] Concentration
D
PM
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COMPOUND 16 (JR-160) 
N
H
N
H
NH2
NH2 Cl
H2N
 
(4-Aminobenzylidenamino)-guanidine Hydrochloride 
 
4-Aminobenzaldehyde (60mg, 0.5 mmol, prepared by the method of Tetrahedron 
Letters, Vol. 25 No. 8, 1984, pp. 839-842) and aminoguanidine hydrochloride (44mg, 0.4 
mmol) were dissolved in methanol (10mL) and reacted according to the above general 
method.  The product solution was dissolved on the rotary evaporator, and the residue 
was stirred in chloroform and filtered to remove the remaining starting material.  The 
filtered product was dried on vacuum overnight to afford a light brown powdery solid (46 
mg, 0.22 mmol, 55% yield, 169-173ºC melting point).  1H NMR (300MHz, d-DMSO) δ 
11.42 (1H, s), 7.93 (1H, s), 7.50 (2H, d, J = 9Hz), 6.58 (2H, d, J = 9Hz), 5.74 (2H, s); 13C 
NMR (300MHz, d-D2O) δ 187.7, 152.3, 152.2, 131.9, 126.0, 118.6; ES+ m/z 178. 
 
JR-160
-5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5 -2.0 -1.5Control NonSpec
0
100
200
300
400
500
600
700
800
900
1000
1100
1200 JR-160+SPD
JR-160
log [M] Concentration
D
PM
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COMPOUND 17 (JR-219) 
N
H
N
H
NH2
NH2 Cl
N
CH 3
H3C
 
(4-Dimethylamino-benzylidenamino)-guanidine Hydrochloride 
 
p-Dimethylaminobenzaldehyde (298.3mg, 2.0 mmol) and aminoguanidine 
hydrochloride (144mg, 1.3 mmol) were dissolved in methanol (15mL) and reacted 
according to the above general method.  The product solution was dissolved on the rotary 
evaporator, and the solid residue was stirred in chloroform and filtered to remove the 
remaining starting material.  The filtered product was dried on vacuum overnight to 
afford a tan-yellow powdery solid (112mg, 0.46 mmol, 36% yield, 179-182ºC melting 
point).  1H NMR (400MHz, d-DMSO) δ 8.02 (1H, s), 7.63 (2H, d, J = 8.8Hz), 6.71 (2H, 
d, J = 8.8Hz), 2.95 (6H, s); 13C NMR δ 155.0, 151.7, 147.5, 129.0, 120.6, 111.6, 39.9; 
ES+ m/z 206. 
 
JR-219
-6.5 -6.0 -5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
1300
1400
JR-219+SPD
JR-219
log [M] Concentration
D
PM
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COMPOUND 18 (JR-122) 
N
H
N
H
NH 2
NH2 Cl
N
OO
 
(3-Nitrobenzylidenamino)-guanidine Hydrochloride 
 
3-Nitrobenzaldehyde (1.13g, 7.5 mmol) and aminoguanidine hydrochloride (553mg, 
5.0 mmol) were dissolved in methanol (50mL) and reacted according to the above 
general method.  The product solution was dissolved on the rotary evaporator, and the 
residue was stirred in chloroform and filtered to remove the remaining starting material.  
The filtered product was dried on vacuum overnight to afford a pale yellow powdery 
solid (1109 mg, 4.55 mmol, 91% yield, 267-268ºC melting point).  1H NMR (300MHz, 
d-D2O) δ 8.53 (1H, t, J = 2.0Hz), 8.28 (1H, ddd, J = 9.0, 2.0, 1.3Hz), 8.09 (1H, s), 8.03 
(1H, td, J = 9.0, 1.3Hz), 7.66 (1H, t, J = 9.0Hz); 13C NMR δ 155.5, 148.2, 146.1, 134.7, 
133.7, 130.1, 125.1, 121.8; ES+ m/z 208. 
 
JR-122
-6 -5 -4 -3 -2Control NonSpec
0
250
500
750
1000
1250
1500
1750
JR-122+SPD
JR-122
log [M] Concentration
D
PM
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COMPOUND 19 (JR-121) 
N
H
N
H
NH2
NH 2 Cl
N
O
O
 
(4-Nitrobenzylidenamino)-guanidine Hydrochloride 
 
4-Nitrobenzaldehyde (1.13g, 7.5 mmol) and aminoguanidine hydrochloride (553mg, 
5.0 mmol) were dissolved in methanol (50mL) and reacted according to the above 
general method.  The product solution was dissolved on the rotary evaporator, and the 
residue was stirred in chloroform and filtered to remove the remaining starting material.  
The filtered product was dried on vacuum overnight to afford a light-yellow powdery 
solid (768 mg, 3.15 mmol, 63% yield, 252-254ºC melting point).  1H NMR (300MHz, d- 
D2O) δ 8.23 (2H, m), 8.0 (1H, m), 7.81 (2H, m); 13C NMR δ 155.4, 147.9, 144.2, 139.6, 
128.4, 123.7; ES+ m/z 208. 
 
JR-121
-6 -5 -4 -3 -2Control NonSpec
0
250
500
750
1000
1250
1500
JR-121+SPD
JR-121
log [M] Concentration
D
PM
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COMPOUND 20 (JR-228) 
N
H
N
H
NH2
NH2 Cl
O
H3C
OH
 
(4-Methoxy-3-hydroxybenzylidenamino)-guanidine Hydrochloride 
 
3-Hydroxy-p-anisaldehyde (456mg, 3.0 mmol) and aminoguanidine hydrochloride 
(110mg, 1.0 mmol) were dissolved in methanol (5mL) and reacted according to the above 
general method.  The product solution was dissolved on the rotary evaporator, and the 
white solid residue was stirred in chloroform and filtered to remove the remaining 
starting material.  The filtered product was dried on vacuum overnight to afford a white 
powdery solid (163mg, 0.79 mmol, 79% yield, 209-210ºC melting point).  1H NMR 
(300MHz, d-DMSO) δ 11.84 (1H, s), 9.146 (1H, s), 8.02 (1H, s), 7.34 (1H, d, J = 2.1Hz), 
7.20 (1H, dd, J = 8.4, 2.1Hz), 6.97 (1H, d, J = 8.4Hz); 13C NMR δ 155.1, 149.8, 146.9, 
146.4, 126.1, 120.4, 113.4, 111.5, 55.65; ES+ m/z 209. 
 
JR-228
-6 -5 -4 -3Control NonSpec
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
1300
JR-228+SPD
JR-228
log [M] Concentration
D
PM
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COMPOUND 21 (JR-223) 
N
H
N
H
NH2
NH2 Cl
N
OO
O
H3C
 
(4-Methoxy-3-Nitrobenzylidenamino)-guanidine Hydrochloride 
 
4-Methoxy-3-nitrobenzaldehyde (287mg, 1.6 mmol) and aminoguanidine 
hydrochloride (110mg, 1.0 mmol) were dissolved in methanol (15mL) and reacted 
according to the above general method.  The product solution was dissolved on the rotary 
evaporator, and the yellow residue was stirred in chloroform and filtered to remove the 
remaining starting material.  The filtered product was dried on vacuum overnight to 
afford a yellow powdery solid (191mg, 0.70mmol, 70% yield, 244-247ºC melting point).  
1H NMR (400MHz, d-DMSO) δ 12.23 (1H, s), 8.47 (1H, d, J = 2.0Hz), 8.18 (1H, s), 8.11 
(1H, dd, J = 4.8Hz, 2.0Hz), 7.42 (1H, d, J = 4.8Hz), 3.97 (3H, s); 13C NMR δ 155.5, 
152.8, 144.3, 139.8, 133.5, 126.3, 123.0, 114.4, 57.0; ES+ m/z 238. 
 
JR-223
-6.5 -6.0 -5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
100
200
300
400
500
600
700
800
900
1000
1100
JR-223+SPD
JR-223
log [M] Concentration
D
PM
 
 172
COMPOUND 22 (JR-218) 
N
H
N
H
NH2
NH2 Cl
Cl
 
(2-Chlorobenzylidenamino)-guanidine Hydrochloride 
 
2-Chlorobenzaldehyde (280mg, 2.0 mmol) and aminoguanidine hydrochloride (144 
mg, 1.3 mmol) were dissolved in methanol (15mL) and reacted according to the above 
general method.  The product solution was dissolved on the rotary evaporator, and the 
yellow liquid residue was left on a vacuum pump overnight, producing a white solid.  
This solid was then stirred in chloroform and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford a white powdery 
solid (248mg, 1.06 mmol, 82% yield, 178-181ºC melting point).  1H NMR (400MHz, d-
DMSO) δ 12.36 (1H, s), 8.55 (1H, s), 8.30 (1H, dd, J = 7.6Hz, 2.0Hz), 7.53 (1H, dd, J = 
7.8Hz, 1.6Hz), 7.47 (1H, dt, J = 7.6Hz, 2.0Hz), 7.42 (1H, dt, J = 7.4Hz, 1.4Hz); 13C NMR 
δ 155.4, 142.6, 133.2, 131.9, 130.6, 129.9, 127.7, 127.5; ES+ m/z 197, 199. 
 
JR-218
-7.5 -6.5 -6.0 -5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5 -1.5Control NonSpec
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
JR-218+SPD
JR-218
log [M] Concentration
D
PM
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COMPOUND 23 (JR-217) 
N
H
N
H
NH2
NH2 Cl
Cl
 
(3-Chlorobenzylidenamino)-guanidine Hydrochloride 
 
3-Chlorobenzaldehyde (280mg, 2.0 mmol) and aminoguanidine hydrochloride 
(144mg, 1.3 mmol) were dissolved in methanol (15mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the white solid residue was stirred in chloroform and filtered to remove the remaining 
starting material.  The filtered product was dried on vacuum overnight to afford a white 
powdery solid (223mg, 1.13 mmol, 87% yield, 226-229ºC melting point).  1H NMR 
(300MHz, d-DMSO) δ 12.13 (1H, s), 8.16 (1H, s), 8.09 (1H, s), 7.75 (1H, m), 7.48 (1H, 
m), 7.46 (1H, m); 13C NMR δ 155.3, 145.0, 135.5, 133.5, 130.4, 129.9, 126.7, 126.2; ES+ 
m/z 197, 199. 
 
JR-217
-6.5 -6.0 -5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
0
250
500
750
1000
1250
1500
JR-217+SPD
JR-217
log [M] Concentration
D
PM
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COMPOUND 24 (JR-220) 
N
H
N
H
NH2
NH2 Cl
Cl
 
(4-Chlorobenzylidenamino)-guanidine Hydrochloride 
 
4-Chlorobenzaldehyde (281mg, 2.0 mmol) and aminoguanidine hydrochloride 
(144mg, 1.3 mmol) were dissolved in methanol (15mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the white solid residue was stirred in chloroform and filtered to remove the remaining 
starting material.  The filtered product was dried on vacuum overnight to afford a white 
powdery solid (173mg, 0.74 mmol, 57% yield, 171-173ºC melting point).  1H NMR 
(400MHz, d-DMSO) δ 12.22 (1H, s), 8.18 (1H, s), 7.91 (2H, d, J = 8.8Hz), 7.51 (2H, d, J 
= 8.4Hz); 13C NMR δ 155.5, 145.4, 134.9, 132.5, 129.3, 128.8; ES+ m/z 197, 199. 
 
JR-220
-6 -5 -4 -3Control NonSpec
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
1300
JR-220+SPD
JR-220
log [M] Concentration
D
PM
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COMPOUND 25 (AG-9) 
N
H
N
H
NH2
NH2 Cl
Cl Cl
 
(2,4-Dichlorobenzylidenamino)-guanidine Hydrochloride 
 
2,4-Dichlorobenzaldehyde (262 mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110 mg, 1 mmol) were dissolved in methanol (15 mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the residue was stirred in chloroform and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford an off white 
powdery solid (150 mg, 0.56 mmol, 56 % yield, 222-223ºC melting point).  1H NMR 
(300MHz, DMSO-d6) δ8.4 (1H,s), 8.3 (1H, d, J=8.4Hz), 7.89 (NH, broad hump), 7.6 
(1H,m), 7.4 (1H,m). 13C NMR (DMSO-d6) δ 155.3, 141.1, 135.3, 133.7, 129.7, 129.1, 
128.7, 127.6 . 
 
SUN-AG9
-6 -5 -4 -3Control NonSpec
200
300
400
500
600
700
800
900
1000
1100
1200
SUN-AG9+SPD
SUN-AG9
log [M] Concentration
D
PM
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COMPOUND 26 (AG-23) 
N
H
N
H
NH2
NH2 Cl
F
 
(2-Fluorobenzylidenamino)-guanidine Hydrochloride 
 
2-Fluorobenzaldehyde (186 mg, 1.5 mmol) and aminoguanidine hydrochloride (110 
mg, 1 mmol) were dissolved in methanol (15 mL) and reacted according to the above 
general method.  The product solution was dissolved on the rotary evaporator, and the 
residue was stirred in chloroform and filtered to remove the remaining starting material.  
The filtered product was dried on vacuum overnight to afford an off white powdery solid 
(158 mg, 0.73 mmol, 73 % yield, 170-171ºC melting point). 1H NMR (300MHz, D2O)  δ 
8.0 (1H,s), 7.80 (1H,m), 7.70 (1H,m), 7.18 (1H,m) ; 13C NMR (DMSO-d6) δ 162.2, 
155.2, 139.1, 132.4, 126.9, 124.6, 120.9, 115.9 . 
 
SUN-AG23
-5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
SUN-AG23+SPD
SUN-AG23
log [M] Concentration
D
PM
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COMPOUND 27 (AG-18) 
N
H
N
H
NH2
NH2 Cl
F
 
(4-Fluorobenzylidenamino)-guanidine Hydrochloride 
 
4-Fluorobenzaldehyde (186 mg, 1.5 mmol) and aminoguanidine hydrochloride (110 
mg, 1 mmol) were dissolved in methanol (15 mL) and reacted according to the above 
general method.  The product solution was dissolved on the rotary evaporator, and the 
residue was stirred in chloroform and filtered to remove the remaining starting material.  
The filtered product was dried on vacuum overnight to afford a white powdery solid (151 
mg, 0.70 mmol, 70 % yield, 189-190ºC melting point). 1H NMR (300MHz,D2O) δ 7.87 
(1H,s), 7.6 (2H,m), 7.15 (2H,m); 13C NMR (DMSO- d6) δ 161.0, 155.3, 145.3, 129.7, 
115.7 
 
SUN-AG18
-5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
SUN-AG18+SPD
SUN-AG18
log [M] Concentration
D
PM
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COMPOUND 28 (AG-24) 
N
H
N
H
NH2
NH2 Cl
FF
 
(2,4-Difluorobenzylidenamino)-guanidine Hydrochloride 
 
2,4-Difluorobenzaldehyde (213 mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110 mg, 1 mmol) were dissolved in methanol (15 mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the residue was stirred in chloroform and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford a white powdery 
solid (187 mg, 0.80 mmol, 80 % yield, 217-218ºC melting point). 1H NMR (300MHz, 
D2O) δ 8.0 (1H,s), 7.84 (1H,m), 7.0 (2H,m); 13C NMR(DMSO- d6) δ 161.6, 159.1, 155.2, 
138.2, 128.5, 117.9, 112.4, 104.2 . 
 
SUN-AG24
-6 -5 -4 -3 -2Control NonSpec
200
300
400
500
600
700
800
900
1000
1100
1200
SUN-AG24+SPD
SUN-AG24
log [M] Concentration
D
PM
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COMPOUND 29 (JR-209) 
N
H
N
H
NH2
NH2 Cl
 
(2-Biphenyl-carboxylidenamino)-guanidine Hydrochloride 
 
2-Biphenylcarboxaldehyde (273mg, 1.5mmol) and aminoguanidine hydrochloride 
(110mg, 1.0 mmol) were dissolved in methanol (15mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the white solid residue was recrystallized in chloroform to afford white short crystals 
(131mg, 0.48 mmol, 48% yield, 205-208ºC melting point).  1H NMR (400MHz, d-
DMSO) δ 12.02 (1H, s), 8.33 (1H, d, J = 7.6Hz), 8.06 (1H, s), 7.48 (5H, m), 7.34 (3H, 
m); 13C NMR δ 155.4, 145.0, 142.1, 138.8, 130.5, 130.3, 129.6, 128.9, 128.6, 128.5, 
128.2, 127.7, 127.6, 126.4; ES+ m/z 239. 
 
JR-209
-6.5 -6.0 -5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
0
250
500
750
1000
1250
1500
JR-209+SPD
JR-209
log [M] Concentration
D
PM
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COMPOUND 30 (AG-4) 
N
H
N
H
NH2
NH2 Cl
 
(1-Naphthylidenamino)-guanidine Hydrochloride 
 
1-Naphthaldehyde (234 mg, 1.5 mmol) and aminoguanidine hydrochloride (110 mg, 1 
mmol) were dissolved in methanol (15 mL) and reacted according to the above general 
method.  The product solution was dissolved on the rotary evaporator, and the residue 
was stirred in chloroform and filtered to remove the remaining starting material.  The 
filtered product was dried on vacuum overnight to afford a cream powdery solid (186 mg, 
0.75 mmol, 75 % yield, 143-144ºC melting point).  1H NMR (300MHz, D2O) δ 8.24 
(1H,m), 8.17 (1H,s), 7.90(2H,m), 7.66 (1H,d), 7.61 (2H,m), 7.46 (1H,m) ; 13C NMR 
(DMSO- d6) δ 155.2, 145.4, 133.2, 130.7, 130.2, 128.6, 128.4, 127.2, 126.4, 126.1, 125.3, 
123.1. 
 
SUN-AG4
-6 -5 -4 -3 -2Control NonSpec
0
250
500
750
1000
1250
1500
1750
SUN-AG4+SPD
SUN-AG4
log [M] Concentration
D
PM
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COMPOUND 31 (JR-213) 
N
H
N
H
NH2
NH2 Cl
 
(2-Naphthylidenamino)-guanidine Hydrochloride 
 
2-Naphthaldehyde (234mg, 1.5 mmol) and aminoguanidine hydrochloride (110mg, 1.0 
mmol) were dissolved in methanol (15mL) and reacted according to the above general 
method.  Upon cooling, clear white crystals fell out of the orange solution, and were 
filtered and collected.  The product crystals were stirred in chloroform and filtered to 
remove the remaining starting material, leaving the fine white crystal product (164mg, 
0.66 mmol, 66% yield, 213-215ºC melting point).  1H NMR (400MHz, d-DMSO) δ 12.17 
(1H, s), 8.35 (1H, s), 8.20 (2H, m), 7.96 (3H, m), 7.57 (2H, m);  13C NMR δ 155.4, 146.8, 
133.9, 132.7, 131.2, 129.5, 128.4, 128.3, 127.8, 127.4, 126.8, 123.0; ES+ m/z 213. 
 
JR-213
-6 -5 -4 -3Control NonSpec
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
1300
1400
1500
1600
1700
1800
1900
2000
JR-213+SPD
JR-213
log [M] Concentration
D
PM
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COMPOUND 32 (JR-203) 
N
H
N
H
NH2
NH2 Cl
CH3  
(2-Methyl-1-naphthylidenamino)-guanidine Hydrochloride 
 
2-Methyl-1-naphthaldehyde (510mg, 3.0 mmol) and aminoguanidine hydrochloride 
(110mg, 1.0 mmol) were dissolved in methanol (15mL) and reacted according to the 
above general method (a first synthetic attempt produced a very low yield, thus the 
procedure was repeated with a 5:1 excess of aldehyde starting material).  The product 
solution was dissolved on the rotary evaporator, and the residue was stirred in chloroform 
and filtered to remove the remaining starting material.  The filtered product was dried on 
vacuum overnight to afford a cream-colored powdery solid (190mg, 0.72 mmol, 72% 
yield, 130-133ºC melting point).  1H NMR (300MHz, d-DMSO) δ 12.18 (1H, s), 8.91 
(1H, s), 8.37 (1H, d, J = 7.5Hz), 7.94 (1H, d, J = 4.2Hz), 7.92 (1H, d, J = 5.4Hz), 7.55 
(2H, m), 7.46 (1H, d, J = 8.4Hz), 2.59 (3H, s); 13C NMR δ 133.2, 146.4, 136.3, 131.7, 
130.8, 129.7, 129.2, 128.2, 127.2, 126.6, 125.3, 124.3, 20.7; ES+ m/z 227. 
 
JR-203
-6 -5 -4 -3Control NonSpec
0
100
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300
400
500
600
700
800
900
1000
1100
1200
1300
JR-203+SPD
JR-203
log [M] Concentration
D
PM
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COMPOUND 33 (JR-204) 
N
H
N
H
NH2
NH2 Cl
H 3C
 
(4-Methyl-1-naphthylidenamino)-guanidine Hydrochloride 
 
4-Methyl-1-naphthaldehyde (225mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110mg, 1.0 mmol) were dissolved in methanol (15mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the yellow solid residue was stirred in chloroform and filtered to remove the remaining 
starting material.  The filtered product was dried on vacuum overnight to afford an off-
white powdery solid (209mg, 0.80mmol, 80% yield, 187-189ºC melting point).  1H NMR 
(300MHz, d-DMSO) δ 12.01 (1H, s), 8.99 (1H, s), 8.48 (1H, dd, J = 7.5Hz), 8.12 (2H, 
m), 7.66 (2H, m), 7.47 (1H, d, J = 7.8Hz), 2.70 (3H, s); 13C NMR δ 155.1, 145.7, 137.4, 
132.1, 130.3, 127.0, 126.8, 126.3, 126.2, 126.1, 124.8, 123.6, 19.5; ES+ m/z 227. 
 
JR-204
-6.5 -6.0 -5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
0
250
500
750
1000
1250
1500
JR-204+SPD
JR-204
log [M] Concentration
D
PM
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COMPOUND 34 (AG-19) 
N
H
N
H
NH2
NH2 Cl
O
O
 
Benzo[1,3]dioxol-5-ylmethyleneamino-guanidine Hydrochloride 
 
Piperonal (225 mg, 1.5 mmol) and aminoguanidine hydrochloride (110 mg, 1mmol) 
were dissolved in methanol (15 mL) and reacted according to the above general method.  
The product solution was dissolved on the rotary evaporator, and the residue was stirred 
in chloroform and filtered to remove the remaining starting material.  The filtered product 
was dried on vacuum overnight to afford an off white powdery solid (208 mg, 0.86 
mmol, 86 % yield, 205-206ºC melting point).  1H NMR (300MHz, D2O) δ 7.8 (1H, s), 
7.2 (1H, s), 7.0 (1H, d, J = 8.5 Hz), 6.8 (1H, d, J = 8.5 Hz); 13C NMR (DMSO-d6) δ 
155.2, 149.1, 147.8, 146.0, 127.8, 124.1, 108.0, 105.5, 101.4 . 
 
SUN-AG19
-5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
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100
200
300
400
500
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800
900
1000
1100
1200
SUN-AG19+SPD
SUN-AG19
log [M] Concentration
D
PM
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COMPOUND 35 (AG-15) 
N
H
N
H
NH2
NH2 Cl
ON
O
O
 
5-(p-Nitrophenyl)-2-furan carboxylidenamino) -guanidine Hydrochloride 
 
5-(p-Nitrophenyl)furfural (325 mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110 mg, 1 mmol) were dissolved in methanol (15 mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the residue was stirred in chloroform and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford a yellow 
powdery solid (284 mg, 0.92 mmol, 92 % yield, 165-166 ºC melting point).  1H NMR 
(300MHz, D2O) δ 8.14 (2H, d, J = 8.2Hz), 7.86 (1H, s), 7.7 (2H, d, J =8 .2Hz); 13C 
NMR(DMSO-d6) δ 155.0, 152.4, 149.8, 146.2, 135.8, 134.9, 124.6, 124.2, 116.7, 112.2. 
 
SUN-AG15
-6.5 -6.0 -5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
0
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200
300
400
500
600
700
800
900
1000
1100
1200
SUN-AG15+SPD
SUN-AG15
log [M] Concentration
D
PM
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COMPOUND 36 (AG-2) 
N
H
N
H
NH2
NH2 ClN
H
 
(Pyrrole-2-carboxylidenamino)-guanidine Hydrochloride 
 
Pyrrole-2-carboxaldehyde (142 mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110 mg, 1 mmol) were dissolved in methanol (15 mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the residue was stirred in chloroform and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford a purple powdery 
solid (151 mg, 0.81 mmol, 81 % yield, 129-130ºC melting point).  1H NMR (300MHz, 
D2O) δ 7.96 (1H,s), 7.10 (1H, m), 6.62 (1H, m), 6.3 (1H,m); 13C NMR (DMSO-d6) δ 
155.1, 137.6, 126.9, 122.1, 113.2, 109.1 . 
 
SUN-AG2
-6 -5 -4 -3 -2Control NonSpec
0
100
200
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COMPOUND 37 (JR-147) 
N N
H
N
H
NH2
NH2 Cl
 
(3-Pyridylmethylenamino)-guanidine Hydrochloride 
 
3-Pyridinecarboxaldehyde (160 mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110 mg, 1 mmol) were dissolved in methanol (15mL) and reacted according to the above 
general method.  The product solution was dissolved on the rotary evaporator, and the 
residue was stirred in chloroform and filtered to remove the remaining starting material.  
The filtered product was dried on vacuum overnight to afford an off white powdery solid 
(175 mg, 0.88mmol, 88 % yield, 228-229ºC melting point).  1H NMR (300MHz, D2O) δ 
8.70 (1H,s), 8.54 (1H,d), 8.15 (1H,d), 8.0 (1H,s), 7.45 (1H,m).; 13C NMR δ 157.4, 152.6, 
150.2, 147.6, 137.7, 132.0, 127. 
 
JR-147
-5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5 -2.0 -1.5Control NonSpec
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COMPOUND 38 (JR-146) 
N
N
H
N
H
NH2
NH2 Cl
 
(4-Pyridylmethylenamino)-guanidine Hydrochloride 
 
4-Pyridinecarboxaldehyde (160 mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110 mg, 1 mmol) were dissolved in methanol (15 mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the residue was stirred in chloroform and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford an off white 
powdery solid (171 mg, 0.86 mmol, 86 % yield, 227-228ºC melting point).  1H NMR 
(300MHz, DMSO-d6) δ 12.4 (1H, broad singlet), 8.65 (2H,m), 8.20 (1H,s), 8.0 (NH, 
broad), 7.85 (2H,m); 13CNMR (DMSO-d6) δ 155.4, 149.8, 144.1, 140.6, 121.2 . 
 
JR-146
-6.5 -5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5 -2.0 -1.5 -0.5Control NonSpec
0
250
500
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1000
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JR-146
log [M] Concentration
D
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COMPOUND 39 (AG-3) 
N
H
N
H
NH2
NH2 ClN
H
 
(Indole-3-carboxylidenamino)-guanidine Hydrochloride 
 
Indole-3-carboxaldehyde (217 mg, 1.5 mmol) and aminoguanidine hydrochloride (110 
mg, 1 mmol) were dissolved in methanol (15 mL) and reacted according to the above 
general method.  The product solution was dissolved on the rotary evaporator, and the 
residue was stirred in chloroform and filtered to remove the remaining starting material.  
The filtered product was dried on vacuum overnight to afford a brown powdery solid 
(182 mg, 0.77 mmol, 77 % yield, 230-231ºC melting point).  1H NMR (300MHz, D2O) δ 
8.10 (1H,d), 7.85 (1H,s), 7.59 (1H,s), 7.57 (1H,d), 7.36 (1H,m), 7.28 (1H,m) ; 13C 
NMR(DMSO-d6) δ 154.6, 144.5, 136.9, 131.7, 123.7, 122.6, 122.2, 120.5, 111.7, 110.4. 
 
Sun-AG-3
-6 -5 -4 -3 -2Control NonSpec
0
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1000
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1750
2000
Sun-AG3+SPD
Sun-AG3
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COMPOUND 40 (JR-207) 
N
H
N
H
NH2
NH2 Cl
HN
 
(Indole-5-carboxylidenamino)-guanidine Hydrochloride 
 
Indole-5-carboxaldehyde (217.5mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110mg, 1.0 mmol) were dissolved in methanol (15mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the light-orange residue was allowed to sit for two days at which point the residue had 
become a peach-colored solid.  This solid was stirred in chloroform and filtered to 
remove the remaining starting material.  The filtered product was dried on vacuum 
overnight to afford a peach-pink powdery solid (148mg, 0.62 mmol, 62%yield, 177-
180ºC melting point).  1H NMR (400MHz, d-DMSO) δ 11.88 (1H, s), 11.45 (1H, s), 8.83 
(1H, s), 8.21 (1H, s), 7.95 (1H, s), 7.71 (1H, dd, J = 8.4Hz, 1.6Hz), 7.43 (1H, d, J = 
8.8Hz), 7.40 (1H, t, J = 2.6Hz), 6.49 (1H, m); 13C NMR δ 155.3, 148.7, 137.2, 127.5, 
126.6, 124.5, 121.5, 119.9, 111.8, 101.9; ES+ m/z 202. 
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COMPOUND 41 (JR-214) 
N
H
N
H
NH2
NH2 ClN
CH3
 
(1-Methylindole-3-carboxylidenamino)-guanidine Hydrochloride 
 
1-Methylindole-3-carboxaldehyde (234mg, 1.5 mmol) and aminoguanidine 
hydrochloride (110mg, 1.0 mmol) were dissolved in methanol (15mL) and reacted 
according to the above general method.  The product solution was dissolved on the rotary 
evaporator, and the residue was stirred in diethyl ether and filtered to remove the 
remaining starting material.  The filtered product was dried on vacuum overnight to 
afford a cream-colored powdery solid (209mg, 0.83 mmol, 83% yield, 136-138ºC melting 
point).  1H NMR (400MHz, d-DMSO) δ 8.33 (1H, s), 8.31 (1H, d, J = 8.0Hz), 7.87 (1H, 
s), 7.49 (1H, d, J = 8.0 Hz), 7.29 (1H, t, J = 8.0Hz), 7.18 (1H, t, J = 8.0 Hz), 3.81 (3H, s); 
13C NMR (300MHz, d-DMSO) δ 154.5, 144.1, 137.4, 135.2, 124.1, 122.8, 122.4, 120.9, 
110.1, 109.5, 32.9; ES+ m/z 216. 
 
JR-214
-6.5 -6.0 -5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
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COMPOUND 42 (JR-215) 
N
H
N
H
NH2
NH2 ClN
H
H3C
 
(6-Methylindole-3-carboxylidenamino)-guanidine Hydrochloride 
 
6-Methylindole-3-carboxaldehyde (119mg, 0.75 mmol) and aminoguanidine 
hydrochloride (55mg, 0.5 mmol) were dissolved in methanol (15mL) and reacted 
according to the above general method.  The product solution was dissolved on the rotary 
evaporator, and the yellow solid residue was stirred in chloroform and filtered to remove 
the remaining starting material.  The filtered product was dried on vacuum overnight to 
afford a tan powdery solid (104mg, 0.83 mmol, 83% yield, 128-132ºC melting point).  1H 
NMR (400MHz, d-DMSO) δ 11.65 (1H, s), 8.32 (1H, s), 8.15 (1H, d, J = 8.0 Hz), 7.79 
(1H, s), 7.23 (1H, s), 6.95 (1H, d, J = 8.0Hz), 2.40 (3H, s); 13C NMR (300MHz, d-
DMSO) δ 154.6, 144.9, 137.5, 132.0, 131.4, 122.4, 122.0, 121.7, 111.7, 110.5, 21.6; ES+ 
m/z 216. 
 
JR-215
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COMPOUND 43 (AG-5) 
N
H
N
H
NH2
NH2 Cl
S
 
(3-Thiophenecarboxylidenamino)-guanidine Hydrochloride 
 
3-Thiophenecarboxaldehyde (168 mg, 1.5 mmol) and aminoguanidine hydrochloride 
(110 mg, 1 mmol) were dissolved in methanol (15 mL) and reacted according to the 
above general method.  The product solution was dissolved on the rotary evaporator, and 
the residue was stirred in chloroform and filtered to remove the remaining starting 
material.  The filtered product was dried on vacuum overnight to afford a brown powdery 
solid (167 mg, 0.82 mmol, 82 % yield, 181-182ºC melting point).  1H NMR (300MHz, 
D2O) δ 8.11 (1H, s), 7.81 (1H, m), 7.56-7.51 (2H, m) ; 13C NMR (DMSO-d6) δ 155.2, 
141.9, 136.6, 128.9, 127.3, 125.2 . 
 
SUN-AG5
-6 -5 -4 -3 -2Control NonSpec
0
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900
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SUN-AG5
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COMPOUND 44 (AG-14) 
N
H
N
H
NH2
NH2 Cl
 
trans-Cinnamylidenamino-guanidine Hydrochloride 
 
trans-Cinnamaldehyde (198 mg, 1.5 mmol) and aminoguanidine hydrochloride (110 
mg, 1 mmol) were dissolved in methanol (15 mL) and reacted according to the above 
general method.  The product solution was dissolved on the rotary evaporator, and the 
residue was stirred in chloroform and filtered to remove the remaining starting material.  
The filtered product was dried on vacuum overnight to afford a very light yellow 
crystalline solid (161 mg, 0.72 mmol, 72 % yield, 81-82ºC melting point).  1H NMR 
(300MHz, DMSO-d6) δ 12.04 (1H, s), 8.0 (1H,d, J = 8.4 Hz), 7.7 (2H, m), 7.55(2H, d, J = 
8.4Hz), 7.40 (1H, m), 7.15 (1H, m), 6.90 (1H, m);13C NMR (DMSO-d6) δ 155.0, 148.7, 
140.1, 135.3, 129.0, 128.8, 126.9, 123.9. 
 
SUN-AG14
-5.5 -5.0 -4.5 -4.0 -3.5 -3.0 -2.5Control NonSpec
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COMPOUND 45 (JR-132) 
N
N
H
N
H
H2N
NH 2
H
H
N NH2
NH2 Cl
Cl
 
p-Bis-benzylidenamino-guanidine Hydrochloride 
 
p-Terephthalaldehyde (402mg, 3.0 mmol) and aminoguanidine hydrochloride (553mg, 
5.0 mmol) were dissolved in methanol (50mL) and reacted according to the above 
general method.  The product solution was dissolved on the rotary evaporator, and the 
residue was stirred in chloroform and filtered to remove the remaining starting material.  
Two separate solid samples were collected as part of the solid product floated above the 
chloroform, and the remainder sunk to the bottom.  The two solid fractions were then 
finely powdered and stirred again with chloroform to ensure separation.  The light-yellow 
powder top product was characterized as a mixture of benzylidino-guanidine-4-
carboxaldehyde and the bis product.  The bottom product was isolated and characterized 
as p-terephthalaldehyde-bis-guanylhydrazone, a fine off-white powder (365 mg, >300ºC 
melting point, m/z 124)  1H NMR (300MHz, d-DMSO) δ 12.24 (2H, s), 8.21 (2H, s), 
7.94 (4H, s); 13C NMR δ 155.3, 145.8, 135.0, 127.7. 
 
JR-132
-6 -5 -4 -3 -2Control NonSpec
0
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1000
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log [M] Concentration
D
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CHAPTER 4: X-RAY CRYSTALLOGRAPHY 
 
4.1 Introduction 
 
The N-methyl-D-aspartate (NMDA) receptors are ligand-gated ionotropic 
glutamate receptor channels, which are regulated by a variety of endogenous molecules 
and multiple receptor complex binding sites. Overactivation of the NMDA receptor can 
lead to hyperexcitability and a number of neurotoxic effects and neurological diseases; 
however, the physiological function of this channel is crucial in many neural functions 
such as learning and memory, and thus a therapeutic agent cannot be one which 
irreversibly inhibits channel flux. 
Channel blockers at the NMDA receptor complex can be very potent antagonists, 
but they possess very high abuse potential and exhibit neurotoxicity.  The polyamine sites 
are an interesting focus of research, as the antagonists at this site exhibited neither of 
these detrimental qualities, while allosterically inhibiting channel activity.  The 
polyamine agmatine has been demonstrated to exhibit antagonist activity at the 
polyamine binding sites of the NR2B subunits of the NMDA receptor complex, but only 
in pathologically high levels of the longer-chain endogenous polyamine-site agonists 
such as spermine and spermidine (Chapter 1).  These intriguing properties begat this 
entire study, in an effort to (1) increase the potency of agmatine analogs for the “high 
affinity” site, which is expected to reduce the neuropathological effects regulated by 
NMDARs, and to (2) maintain or increase the selectivity of agmatine analogs for this site 
as opposed to the “low-affinity” site, which likely causes the unwanted side effects seen 
with the direct channel blockers (see Chapters 1-3). 
Aminoguanidine hydrochloride, an agmatine analog missing the n-butyl chain, 
has been examined as a possible NMDAR antagonist, but was shown to have no activity 
in the P2 membrane [3H]MK-801 displacement assay (Section 3.1).  However, a small 
library of conjugates of aminoguanidine with an array of arylaldehydes were synthesized 
and screened in the above assay; the 45 compounds tested thus far have demonstrated a 
100% hit rate as NMDAR inhibitors. 
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The structure-activity relationships of these compounds appears to be quite 
complex, and any additional structural data of these products could vastly improve our 
ability to construct a potential pharmacophore.  Therefore, several of the arylidenamino-
guanidine compounds from Chapter 3 were crystallized and submitted for X-ray structure 
determination to obtain more in-depth structural information. 
Crystal structure determination by X-ray crystallography is a technique which has 
been used for almost fifty years, and has become a vital tool in inorganic and organic 
structure analysis. Particularly, X-ray crystallography is important for determining the 
structures of small molecules and macromolecules, such as protein structures and their 
interactions with drug molecules.  In order to detect and analyze the diffraction pattern 
generated by a molecular structure, a large amount of symmetrical molecules in a crystal 
structure must be used.  The crystallization process often presents difficulty, especially 
with proteins, but is much more facile for small organic molecules such as those 
presented in this chapter.  Using the crystals in a small amount of an appropriate solvent, 
the structure can be interpreted from an electron density map generated by the diffraction 
pattern. 
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4.2 Methods 
 
The three arylidenamino-guanidine compounds were synthesized by the Schiff 
base formation of the substituted benzaldehydes with aminoguanidine hydrochloride 
(Scheme 4.1).   
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Scheme 4.1 Synthesis of the three arylidenamino-guanidine compounds which 
underwent X-ray structure determination 
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Compound 7 (JR-125, (4-cyanobenzylidenamino)-guanidine hydrochloride), 
compound 18 (JR-122, (3-nitrobenzylidenamino)-guanidine hydrochloride), and 
compound 21 (JR-223, (4-methoxy-3-nitrobenzylidenamino)-guanidine hydrochloride) 
were prepared according to Scheme 4.1.  Further experimental and analytical details are 
described in Section 3.6.  Suitable crystals for X-ray analysis were prepared with the 
following solvents: compound 7 was crystallized from a mixture of ethanol, isopropanol, 
and water; compound 18 was crystallized from ethanol and water; and compound 21 
was crystallized from methanol. 
The crystals were submitted to Dr. Sean Parkin at the UK Chemistry X-Ray 
Laboratory for X-ray analysis.  Software programs used in the analysis were as follows.  
Data collection: COLLECT (Nonius, 1999); cell refinement: SCALEPACK (Otwinowski 
and Minor, 1997); data reduction: DENZO-SMN (Otwinowski and Minor, 1997); 
program used to solve structure: SHELXS97 (Sheldrick, 1997); program used to refine 
structure: SHELXL97 (Sheldrick, 1997); molecular graphics: XP in SHELXTL/PC 
(Sheldrick, 1995); software used to prepare materials for publication: SHELXL97 
(Sheldrick, 1997) and local procedures. 
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4.3 Results and Discussion 
 
4.3.1 X-ray Structure Results: 
 
Compound 21 was discovered to have a low IC50 value in the displacement of 
MK-801, and in addition, yielded a biphasic curve for this displacement in the presence 
of spermidine, a neurotoxic agent at high concentrations.  The biphasic nature of the 
curve is indicative of a high degree of selectivity for the “agmatine” site of the NMDAR 
complex.  
 
Figure 4.1 X-ray structure of compound 21, (4-methoxy-3-
nitrobenzylidenamino)-guanidine hydrochloride.  
Displacement ellipsoids are drawn at the 50% probability  
N
H
N
H
NH2
NH2 Cl
N
OO
O
H3C
level with hydrogen atoms included. 
 
Compound 18 was neither as selective for, nor as potent as compound 21 at the 
high-affinity agmatine site of the NMDA receptor complex.  However, the structures of 
these two compounds are quite similar, differing only by the inclusion of a methoxy 
group at position 4 of the phenyl ring in compound 21.  Therefore, this compound was 
subjected to X-ray structure analysis in order to determine if the addition of the methoxy 
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group, which resulted in such a large difference between the activities of the two 
compounds, might have caused a significant structural change elsewhere in the molecule, 
particularly at the aminoguanidine moiety.  
 
N
H
N
H
H2N
NH2Cl
N
O O
Figure 4.2 X-ray structure of compound 18, (3-
nitrobenzylidenamino)-guanidine hydrochloride.  
Displacement ellipsoids are drawn at the 50% probability 
level with hydrogen atoms included. 
 
Compound 7 was one of the least potent and selective NMDAR complex 
agmatine site inhibitors of the arylidenamino-guanidine compounds synthesized.  The 
structure of this compound was elucidated by X-ray crystallography in an attempt to 
determine if the presence of the cyano group had any noticeable effect on the structure of 
the molecule, particularly in the guanidino moiety, which could explain its lack of 
activity.  
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Figure 4.3 X-ray structure of compound 7,  
N
H
N
H
NH2
NH2 Cl
C
N
(4-cyanobenzylidenamino)-guanidine hemisulfate.  
Displacement ellipsoids are drawn at the 50%  
probability level, without hydrogen atoms 
 
The crystal structure of the starting material, aminoguanidine hydrochloride, was 
among the first published X-ray data (Bryden, 1957).  As the Schiff base formation with 
the aminoguanidine moiety is believed to be the crucial (and entirely conserved) part of 
the structural motif in the arylidenamino-guanidine series, the detailed structure of the 
starting material was deemed to be quite relevant to the interpretation of structure-activity 
in these products. 
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Figure 4.4 Structure of aminoguanidine hydrochloride with bond lengths and 
resonance structures.  Location of Schiff base formation is denoted (R).  (Bryden, 
1957) 
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4.3.2 Discussion: 
 
In order to gain further information about the class of arylidenamino-guanidine 
compounds utilized in these studies, suitable crystals of three of these compounds were 
prepared for X-ray analysis.  Structures were elucidated for each of them (Figures 4.1-
4.3).  The main points from structural information obtained were as follows:  
 
1) Carbon-nitrogen bond lengths within the guanidine moiety; the lengths of 
these three bonds are an indication of  the relative dispersal of  π-orbital 
electrons of the C-N double bonds, and in turn, reflect the relative partial 
charge distribution among the three nitrogen atoms. 
2) The planarity of the molecule as a whole is an indication of a high degree of 
double-bond conjugation, specifically between the phenyl ring and the 
guanidine moiety. 
3) Bond lengths and dihedral angles along the bridge between the phenyl ring 
and guanidine moiety are also factors that may be an indication of a high 
degree of conjugation. 
4) Orientation of the double bond formed between the aldehyde and 
aminoguanidine, i.e. E or Z geometry; in addition, if any double-bond 
character is shared with the N-N bond in the aminoguanidine moiety, this 
bond may exist in the E or Z orientation. 
5) The possibility of intramolecular hydrogen bonding (i.e. between the protons 
of the terminal nitrogen molecules in the aminoguanidine moiety and the 
oxygen molecules of the ring-substituted nitro groups for compound 23); with 
the correct double-bond orientation along the chain between the ring and the 
guanidine moiety, several of these are possible. 
 
While aminoguanidine hydrochloride (and most terminal guanidine-containing 
compound such as arginine) exists in resonance stabilized forms with the double bond 
characteristic primarily in the exo-position (Figure 4.4), some compounds such as 
canavanine have a different resonance stabilized structure which favors the endo-
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position, due to electronegativity effects of the neighboring oxygen atom.  In the case of 
these arylidenamino-guanidine compounds, a resonance structure favoring the endo-
position of the guanidino moiety would also confer additional conjugation, which would 
reach into the ring, and possibly provide another measure of stability and conformational 
rigidity to the molecule.   
The values for the bond lengths in the guanidine moiety in each of the 
arylidenamino-guanidino compounds were comparable to those found in the starting 
material, aminoguanidine hydrochloride.  The molecular distances reported for 
aminoguanidine hydrochloride were 1.32 Å for the exo C-N bonds, and 1.35 Å for the 
one in the endo position, which were calculated to correspond to a weighting of roughly 
40% double-bond contribution for each of the exo double-bond forms, and 20% for the 
endo double-bond (Bryden, 1957).  The values obtained for the corresponding bond 
lengths in the three arylidenamino-guanidine compounds are shown in Table 4.1 below. 
 
Table 4.1 Carbon-nitrogen bond lengths within the guanidino group of 
Aminoguanidine hydrochloride and the three arylidenamino-guanidine compounds 
from this chapter (numbering of nitrogen atoms are denoted as in Figure 4.4) 
 
 C1 – N2 (endo) C1-N3 (exo) C1-N4 (exo) 
Aminoguanidine 
Hydrochloride 
1.35 Å 1.32 Å 1.32 Å 
Compound 7 1.346 (8) Å 1.310 (8) Å 1.326 (8) Å 
Compound 18 1.341 (3) Å 1.327 (3) Å 1.315 (3) Å 
Compound 21 1.350 (2) Å 1.324 (2) Å 1.317 (2) Å 
 
 
 The C-N bond length values observed in the structurally similar compounds 18 
and 21 were remarkably similar for both the endo and exo C-N bonds, and they were also 
very close to the bond lengths found in aminoguanidine hydrochloride.  In both of these 
arylidenamino-guanidine compounds, the C1-N3 bond lengths were significantly longer 
than the C1-N4 bond lengths; the longer C1-N3 bonds corresponded to the exo nitrogen 
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atom which is located farthest from the phenyl ring (see Figure 4.4).  However, while the 
C-N bond lengths of the guanidine moiety in compound 7 were also not significantly 
different from those in aminoguanidine hydrochloride, the two exo-position C-N bond 
lengths were different than the exo C-N bond lengths in compounds 18 and 21: in 
compound 7, the exo C-N bond farthest from the phenyl ring (C1 – N3) was the shorter of 
the two (1.310 (±8) Å, compared to 1.326 (±8) Å for the other exo C-N bond, C1-N4).  
This difference in the exo C-N bond lengths does not seem to be large enough to 
contribute significantly to charge distribution within the guanidine moiety, but 
nevertheless should be examined.  The bond length difference is most likely due to the 
difference in environment of the two terminal nitrogen atoms, N3 and N4.  Compounds 
18 and 21 have an aromatic meta-nitro group in their structure, which may affect the way 
the crystals, specifically the guanidine moieties of these molecules, interact with the 
solvent or counter-ion.  Compound 7 has an aromatic cyano group in the para-position, 
and the distance of this substituent from the guanidine moiety may be large enough to 
remove any effects on the exo C-N bond lengths.  The overall observation remains that 
the Schiff base formation that yields these arylidenamino-guanidino products does not 
significantly change the double-bond distribution within the resulting products’ guanidine 
moieties from that observed in the starting material, aminoguanidine hydrochloride.  
Therefore, the double bond character in the exo C-N bonds is similar to what it was in the 
starting material, with the positive charge spread mostly between the two terminal 
nitrogen atoms, N3 and N4 (Figure 4.4).  Nevertheless, even 20% double bond character 
in the endo C-N bond of the guanidine moiety, as seen in the starting material, 
contributes significantly to conjugation of the molecule as a whole. 
While the classical structure of the guanidino moiety does not indicate double 
bond character in the endo C-N bond, a extended distribution of π-orbital electron 
characteristic throughout the bonds of the molecule is suggested by the planarity seen in 
each of the three compounds.  As seen in Figures 4.5 - 4.7, the guanidino moiety, the 
phenyl ring, and the imine which lies between them are all planar to each other.  A 
general structure of this resonance stabilization is seen in figure 4.9. 
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Figure 4.5 Crystal packing of compound 7, viewed along the A-direction 
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Figure 4.6 Crystal packing of compound 18, viewed along the B-direction 
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Figure 4.7 Crystal packing of compound 21, viewed along the C-direction; 
nitro-groups appear as the only non-planar parts of each molecule 
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While the crystal packing diagrams of compounds 7, 18, and 21 illustrated in Figures 
4.5 - 4.7 appear to show the planarity of the three molecules, the torsion angles have been 
measured and provide numerical evidence of the planarity.  In the molecules illustrated in 
Figure 4.8, it can be seen that the torsion angles would be +180° (or -180°) in a planar 
chain.   
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Figure 4.8 Torsion and bond angle measurements, with Newman projections. 
 
A general representation of the resonance stabilization between the phenyl ring and the 
guanidine moiety is shown in Figure 4.9, which demonstrates the conjugation of the 
molecule when the guanidino moiety C-N double bond exists in the endo position, and 
the accompanying planarity.  The torsion angles along the bonds between the phenyl ring 
and the guanidine moiety are given in Table 4.2. 
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Figure 4.9 General planar arylidenamino-guanidine compound structure, as 
conferred by resonance stabilization (relevant atoms are numbered for  
torsion and bond angle measurements in Tables 4.2 and 4.3, respectively) 
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Table 4.2 Torsion angles which link the phenyl and guanidine moieties in  
Figure 4.9 for compounds 7, 18, and 21 
Torsion Angle Compound 7 Compound 18 Compound 21 
C4-C3-C2-N1 177.6° (6) 177.0° (2) 176.38° (16) 
C3-C2-N1-N2 178.5° (6) 179.2° (2) 178.78° (14) 
C2-N1-N2-C1 182.4° (6) 182.5° (2) 176.16° (15) 
N1-N2-C1-N3 178.6° (6) 173.8° (2) 187.91° (14) 
 
None of the torsion angles deviate more than 4 degrees from the plane of the 
molecule, excepting the torsion angle which ends at the exo guanidino N3 amine (Figure 
4.9).  While this final torsion angle does not deviate more than 8 degrees from 180, it 
could be indicative of a slight rotational freedom along the C1-N2 bond, the endo 
guanidino C-N bond.   
Planarity, however, is not necessarily an indication of sp2 hybridization, which 
would be accompanied by double-bond conjugation or the delocalization of π-bond 
electrons throughout the molecule.  As demonstrated in Figure 4.8B, single-bonds can 
also have 180° torsion angles, and thus four carbon atoms of an aliphatic chain (e.g. n-
butyl) can all be coplanar; this planarity is likely a transient state in solution, as it is not 
due to the lack of rotational freedom associated with double bonds.  However, in crystal 
structures, the packing will force such unsaturated chains into a single form, and it is 
important to attribute the planarity of the arylidenamino-guanidino compounds to its 
proper cause by defining the multiplicity of the bonds.  Single and double bonds can 
easily be differentiated by their bond angles.  A double bond compound will have sp2 
hybridization and roughly 120° bond angles will be formed between the two bonded 
atoms and their substituents (Figure 4.8A), while a single bond compound will have sp3 
hybridization and form roughly 109.5° bond angles between the two bonded atoms and 
their substituents (Figure 4.8B).  The angles of the bonds which arise between the phenyl 
ring and the guanidine moiety due to the Schiff base formation of these compounds are 
shown in Table 4.3. 
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Table 4.3 Bond angles formed between the phenyl and guanidine moieties in  
Figure 4.9 for compounds 7, 18, and 21 
Bond Angle Compound 7 Compound 18 Compound 21 
C3-C2-N1 120.5° (6) 119.9° (2) 120.63° (15) 
C2-N1-N2 116.0° (6) 116.3° (2) 115.00° (14) 
N1-N2-C1 118.8° (6) 117.4° (2) 118.48° (14) 
N2-C1-N3 119.8° (6) 118.7° (2) 117.05° (15) 
 
 These data reveal bond angles within 3° of a perfect sp2 120° for each of the 
angles associated with the imino moiety and the aminoguanidine moiety, except for the 
bond angles of the C2-N1-N2 atoms (Figure 4.9), which were in the range of 115.0° to 
116.3° for each compound.  This bond angle lies in between the ideal sp2 and sp3 dihedral 
angles; this is unexpected, considering the fact that the C2-N1 imine bond is the only bond 
between the phenyl ring and the guanidino moiety which is expected to have double-bond 
characteristics.  Resonance structures for these specific compounds cannot justify the N1 
atom converting to an sp3-hybridized state (such a resonance structure can be drawn in 
the presence of electron-donor substituents on the phenyl ring, but compounds 7 and 18 
have no such substituent).  In addition, there are no ortho-position phenyl substituents 
which could be sterically repulsing the exo N4 atom in the guanidine moiety, which could 
lower the C2-N1-N2 bond angle.  Regardless, this bond angle is clearly larger than the 
109.5° bond angle expected in a single bond.  The observation remains that the C2, N1, 
and N2 atoms that serve to connect the phenyl ring to the guanidine moiety display 
primarily sp2 hybridization, based on the bond angles and torsion angles they form.  This 
double-bond characteristic causes an extended conjugation of the molecules (Figure 4.9), 
resulting in a hybridization of these Lewis structures and distribution of π-bond electrons 
from the phenyl ring through to the guanidine moiety.   
In addition to the bond angles and torsion angles, it can be observed that 
formation of the Schiff base at the C2-N1 bond also impacted the length of the N1-N2 
bond. This bond was reported as 1.42 Å in the aminoguanidine hydrochloride starting 
material, but in the products was observed as having a length of 1.372 (±7) Å in 
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compound 7, 1.374 (±3) Å in compound 18, and 1.381(±2) Å in compound 21.  These 
data are further evidence of the significant π-bond characteristics of this bond. 
Data obtained from the X-ray analysis clearly demonstrated an exclusive E-
geometry in the newly formed imine double-bond, for each of the three products 
examined; in addition, the N1-N2 (Figure 4.9) bond has significant double-bond 
characteristics, and also has the “E-geometry” in each compound.  In this way, the rigid 
C3-C2-N1-N2-C1 chain is elongated and extends the guanidine moiety to a maximum 
distance from the phenyl ring, eliminating the possibility of intramolecular hydrogen 
bonding between the guanidino group and the phenyl ring or its substituents (Figure 4.9, 
along with the X-ray structures of Figures 4.1-4.3).  This information about the 
orientation of the double bond is crucial, as it is important to know that each of these 
compounds had the same orientation, and it is likely that the same geometry of the imino 
moiety is present in all the arylidenamino-guanidine compounds synthesized.   
The structural conservation between the three compounds subjected to X-ray 
analysis is especially important in the development of a pharmacophore model.  The lack 
of rotational freedom resulting from the double-bond conjugation through the molecules 
from the guanidine moiety to the phenyl ring provides an excellent basis for establishing 
the locations of agmatine binding site residues which interact with this novel class of 
ligands.  While the data from Chapter 3 clearly indicates that structural modification of 
the aromatic ring moiety, as well as the ring substituents, can result in increased potency 
and selectivity for the agmatine binding site of the NMDAR complex, the definitive X-
ray data of the conserved “backbone” moiety (Figure 4.10) allows the SAR study to focus 
on these substituents with knowledge of the structurally integrity of the rest of the 
molecule. 
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Figure 4.10 X-ray structure of compound 21 with boxed  
“conserved backbone moiety” 
 
4.4 Conclusions 
  
 Three of the arylidenamino-guanidine compounds which were synthesized and 
screened (see Chapter 3) have been subjected to X-ray analysis in order to obtain more 
structural information that may be pertinent to their interaction with the agmatine binding 
site of the NMDA receptor complex.  The three compounds were compound 21, one of 
the most potent and selective agmatine-site NMDAR inhibitors, compound 18, which 
was structurally similar to compound 21 but significantly less active, and compound 7, 
which was one of the least potent and selective agmatine-site NMDAR inhibitors in this 
set.  
The data obtained yielded important structural information, which was very 
similar within the subset of these three compounds.  The guanidine moiety in these 
compounds has double bond character primarily shared between the exo C-N bonds, as is 
seen in the starting material, aminoguanidine hydrochloride.  However, the endo C-N 
bond is shorter than a standard C-N single bond, indicating that it has double-bond 
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character as well, and the formal positive charge is shared between the endo nitrogen (N2 
in Figure 4.9) and the two exo nitrogen atoms (N3 and N4 in Figure 4.9).  The N1-N2 
bond, which was observed as a typical single bond in the starting material, 
aminoguanidine hydrochloride, has shortened significantly in the process of the Schiff 
base formation.  This is very significant as this bond is clearly taking part in resonance 
stabilization of the molecule, and joining the π-electron clouds of the guanidine moiety 
with that of the phenyl ring, which confers a rigid planarity to these molecules. 
The X-ray structure (Figures 4.4 - 4.7) clearly shows that these compounds are 
almost completely planar.  Each of the torsion angles which connect the imino moiety to 
the guanidine moiety and the phenyl ring are close to 180°, and the dihedral angles along 
this bridge were very close to 120°, data which reveal the sp2 characteristic of the atoms 
between the guanidine moiety to the phenyl ring.  The C2-N1 and N1-N2 bonds (Figure 
4.9), both of which have double bond character, are observed to be strictly in the E 
geometrical form, for all three compounds.  These trans double bonds are very significant 
in that they form a rigid backbone which distances the guanidine moiety from the phenyl 
ring.  The space between these two moieties will disallow any interactions (e.g. hydrogen 
bonding) between the guanidine and the ring substituents (at least at the meta- and para-
positions). 
While none of the data obtained from these X-ray structures was sufficient to 
substantially differentiate these compounds from each other based on structural 
characteristics, it is of obvious importance in the development of a pharmacophore 
model.  The conformational rigidity of these structures dramatically simplifies SAR 
within this set of arylidenamino-guanidine compounds, and molecular modeling and 
pharmacophore model development will be easier to carry out as a result this information. 
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 CHAPTER 5: MOLECULAR MODELING 
 
5.1 Introduction 
 
With many structure-activity studies, optimization of lead compounds is a 
continuous process which is never complete as long as there are untested molecules; this 
work is no exception.  While a number of promising inhibitory modulators of the NMDA 
receptor complex have been developed and will be further examined in pharmacological 
assays, these leads may be rudimentary precursors of therapeutically useful drug 
molecules yet to be discovered.  The search for a quantitative structure-activity 
relationship between these molecules and their activity is indeed a very important and 
relevant step towards understanding the agmatine binding site and the way drug 
molecules will interact with it. 
Important structure-activity data was interpreted by scrutiny of each compound in 
the set of arylidenamino-guanidine compounds, and several observations have been made 
which postulate the importance of steric and electronic effects on both the agmatine-site 
affinity and selectivity of these molecules.   
 While several promising lead compounds have resulted from this study, the 
activity of this group of arylidenamino-guanidines as a whole attests to the importance of 
further examination of the structural descriptors of each molecule as they relate to 
inhibitory activity.  Molecular modeling with partial least squares and neural network 
approaches will thus be undertaken with this set of structurally similar molecules in an 
effort to facilitate further development of this intriguing set of compounds.  Indeed, the 
phenylidenamino-guanidine moiety (Figure 4.10) is predominantly conserved in this set 
of 45 active compounds, thus a structure-activity examination of the ring substituents 
may reveal much about the polyamine binding sites of the NMDA receptor complex. 
 As stated above, many of the structural features of the arylidenamino-guanidines 
were examined and discussed in Chapter 3 of this work.  However, using the technology 
of the present time, computational methodologies can be used to discover and 
differentiate molecular descriptors that are less readily apparent to even the most well-
trained chemist.  Utilizing computer-generated descriptors, a number of models can be 
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generated, which highlight important features to include (and in some cases, exclude) in 
the design of potentially potent candidates.  In addition, using these models to evaluate 
potential inhibitors in silico can save synthetic time and money, while dramatically 
increasing the hit rate of those molecules which are generated from such a process. 
 Two different computational models were developed in order to inspect the 
relationships between structural descriptors and the observed SAR in the NMDA receptor 
assay.  These included utilization of partial least squares (PLS) regression, as well as a 
back-propagation artificial neural network (ANN) analysis method.  The former is a 
linear model which generates an equation weighting the values of the descriptors to 
afford an equation which predicts IC50 values of compounds based on their molecular 
properties.  The latter is a more complex non-linear modeling system, which imitates the 
function of the human brain by propagating signals of multivariable data through 
processing elements called neural nodes, which analyze and process the data.  These 
neural nodes are arranged into a sequence of layers, and they are interconnected to form a 
feed-forward back-propagation network.  In the input layer, each input node corresponds 
to one of the variables (or descriptors) used in the model; from the input layer, signals are 
propagated through a hidden layer and thence to the output layer, generating the predicted 
values.  
 
 
5.2 Methods 
 
 The modeling process consisted of three steps: (i) construction and minimization 
of molecular structure, (ii) selection of descriptors according to the experimental data, 
and (iii) determination of the neural network configuration.   
 Molecular structure was modeled in silico with the use of the Sybyl discovery 
software 7.0.  Each molecule used in the study was drawn using the program, and formal 
charges were assigned. The geometry optimization (energy minimization) was first 
performed by using the molecular mechanics (MM) method with the Tripos force field 
and the default convergence criterion. To consider various possible conformation of a 
molecule, a variety of conformations for a given molecule were obtained that were 
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associated with local minima on the potential energy surface from RANDOMSEARCH 
in Sybyl.  Each of these conformations was geometrically optimized with semi-empirical 
molecular orbital (MO) energy calculations at the PM3 level to locate the most stable 
conformation, i.e. the ones with the lowest energy. 
 For each set of molecules examined, a set 313 molecular variables was generated 
by using the DRAGON program; these variables consisted of zero-dimensional 
(constitutional) descriptors, one-dimensional descriptors (empirical and physical 
descriptors as well as functional group indications), two-dimensional (topological) 
descriptors, and three-dimensional (WHIM) descriptors.  These descriptors were then 
transferred to a Microsoft Excel database, along with the pIC50 values of the 
corresponding molecules; a value for the correlation of each descriptor to the pIC50 
values of each compound was generated using the CORREL function, and the descriptors 
with the best correlation were selected to be further examined, while those with an 
extremely low correlation were discarded.  For example, in the first set of compounds 
modeled, which included the preliminary 28 arylidenamino-guanidines, only the 134 
descriptors with a CORREL function absolute value of greater than 0.3 were examined. 
 The partial least squares (PLS) model, used to examine the set of arylidenamino-
guanidines mentioned above, was developed mainly by tedious selection and 
improvement upon inclusion of individual descriptors.  Using the PLS modeling program 
in the Sybyl software package combined with the refined list of descriptors, R & rcv-
squared values could be generated for selected parameters.  Thus, a model could be 
swiftly generated for any combination of descriptors, with corresponding cross-validated 
rcv2 values and standard error.  However, in order to generate a predictive model, 
selection of descriptors proceeded by using the PLS method to determine the highest R2-
value of a model including each descriptor one at a time, selecting the best model, then 
repeating the process of adding each remaining descriptor to form a new model.  Each 
iteration therefore necessitated the generation of over 100 models and selection of the 
“best” individual model, while at the same time indicating the descriptors which were 
most related to the compound’s activity.  Each added descriptor resulted in an increase in 
the R2-value, but eventually this increase became negligible or 0, at which point the 
model was deemed complete, and addition of further descriptors would only serve to 
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complicate the linear equation without contributing significantly to the model itself.  
Addition of further descriptors would also dilute the importance of the descriptors which 
were most related to activity. 
 The descriptors which accounted for the best PLS model were then used in the 
artificial neural network (ANN) model, using methods refined by Dr. Fang Zheng in the 
laboratory of Dr. Crooks.  This method of feed-forward back-propagation model 
development used the neural network C program.  Each compound in the data set was 
singularly presented to the working ANN model for the learning process, with its 
descriptors being input to the input layer, and the final output from the output layer being 
compared to the experimental value for experimental pIC50 which was generated in the 
laboratory  Leave-one-out cross validation was employed in the modeling, and the 
validity of each model was evaluated based on the discrepancy of the set of output values 
and the set of experimental values.  The model assessment was based on the Pearson 
correlation coefficient (R), the root mean square deviation (RMSD), and the predictive 
coefficient (rcv).  The latter value was defined as: 
SD
PRESSSDrcv −=  
Where SD is the sum of squared deviations of each measured log(1/IC50) value from its 
mean and PRESS is the predictive sum of squared differences (the sum of squared 
differences between actual and predicted values).  
 
 
5.3 Results and Discussion 
 
 The modeling work described in this dissertation was performed in order to lend 
insight into the structure-activity relationships between the molecules synthesized and 
their inhibitory activity demonstrated by the displacement of [3H]MK-801 from the 
NMDA receptor complex, as described in Chapters 2 and 3.  In addition, the models have 
contributed, and will continue to contribute towards the development of more active 
arylidenamino-guanidine compounds at this site, while reducing the cost and time 
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associated with the laboratory synthesis by indicating which structures should be 
synthesized based solely on predicted structures and activities. 
 Attempts were made to model the “agmatine binding site” based on the agmatine 
analogs prepared and evaluated in Chapter 2.  These compounds possessed a wide 
spectrum of activity in the NMDAR assay utilized in this study, and represented a wide 
variety of structures as well.   However, when these compounds were assigned 
descriptors, and each descriptor correlated with their pIC50-values, it became readily 
apparent by the utter lack of any correlation that such a set was too varied in structure to 
model as a single group of compounds.  This may be due to the structural variation, but 
more likely that the wide range of functional groups allowed the molecules to act at 
different polyamine recognition sites as well as the channel site, and thus the activity was 
not uniformally attributable to their action at a single binding site. 
 It was therefore necessary to examine a smaller subset of compounds which were 
more structurally similar, and thus hypothesized to act at the same binding site.  The 
group of arylidenamino-guanidino compounds provided a subset which met these 
qualifications.  At that time, a preliminary set of 28 compounds had been tested, which 
included the AG-compounds synthesized by Dr. Sundar Neelakantan, and the JR-
compounds in the range of JR-121 to JR-197.  There compounds maintained the aromatic 
“arylidenamino-guanidine” moiety of Figure 4.10 (the only exception being AG-14, in 
which the aromatic ring is separated from the guanidino moiety of the molecule with an 
E-double bond linker), and possessed a variety of differing aromatic rings as well as 
aromatic ring-substituents. The pIC50-values of these compounds spanned the range of -
3.0 to -5.0, ensuring that there would be a sufficient difference in activity that might be 
assignable to structural and electronic differences.  As a minimum of roughly 40 
compounds are normally required in order to obtain an artificial neural network model, 
the partial least squares method was chosen as the preliminary computer model for this 
subset of compounds. 
 The set of 313 descriptors was entered into a Microsoft Excel spreadsheet, and 
using the CORREL function, each descriptor was compared to the set of experimental 
pIC50-values for correlation.  The 134 descriptors with a CORREL function absolute 
value of greater than 0.3 were then transferred to the Sybyl program in order to evaluate 
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them in the PLS model.  To prevent confusion, it should be explained that the Sybyl 
software additionally assigned several title columns, as well as one to the observed IC50 
values, and thus the # values below, which go above 134, are not the descriptor numbers 
but the Sybyl-assigned column numbers.  As stated above, each descriptor was added 
individually, and a model was “made” in order to discover the descriptor which produced 
the greatest cross-validated rcv2 value, either by itself in the case of the first addition, or in 
conjunction with the previously added descriptors.  While the following description of 
the selection of descriptors for the PLS model is tedious and perhaps will not enthrall the 
reader, it is an important demonstration of the procedure utilized to generate such a 
model.   
The first descriptor added in this procedure was #85 (see the descriptions below in 
Table 5.1), which, not coincidentally, produced the largest CORREL function value of 
0.654.  The rcv2 value with only this descriptor and the experimental pIC50-values was 
0.308, significantly higher than the values obtained by a model with any other single 
descriptor.  Each of the remaining 133 descriptors was individually added to this model, 
and it was found that the addition of #135 (again, one of the most highly-correlated 
descriptors from the CORREL function) resulted in an rcv2 value of 0.650.  The 
subsequent inclusion of descriptor #128 resulted in a PLS model with an rcv2 value of 
0.715.  Addition of a fourth descriptor afforded a meager improvement: #119 was the 
only descriptor which improved the model at all, to an rcv2 value of 0.717.  The model 
was significantly improved upon addition of a fifth descriptor, #127, which increased the 
rcv2 value to 0.760.  Unfortunately, supplementing the model with a sixth descriptor only 
served to worsen the PLS model, with the best rcv2 value being 0.758 in the presence of 
#7.  It was determined that the best progress might be made by removing each of the six 
chosen descriptors one at a time, and examining the rcv2 values resulting from the 
combinations of the five remaining descriptors.  Surprisingly, removing #128 while 
retaining #85, #135, #119, #127, and #7 resulted in an rcv2 value of 0.771, a slight 
improvement over the previous model, which included six descriptors.  From thence 
forward, every descriptor addition was followed by individual removal of each descriptor 
that had been added to that point, in order to assess the potential for the model to improve 
by condensing the number of descriptors utilized.  The iterative addition of descriptors 
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began anew, with the addition of #56 to yield an rcv2 value of 0.788.  A series of small 
improvements were obtained with the further addition of descriptors #66, #125, and #31, 
resulting in a 9-descriptor model with a 0.805 rcv2-value.  In the same manner, the 
subsequent addition of #86 brought the rcv2-value to 0.809, with addition of #61 affording 
an rcv2 of 0.812, and the addition of #35 affording an rcv2 of 0.814.  While these small 
increases in rcv2 values were unremarkable, this process was continued until, with a model 
containing 12 descriptors, neither addition nor subtraction of descriptors improved at all 
upon the model.  For the sake of comparison with the ANN models, which generate 
“training” R2-values in addition to the rcv2-values, the R2 value for this PLS model was 
0.887 (or R = 0.942) with a standard error of estimate of 0.168.  The computer-generated 
“probability of R2 = 0” was 0.000. 
The regression equation generated, which linearly correlates the predicted pIC50 to 
the descriptors is: 
 
pIC50 = 4.992 – (0.113 * Desc7) + (0.158 * Desc31) – (0.077 * Desc35) 
+ (0.041 * Desc56) + (2.229 * Desc61) + (0.496 * Desc66) + (8.235 * Desc85) 
+ (12.258 * Desc86) – (0.008 * Desc119) – (11.71 * Desc125) 
+ (2.347 * Desc127) – (0.002 * Desc135) 
 
R2 = 0.887 (R = 0.942); rcv2 = 0.814 (rcv = 0.902); Standard Error = 0.168; F = 8.495 
 
The definitions of the descriptors are shown in Table 5.1 below, and their values 
are listed in Table 5.2, together with the predicted IC50-values from this PLS model and 
the observed IC50-values from the [3H]MK-801 displacement assay.  In addition, the 
weight was calculated for each descriptor in the determination of the predicted pIC50-
value.  These weights were determined by standard deviation of the descriptors as a 
group, and then multiplying by the factor from the model-generated regression equation.  
Each of these products was then divided by the sum of the twelve products generated, and 
multiplied by 100 to generate a percentage weight.  It is evident that the descriptors are of 
nearly equal importance, with the largest being worth 15.0% and the smallest 6.9%. 
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Table 5.1 Definitions of descriptors used in the 12-descriptor PLS model for the 
preliminary set of 28 arylidenamino-guanidine compounds 
 
Desc. # Name Definition 
7 C-027 R--CH—X, instances of a heteroatom (N, S) being covalently 
bound to a mono-protonated carbon molecule 
31 nNHR Number of secondary amines (aliphatic) 
35 GGI1 Topological charge index of order 1 
56 HATSm Leverage-weighted total index / weighted by atomic masses 
61 HATS4v Leverage-weighted autocorrelation of lag 4/weighted by atomic van 
der Waals volumes 
66 R2u R autocorrelation of lag 2 / unweighted 
85 R4v+ R maximal autocorrelation of lag 4 / weighted by atomic van der 
waals volumes 
86 R5v+ R maximal autocorrelation of lag 5 / weighted by atomic van der 
Waals volumes 
119 T(N..N) Sum of topological distances between N..N 
125 G2m 2nd component symmetry directional WHIM index / weighted by 
atomic masses 
127 E2v 2nd component accessibility directional WHIM index / weighted by 
atomic van der Waals volumes 
135 PSA Polar surface area (includes all O, N, S atoms and covalently 
bonded H’s) or fragment-based polar surface area 
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Table 5.2 Descriptors utilized in the preliminary 28-molecule PLS model 
 
Desc: 7 31 35 56 61 66 85 
        
Name C-027 nNHR GGI1 HATSm HATS4v R2u R4v+ 
AG-2 0 1 2.0 1.138 0.096 1.428 0.012 
AG-3 0 1 2.5 1.456 0.123 1.536 0.020 
AG-4 0 0 2.5 1.411 0.131 1.510 0.021 
AG-5 2 0 2.0 2.156 0.102 1.388 0.014 
AG-6 0 0 3.0 0.693 0.097 1.666 0.015 
AG-8 0 0 3.0 1.460 0.124 1.823 0.022 
AG-9 0 0 3.5 6.107 0.211 1.363 0.047 
AG-10 0 0 3.5 1.475 0.112 1.840 0.018 
AG-11 2 0 2.0 1.447 0.129 1.458 0.014 
AG-12 0 0 2.5 1.236 0.111 1.677 0.025 
AG-13 0 0 3.5 1.539 0.120 1.277 0.013 
AG-14 0 0 2.0 1.292 0.122 1.447 0.019 
AG-15 0 0 4.5 2.876 0.152 1.545 0.018 
AG-17 0 0 2.0 1.208 0.118 1.468 0.012 
AG-18 0 0 3.0 1.728 0.113 1.456 0.012 
AG-19 0 0 3.0 1.363 0.090 1.730 0.020 
AG-20 0 0 4.5 8.503 0.118 1.533 0.020 
AG-23 0 0 2.5 1.608 0.131 1.442 0.021 
AG-24 0 0 3.5 3.641 0.126 1.444 0.019 
JR-121 0 0 3.5 3.489 0.166 1.496 0.021 
JR-122 0 0 3.5 2.960 0.117 1.390 0.021 
JR-124 0 0 3.0 2.399 0.158 1.368 0.027 
JR-125 0 0 3.0 1.863 0.154 1.399 0.017 
JR-132 0 0 3.0 1.870 0.124 1.382 0.016 
JR-146 2 1 2.0 1.207 0.109 1.462 0.012 
JR-147 2 1 2.0 1.210 0.107 1.453 0.013 
JR-160 0 0 3.0 1.191 0.119 1.446 0.013 
JR-197 0 0 3.0 0.905 0.095 1.423 0.016 
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Table 5.2 (cont.) Descriptors utilized in the preliminary 28-molecule PLS model 
 
Desc: 86 119 125 127 135   
        
Name R5v+ T(N..N) G2m E2v PSA 
IC50,OBS 
(Littleton 
et al.) 
IC50,Cal 
(Littleton 
et al.) 
AG-2 0.012 25 0.185 0.243 180.76 96.6 88.5 
AG-3 0.012 29 0.174 0.257 179.98 57.5 45.8 
AG-4 0.020 6 0.171 0.278 151.45 26.9 24.2 
AG-5 0.013 6 0.188 0.246 210.68 182.0 159.5 
AG-6 0.009 6 0.175 0.261 152.92 51.3 53.1 
AG-8 0.012 6 0.174 0.268 172.96 38.0 29.7 
AG-9 0.020 6 0.181 0.357 166.84 10.2 8.2 
AG-10 0.017 6 0.168 0.294 167.70 28.8 22.8 
AG-11 0.013 33 0.183 0.260 180.65 195.0 159.0 
AG-12 0.023 6 0.174 0.303 153.87 17.0 18.4 
AG-13 0.010 6 0.177 0.263 250.76 213.8 122.7 
AG-14 0.015 6 0.174 0.276 197.91 58.9 41.0 
AG-15 0.015 49 0.167 0.340 236.75 89.1 66.4 
AG-17 0.012 6 0.181 0.265 152.89 71.6 53.3 
AG-18 0.012 6 0.181 0.265 146.82 90.3 61.3 
AG-19 0.016 6 0.175 0.304 195.25 42.7 34.5 
AG-20 0.019 6 0.175 0.315 166.40 22.9 18.9 
AG-23 0.012 6 0.181 0.270 159.27 67.6 45.7 
AG-24 0.014 6 0.181 0.270 161.56 43.7 45.7 
JR-121 0.014 37 0.177 0.268 239.65 78.0 78.9 
JR-122 0.017 33 0.177 0.304 288.33 155.0 105.8 
JR-124 0.021 37 0.179 0.324 204.96 44.0 47.0 
JR-125 0.012 41 0.179 0.253 216.12 224.0 126.2 
JR-132 0.011 6 0.177 0.267 204.14 32.0 68.6 
JR-146 0.011 33 0.181 0.271 249.10 537.0 167.7 
JR-147 0.011 29 0.181 0.268 192.05 490.0 121.9 
JR-160 0.010 37 0.177 0.267 225.39 109.0 148.2 
JR-197 0.014 33 0.177 0.265 223.62 224.0 139.0 
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 A graphical representation of the observed versus PLS model-predicted IC50-
values is shown in figure 1.  The points are well-clustered along the ideal line, with the 
exception of the two pyridino compounds, JR-146 and JR-147 (compounds 37 and 38), 
which were predicted to possess approximately four times greater inhibitory activity than 
they demonstrated in the [3H]MK-801 displacement assay. 
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Figure 5.1 Comparison of observed pIC50 values versus calculated pIC50 values 
using the 12-descriptor PLS model for the initial set of 28 compounds 
 
Structures of the subsequent set of arylidenamino-guanidine compounds (JR-202 
– JR-228) were drawn and input into the Sybyl software program, and the same twelve 
molecular descriptors were then generated with the DRAGON program.  These 
compounds were predicted to have activity of the order of 4-5 pIC50, or IC50-values of 10-
100 μM.  When synthesized and screened in the same assay, the observed activities of the 
new set of compounds were compared to the predicted values from the linear PLS model.   
While this new “training set” afforded mixed results in the comparison of 
predicted and observed inhibitory activity (see Figure 5.2), the observed IC50 values that 
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differed the most from the predicted values were compounds which were more potent 
than predicted.  In addition, while there were five points that differed in predicted and 
observed IC50-values by a full order of magnitude, three of these were the compounds 
which generated biphasic dose-response curves. 
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Figure 5.2 Observed versus calculated IC50 correlation from the 12-component PLS 
model with original data points and testing set values 
 
 With a larger set of compounds and a model which required refinement in order to 
better take into account the improved values generated by the compounds that exhibited a 
biphasic binding profile (and also to possibly explain the differences seen in comparing 
the predicted and observed inhibition of the pyridino compounds), it was decided to 
design a new partial-least squares model, and select descriptors for use in an artificial 
neural network model. 
 This second PLS model was generated by using the same techniques as described 
previously, with a new refined set of descriptors selected from the list of over 300 
possible descriptors.  The refined set was larger in this case than in the earlier model 
(comprising nearly 200 descriptors), and allowing the inclusion of more possible 
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descriptors rendered the analysis much more time-consuming; however, the added 
degrees of freedom ensured that the best possible model was extruded from the data.  It is 
generally accepted that the number of descriptors chosen for an artificial neural network 
model should be relatively small (roughly equal to or less than ten), and thus, while the 
best PLS model for these data was obtained with fourteen descriptors, it was decided that 
the best set of descriptors to use in the development of the ANN model was one which 
contained eleven descriptors.  The training R2-value began to plateau around this number 
of descriptors, and the value of 0.815 for the 11 descriptors was a significant 
improvement over the 10-descriptor PLS model, which afforded an R2-value of 0.762.  
The standard error of estimate was also reduced from 0.267 in the 10 descriptor model to 
0.229 in the 11 descriptor model, with a minimum value of 0.200 for the 14-descriptor 
model. 
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This second PLS model, with eleven descriptors and based on data and structures 
from 45 molecules, had the following regression equation: 
 
pIC50  =   3.120 - (1.137 * Desc18) - (0.186 * Desc21) + (2.540 * Desc33) 
+ (0.497 * Desc42) - (0.395 * Desc78) + (0.366 * Desc93) 
- (0.717 * Desc109) - (9.306 * Desc139) + (18.626 * Desc167) 
+ (2.419 * Desc172) + (19.671 * Desc181) 
R2 = 0.815 (R = 0.903); rcv2 = 0.718 (rcv = 0.847); Standard Error = 0.229; F = 23.218 
 
The definitions of the descriptors are shown in Table 5.3.  While only one of these 
descriptors is also found in the earlier PLS model (C-027), many of the descriptors are 
very similar, and reflect molecular traits related to those which were judged to be 
important in the first set of descriptors.  In addition, the values of each of the descriptors 
used in the final set of arylidenamino-guanidine compounds are shown in Table 5.4. 
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Table 5.3 Definitions of descriptors used in the 11-descriptor PLS model for the 
final set of 45 arylidenamino-guanidine compounds 
 
Desc. # Name Definition 
18 G3m 3st component symmetry directional WHIM index/weighted by 
atomic masses 
21 L2v 2nd component size directional WHIM index/weighted by atomic 
van der Waals volumes 
33 Gu G total symmetry index/unweighted 
42 nCIC Total number of rings 
78 C-027 R--CH—X, instances of a heteroatom (N, S) being covalently 
bound to a mono-protonated carbon molecule 
93 MLOGP Moriguchi octanol-water partition coefficient (logP) 
109 H3u H autocorrelation of lag 3/unweighted 
139 HATS5v leverage-weighted autocorrelation of lag 5/weighted by atomic van 
der Waals volumes 
167 R2v+ R maximal autocorrelation of lag 2/weighted by atomic van der 
Waals volumes 
172 R6e R autocorrelation of lag 6/weighted by atomic Sanderson 
electronegativities 
181 R5p+ R maximal autocorrelation of lag 5/weighted by atomic 
polarizabilities 
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Table 5.4 Descriptors utilized in the final 45-molecule PLS and ANN models 
 
 Desc: 3 18 21 33 42 78 93 
         
 IC50 pIC50 G3m L2v Gu nCIC C-027 MLOGP
JR-121 78.0 4.1079 0.388 1.437 0.303 1 0 0.675 
JR-122 149.3 3.8259 0.474 2.102 0.266 1 0 0.675 
JR-124 43.4 4.3625 0.254 2.202 0.247 1 0 0.425 
JR-125 231.2 3.6360 0.192 1.357 0.217 1 0 0.425 
JR-132 32.2 4.4921 0.188 1.319 0.506 1 0 -0.413 
JR-146 195.0 3.7100 0.253 1.357 0.231 1 2 -0.679 
JR-147 677.6 3.1690 0.421 1.335 0.261 1 2 -0.679 
JR-160 104.2 3.9821 0.443 1.381 0.252 1 0 0.19 
JR-197 199.5 3.7001 0.474 1.887 0.282 1 0 0.19 
JR-202 6.0 5.2218 0.176 1.467 0.207 1 0 1.622 
JR-203 26.5 4.5768 0.167 3.759 0.172 2 0 1.974 
JR-204 11.5 4.9393 0.167 2.692 0.172 2 0 1.974 
JR-207 50.6 4.2958 0.249 1.355 0.245 2 0 0.336 
JR-209 8.5 5.0706 0.165 3.039 0.171 2 0 2.199 
JR-211 22.8 4.6421 0.163 1.501 0.173 1 0 1.903 
JR-212 42.5 4.3716 0.163 1.684 0.163 1 0 1.903 
JR-213 8.7 5.0605 0.499 1.484 0.28 2 0 1.702 
JR-214 48.8 4.3116 0.28 2.466 0.221 2 0 0.36 
JR-215 32.9 4.4828 0.197 1.496 0.186 2 0 0.36 
JR-217 18.4 4.7352 0.246 1.828 0.236 1 0 1.295 
JR-218 7.1 5.1487 0.374 1.8 0.268 1 0 1.295 
JR-219 7.9 5.1024 0.186 1.53 0.174 1 0 0.811 
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Table 5.4 (cont.) Descriptors utilized in the final 45-molecule PLS and ANN models 
 
 Desc: 3 109 139 167 172 181 
        
 IC50 pIC50 H3u HATS5v R2v+ R6e R5p+ 
JR-121 78.0 4.1079 1.392 0.108 0.034 0.482 0.015 
JR-122 149.3 3.8259 1.391 0.09 0.028 0.589 0.013 
JR-124 43.4 4.3625 1.39 0.106 0.045 0.514 0.019 
JR-125 231.2 3.6360 1.43 0.083 0.042 0.47 0.012 
JR-132 32.2 4.4921 1.917 0.069 0.023 0.653 0.011 
JR-146 195.0 3.7100 1.156 0.073 0.053 0.471 0.013 
JR-147 677.6 3.1690 1.146 0.072 0.045 0.506 0.012 
JR-160 104.2 3.9821 1.43 0.067 0.033 0.464 0.01 
JR-197 199.5 3.7001 1.344 0.084 0.033 0.475 0.017 
JR-202 6.0 5.2218 1.411 0.085 0.051 0.557 0.011 
JR-203 26.5 4.5768 2.051 0.117 0.034 0.784 0.015 
JR-204 11.5 4.9393 1.867 0.11 0.028 0.797 0.018 
JR-207 50.6 4.2958 1.68 0.097 0.028 0.551 0.013 
JR-209 8.5 5.0706 2.275 0.136 0.042 0.916 0.016 
JR-211 22.8 4.6421 1.473 0.073 0.043 0.598 0.009 
JR-212 42.5 4.3716 2.266 0.089 0.026 0.694 0.017 
JR-213 8.7 5.0605 1.639 0.065 0.033 0.497 0.009 
JR-214 48.8 4.3116 1.577 0.097 0.03 0.658 0.018 
JR-215 32.9 4.4828 1.423 0.064 0.029 0.488 0.009 
JR-217 18.4 4.7352 1.391 0.093 0.061 0.474 0.022 
JR-218 7.1 5.1487 1.307 0.09 0.064 0.481 0.025 
JR-219 7.9 5.1024 1.256 0.084 0.045 0.571 0.013 
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Table 5.4 (cont.) Descriptors utilized in the final 45-molecule PLS and ANN models 
 
 Desc: 3 18 21 33 42 78 93 
         
 IC50 pIC50 G3m L2v Gu nCIC C-027 MLOGP
JR-220 3.6 5.4437 0.246 1.363 0.236 1 0 1.295 
JR-223 7.8 5.1079 0.171 1.887 0.171 1 0 0.512 
JR-226 72.4 4.1403 0.287 3.915 0.244 1 0 0.768 
JR-227 71.1 4.1481 0.807 1.293 0.296 1 0 0.768 
JR-228 63.1 4.2000 0.172 1.513 0.179 1 0 0.004 
SUN-AG2 59.3 4.2269 0.276 1.163 0.231 1 0 -1.339 
SUN-AG3 36.9 4.4330 0.402 1.597 0.272 2 0 0.068 
SUN-AG4 21.4 4.6696 0.171 2.207 0.177 2 0 1.702 
SUN-AG5 117.2 3.9311 0.219 1.277 0.216 1 2 -0.551 
SUN-AG6 80.7 4.0931 0.208 1.361 0.206 1 0 1.027 
SUN-AG8 34.7 4.4597 0.174 1.414 0.174 1 0 0.508 
SUN-AG9 10.2 4.9914 0.233 1.839 0.24 1 0 1.867 
SUN-AG10 28.8 4.5406 0.168 1.819 0.179 1 0 0.307 
SUN-AG12 12.8 4.8928 0.174 1.844 0.177 1 0 0.508 
SUN-AG13 167.5 3.7760 0.275 1.493 0.24 1 0 -0.314 
SUN-AG14 58.3 4.2343 0.195 1.507 0.181 1 0 0.98 
SUN-AG15 109.4 3.9610 0.31 1.356 0.236 2 0 0.302 
SUN-AG17 73.1 4.1361 0.22 1.358 0.197 1 0 0.71 
SUN-AG18 66.1 4.1798 0.184 3.577 0.177 1 0 1.138 
SUN-AG19 38.5 4.4145 0.175 1.818 0.175 2 0 0.018 
SUN-AG20 25.1 4.6003 0.255 2.205 0.202 1 0 1.746 
SUN-AG23 74.9 4.1255 0.881 1.391 0.321 1 0 1.138 
SUN-AG24 55.2 4.2581 0.785 1.396 0.307 1 0 1.563 
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Table 5.4 (cont.) Descriptors utilized in the final 45-molecule PLS and ANN models 
 
 Desc: 3 109 139 167 172 181 
        
 IC50 pIC50 H3u HATS5v R2v+ R6e R5p+ 
JR-220 3.6 5.4437 1.402 0.072 0.052 0.485 0.015 
JR-223 7.8 5.1079 1.482 0.143 0.037 1.022 0.023 
JR-226 72.4 4.1403 1.592 0.067 0.031 0.567 0.015 
JR-227 71.1 4.1481 1.279 0.062 0.03 0.604 0.012 
JR-228 63.1 4.2000 1.369 0.104 0.04 0.716 0.018 
SUN-AG2 59.3 4.2269 1.125 0.062 0.051 0.495 0.012 
SUN-AG3 36.9 4.4330 1.644 0.082 0.033 0.536 0.012 
SUN-AG4 21.4 4.6696 1.949 0.114 0.031 0.696 0.02 
SUN-AG5 117.2 3.9311 0.876 0.072 0.056 0.499 0.017 
SUN-AG6 80.7 4.0931 1.287 0.055 0.027 0.331 0.009 
SUN-AG8 34.7 4.4597 1.397 0.1 0.043 0.562 0.015 
SUN-AG9 10.2 4.9914 1.378 0.093 0.065 0.497 0.023 
SUN-AG10 28.8 4.5406 1.319 0.113 0.03 0.901 0.017 
SUN-AG12 12.8 4.8928 1.401 0.125 0.033 0.819 0.023 
SUN-AG13 167.5 3.7760 1.401 0.089 0.027 0.561 0.015 
SUN-AG14 58.3 4.2343 1.758 0.116 0.046 0.595 0.016 
SUN-AG15 109.4 3.9610 2.14 0.123 0.035 0.619 0.014 
SUN-AG17 73.1 4.1361 1.39 0.067 0.045 0.476 0.011 
SUN-AG18 66.1 4.1798 1.396 0.068 0.044 0.492 0.012 
SUN-AG19 38.5 4.4145 1.3 0.087 0.033 0.436 0.02 
SUN-AG20 25.1 4.6003 1.282 0.112 0.046 0.536 0.015 
SUN-AG23 74.9 4.1255 1.25 0.034 0.033 0.341 0.009 
SUN-AG24 55.2 4.2581 1.403 0.078 0.044 0.534 0.011 
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For the second partial least squares model, the observed IC50-values generated 
from the [3H]MK-801 displacement assay were plotted versus the PLS model-predicted 
IC50-values (see Figure 5.3).  While the R2 value of this model is lower than that obtained 
in the first PLS model (mainly due to an increase in the number of components), this new 
set of points is well-clustered around the ideal diagonal midline, with very few data 
points differing by more than half an order of magnitude.  Specifically, the predicted 
values for the pyridino compounds are much closer to the observed values, and the three 
biphasic compounds are also much better predicted than in the previous model. 
The data for this model are disclosed in Table 5.5 along with the artificial neural 
network-generated data. 
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Figure 5.3 Comparison of observed pIC50 values versus calculated pIC50 values 
using the 11-descriptor PLS model for the final set of 45 compounds 
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Table 5.5 Observed and predicted IC50-values of arylidenamino-guanidines 
 
Comp. Comp. Structure Exper. PLS-11D NN-train. NN-LOO 
No. Code  IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) 
1 AG-17 N
H
N
H
NH2
NH2 Cl
 
73.1 96.3 33.6 29.2 
2 AG-6 N
H
N
H
NH2
NH2 Cl
H3C
 
80.7 84.6 99.2 114.5 
3 JR-202 N
H
N
H
NH2
NH2 Cl
 
6.0 10.6 10.4 11.8 
4 JR-212 N
H
N
H
NH2
NH2 Cl
 
42.5 53.3 51.1 79.2 
5 JR-211 N
H
N
H
NH2
NH2 Cl
 
22.8 10.5 11.4 9.7 
6 JR-124 
N
H
N
H
NH2
NH2 Cl
C
N
 
43.4 67.0 60.0 67.3 
7 JR-125 N
H
N
H
NH2
NH2 Cl
C
N
 
231.2 61.0 65.1 53.9 
8 JR-226 
N
H
N
H
NH2
NH2 Cl
O O
H3C
 
72.4 114.2 98.1 55.7 
 
 
1 - PLS-11D: Predicted IC50 value from the primary Partial Least Squared model with 11 descriptors 
2 – NN-train: Predicted IC50 value from the training set of the final Neural Network model 
3 - NN-LOO: Predicted IC50 value from the leave-one-out set of the final Neural Network model 
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Table 5.5 (cont.) Observed and predicted IC50-values of arylidenamino-guanidines 
 
 
Comp. Comp. Structure Exper. PLS-11D NN-train. NN-LOO 
No. Code  IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) 
9 JR-227 N
H
N
H
NH2
NH2 ClO
O
H3C
 
71.1 55.7 61.5 28.4 
10 AG-20 N
H
N
H
NH2
NH2 Cl
CF3  
25.1 27.8 25.3 25.3 
11 AG-13 N
H
N
H
NH2
NH2 Cl
OHHO
 
167.5 143.4 169.4 168.1 
12 AG-12 N
H
N
H
NH2
NH2 Cl
O
H3C  
12.8 25.6 23.4 28.7 
13 AG-8 N
H
N
H
NH2
NH2 Cl
O
H3C
 
34.7 49.3 49.5 51.9 
14 AG-10 N
H
N
H
NH2
NH2 Cl
O
O
H3C
H3C
 
28.8 18.6 20.3 17.1 
15 JR-197 N
H
NH2
N
H
NH2
NH2 Cl
 
199.5 136.3 131.4 119.4 
16 JR-160 N
H
N
H
NH2
NH2 Cl
H2N
 
104.2 140.9 164.1 175.6 
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Table 5.5 (cont.) Observed and predicted IC50-values of arylidenamino-guanidines 
 
 
Comp. Comp. Structure Exper. PLS-11D NN-train. NN-LOO 
No. Code  IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) 
17 JR-219 N
H
N
H
NH2
NH2 Cl
N
CH 3
H3C
 
7.9 22.3 21.0 12.7 
18 JR-122 
N
H
N
H
NH 2
NH2 Cl
N
OO
 
149.3 105.5 120.2 114.8 
19 JR-121 N
H
N
H
NH2
NH 2 Cl
N
O
O
 
78.0 96.3 96.7 105.8 
20 JR-228 N
H
N
H
NH2
NH2 Cl
O
H3C
OH
 
63.1 33.3 32.3 98.1 
21 JR-223 
N
H
N
H
NH2
NH2 Cl
N
OO
O
H3C
 
7.8 12.2 12.1 14.7 
22 JR-218 N
H
N
H
NH2
NH2 Cl
Cl
 
7.1 8.2 7.9 8.3 
23 JR-217 N
H
N
H
NH2
NH2 Cl
Cl
 
18.4 11.9 9.9 7.8 
24 JR-220 N
H
N
H
NH2
NH2 Cl
Cl
 
3.6 12.1 10.6 14.7 
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Table 5.5 (cont.) Observed and predicted IC50-values of arylidenamino-guanidines 
 
 
Comp. Comp. Structure Exper. PLS-11D NN-train. NN-LOO 
No. Code  IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) 
25 AG-9 N
H
N
H
NH2
NH2 Cl
Cl Cl
 
10.2 4.8 6.4 5.7 
26 AG-23 N
H
N
H
NH2
NH2 Cl
F
 
74.9 101.8 100.0 126.5 
27 AG-18 N
H
N
H
NH2
NH2 Cl
F
 
66.1 60.2 62.3 60.1 
28 AG-24 N
H
N
H
NH2
NH2 Cl
FF
 
55.2 38.7 35.4 27.2 
29 JR-209 
N
H
N
H
NH2
NH2 Cl
 
8.5 9.6 10.9 13.1 
30 AG-4 
N
H
N
H
NH2
NH2 Cl
 
21.4 16.7 14.2 12.9 
31 JR-213 
N
H
N
H
NH2
NH2 Cl
 
8.7 15.2 13.6 20.1 
32 JR-203 
N
H
N
H
NH2
NH2 Cl
CH3  
26.5 22.4 24.8 22.6 
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Table 5.5 (cont.) Observed and predicted IC50-values of arylidenamino-guanidines 
 
 
Comp. Comp. Structure Exper. PLS-11D NN-train. NN-LOO 
No. Code  IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) 
33 JR-204 
N
H
N
H
NH2
NH2 Cl
H 3C
 
11.5 9.5 10.5 10.1 
34 AG-19 N
H
N
H
NH2
NH2 Cl
O
O
 
38.5 44.8 38.0 37.6 
35 AG-15 N
H
N
H
NH2
NH2 Cl
ON
O
O
 
109.4 108.4 117.5 120.9 
36 AG-2 N
H
N
H
NH2
NH2 ClN
H
 
59.3 65.6 75.7 61.1 
37 JR-147 N N
H
N
H
NH2
NH2 Cl
 
677.6 477.6 362.3 302.4 
38 JR-146 
N
N
H
N
H
NH2
NH2 Cl
 
195.0 316.8 293.6 333.1 
39 AG-3 N
H
N
H
NH2
NH2 ClN
H
 
36.9 52.3 54.3 97.0 
40 JR-207 N
H
N
H
NH2
NH2 Cl
HN
 
50.6 47.1 46.9 45.8 
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Table 5.5 (cont.) Observed and predicted IC50-values of arylidenamino-guanidines 
 
 
Comp. Comp. Structure Exper. PLS-11D NN-train. NN-LOO 
No. Code  IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) 
41 JR-214 N
H
N
H
NH2
NH2 ClN
CH3
 
48.8 31.5 30.0 26.1 
42 JR-215 
N
H
N
H
NH2
NH2 ClN
H
H3C
 
32.9 31.8 33.6 34.3 
43 AG-5 N
H
N
H
NH2
NH2 Cl
S
 
117.2 106.2 119.3 135.4 
44 AG-14 N
H
N
H
NH2
NH2 Cl
 
58.3 62.5 59.7 60.2 
45 JR-132 
N
N
H
N
H
H2N
NH 2
H
H
N NH2
NH2 Cl
Cl 32.2 31.6 31.2 40.5 
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 While this second PLS model was more accurate for the full set of forty-five 
arylidenamino-guanidine compounds than the PLS model for the preliminary set of 
twenty-eight compounds, it also yielded a set of eleven descriptors which were then used 
in the development of the artificial neural network model.   
 In order to determine the optimal configurations for the ANN model, parameters 
were modified while training, cross-validating, and testing the network in an effort to 
obtain the best predictive final model.  These parameters, as well as the results obtained, 
are displayed in Table 5.6.  It had been previously determined that the optimal learning 
rate (LR) was 0.01, and that the optimal momentum rate (MR) was 0.05; these 
parameters are consistent throughout the experiments.    In addition, the number of nodes 
in the input layer were constant at 11 (the number of descriptors), as well as the number 
of output layers and nodes at 1.  The parameters that were modified were the number of 
nodes in the hidden layer (from 1 to 4), and the number of total training cycles (from 
10,000 to 100,000).  Using each set of these two variables, models were generated and 
evaluated based on the correlation of predicted and observed data (R-value) and root-
mean square deviation (RMSD) for the training results, as well as for the leave-one-out 
validation results, which generated separate correlation coefficients (rcv) and error values 
(looRMSD) (see method section for definitions). 
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Table 5.6 Parameter modification of the artificial neural network model,  
using 45 molecules and 11 descriptors 
 
 
Config. Cycles LR MR R RMSD rcv2 rcv looRMSD 
PLS(11D)    0.903 S=0.229 0.718 0.847 S=0.282 
NN11-1-1 12000 0.01 0.05 0.904 0.206 0.658 0.811 0.282 
NN11-1-1 30000 0.01 0.05 0.905 0.205 0.705 0.84 0.262 
NN11-1-1 50000 0.01 0.05 0.905 0.205 0.694 0.833 0.267 
NN11-1-1 100000 0.01 0.05 0.905 0.205 0.686 0.828 0.27 
NN11-2-1 10000 0.01 0.05 0.905 0.206    
NN11-2-1 12000 0.01 0.05 0.906 0.205 0.6583 0.811 0.282 
NN11-2-1 20000 0.01 0.05 0.907 0.203 0.690 0.831 0.268 
NN11-2-1 25000 0.01 0.05 0.908 0.202 0.6959 0.834 0.266 
NN11-2-1 30000 0.01 0.05 0.909 0.201 0.6956 0.834 0.266 
NN11-2-1 40000 0.01 0.05 0.911 0.199 0.689 0.830 0.269 
NN11-2-1 50000 0.01 0.05 0.913 0.196 0.6809 0.825 0.272 
NN11-2-1 75000 0.01 0.05 0.922 0.187 0.657 0.811 0.282 
NN11-2-1 100000 0.01 0.05 0.933 0.174 0.6293 0.807 0.294 
NN11-3-1 12000 0.01 0.05 0.906 0.204 0.6802 0.825 0.273 
NN11-3-1 20000 0.01 0.05 0.907 0.203 0.713 0.845 0.258 
NN11-3-1 25000 0.01 0.05 0.909 0.201 0.715 0.846 0.257 
NN11-3-1 30000 0.01 0.05 0.910 0.200 0.720 0.849 0.250 
NN11-3-1 40000 0.01 0.05 0.913 0.197 0.694 0.833 0.266 
NN11-3-1 50000 0.01 0.05 0.915 0.194 0.6821 0.826 0.272 
NN11-3-1 100000 0.01 0.05 0.924 0.184    
NN11-4-1 12000 0.01 0.05 0.903 0.209 0.632 0.795 0.293 
NN11-4-1 30000 0.01 0.05 0.907 0.203 0.700 0.836 0.264 
NN11-4-1 40000 0.01 0.05 0.909 0.201 0.695 0.834 0.266 
NN11-4-1 50000 0.01 0.05 0.910 0.200 0.685 0.828 0.271 
NN11-4-1 100000 0.01 0.05 0.922 0.187    
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From the 3-dimensional display in Figure 5.4, it can be seen that the R-value from 
the training results increases with the number of training cycles and the RMSD decreases 
accordingly.  These values are therefore not useable in the determination of the best 
model.  However, it was also seen that the addition of a second and third node to the 
hidden layer yielded models with greater correlation than the models with 1 or 4 nodes in 
the hidden layer.   
 The leave-one-out validation paints a clearer picture, and a clear maximum of 
correlation is produced by the models with 1 hidden layer containing 3 hidden nodes, 
affording an rcv-value of 0.849 at 30,000 training cycles (see Figure 5.5).  The error is 
also minimized with this set of parameters to 0.250 looRMSD.  While two hidden layers 
generated the best overall correlation, the 30,000 training cycles also generated the best 
rcv values with each of the other hidden node values, resulting in the semispherical 
topology generated in Figure 5.5. 
 The correlation and error data from the second PLS model using the same eleven 
descriptors are also displayed in Table 5.6.  While it is evident that the artificial neural 
network model did dramatically improve upon the training set R and its corresponding 
error, the correlation of the leave-one-out validation was only slightly better in the best 
ANN model, at 0.849 compared to 0.847 in the PLS model.  However, the error was 
decreased significantly in the leave-one-out method, from 0.282 in the PLS model to 
0.250 in the ANN model. 
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Figure 5.4 Optimization of R by variation of cycles and nodes using the 
training method of the artificial neural network model 
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Figure 5.5 Optimization of rcv by variation of cycles and hidden nodes using the 
leave-one-out method of the artificial neural network model 
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 The experimental IC50-values for the arylidenamino-guanidino compounds which 
were generated from the screening data, as well as those predicted by both the training 
and leave-one-out values are displayed in Table 5.5.  The observed values are plotted 
against the predicted values from the training method and the leave-one-out method in 
Figures 5.6 and 5.7, respectively. 
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Figure 5.6 Comparison of observed pIC50 values versus pIC50 training values  
calculated using the artificial neural network model 
 249
The plotted training values are, not surprisingly, very linear when compared to the 
observed values (see Figure 5.6).  Each of the points lies within half an order of 
magnitude of the diagonal line of perfect correlation.   
Figure 5.7 is very similar to 5.6, with most of the points lying within roughly one 
half of an order of magnitude of the ideal rcv = 1 line.  While this final predictive model 
had several points which were somewhat different from the values observed in the 
[3H]MK-801 displacement assay, it should be remembered that this model is a tool to be 
used for pre-synthetic prediction of a molecule’s activity.  This model should be able to 
make a good prediction for the IC50 value of any compound with the general 
arylidenamino-guanidine structure, however there may be some structural features which 
impact site binding that have not yet been introduced into this ANN model, and would 
create anomalies with the current model.  Therefore, the continual addition of more 
molecular structures would refine and re-train the model, making it more accurate and 
reducing the number of outlying points. 
Regardless of future improvement, the ANN model in its current form is a 
successful predictive tool with excellent correlation values.  The standard proof of a 
model’s high predictive ability is considered to be an rcv2 value of greater than 0.5.  The 
best artificial neural network model obtained in this study possesses a cross-validation rcv 
of 0.849 (rcv2 of 0.720) and a correlation coefficient r of 0.910. 
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Figure 5.7 Comparison of observed pIC50 values vs. pIC50 leave-one-out values 
calculated using the artificial neural network model 
 
 While the predicted IC50 values generated from the ANN method are generally 
nonlinear and thus quite complicated to compare directly to the descriptors, the two PLS 
models have given some new insight into structure-activity relationships of 
arylidenamino-guanidine compounds and their ability to reduce bound [3H]MK-801 in 
the NMDAR screening assay. 
In both models, increasing the “C-027” descriptor would reduce the predicted 
inhibition, increasing the predicted IC50-value.  This descriptor is a measure of the 
number of unsubstituted heteroatoms adjacent to a monoprotonated carbon, i.e. those 
contained within an aromatic ring (but without complete adjacent substitution as in the 
case of compound 35).  Therefore, inclusion of pyridine, furan, or thiophene rings in the 
structure of analogs appears to be detrimental to the inhibitory activity of this class of 
compounds.  Conversely, in the first model, the descriptor nNHR was shown to have a 
positive effect on inhibition; i.e. increasing the number of substituted protonated amino 
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groups increased receptor inhibition.  While this latter descriptor was not used in the 
second PLS model nor the ANN model, these combined data indicate that indole and 
pyrrolidine rings, which contain non-basic protonated nitrogen atoms, are not detrimental 
to NMDA inhibition. 
The first PLS model also demonstrated that decreasing the PSA descriptor 
increases the inhibitory activity of the molecule.  This descriptor is a measure of polar 
surface area, and while it would be difficult to differentiate most of these compounds 
based on large differences in molecular surface area, this observation indicates that 
increasing molecular size (and thus PSA) could be detrimental to the inhibitory activity 
of the molecules. 
 Another structural detriment was the descriptor nCIC, defined as the total number 
of rings in the molecule.  While the forty-five molecules used in the second 
computational model contained only two options for this descriptor, i.e. one or two rings, 
the model predicted that two rings were generally better than one for inhibitory activity. 
 Finally, an increase in the descriptor mlogP predicted an increase in the inhibitory 
activity of the arylidenamino-guanidino compounds in the second model.  This 
Moriguchi octanol-water partition coefficient is a measure of the lipophilicity of the 
compound.  Thus, increasing the mlogP value in these analog structures lowered the 
predicted IC50-value.  The compounds with the highest value for this descriptor included 
compound 9 [(2-biphenyl-carboxylidenamino)-guanidine hydrochloride] as well as 
compounds 32 and 33 (the 2- and 4-methylated 1-naphthylidenamino-guanidine 
hydrochloride compounds, respectively).  This finding is interesting in that these more 
hydrophobic compounds were difficult to evaluate in the screens, due to their low 
solubility.  This also raises issues with regard to such compounds as (4-biphenyl-
carboxylidenamino)-guanidine hydrochloride, which was too insoluble in water to be 
screened.  However, the general finding can be a valid consideration that testing further 
compounds which have increased lipophilicity may improve their inhibitory properties at 
the NMDA receptor. 
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5.4 Conclusions 
 
 Using a combination of both the partial least squares (PLS) and back-propagation 
artificial neural network (ANN) pattern recognition methods, several models have been 
developed to predict the activity of arylidenamino-guanidine compounds as inhibitory 
modulators of the N-methyl-D-aspartate receptor complex.  This was done by correlating 
structural and physicochemical descriptors obtained from computation software to the 
observed [3H]MK-801 displacement ability of 45 synthesized and screened 
arylidenamino-guanidine compounds. 
 A preliminary PLS model was developed using a smaller set of inhibitory 
compounds in this class, and this model was further refined with a set of additional 
arylidenamino-guanidines, while reducing the number of descriptors needed to yield a 
viable model.  These models yielded correlation coefficients of r = 0.941 and r = 0.903, 
respectively; this decrease in correlation is due to the increase in sample size in addition 
to the inclusion of several biphasic compounds (see Chapter 3 for more details).   
 The ANN model was created with utilization of the eleven descriptors from the 
second PLS model.  While this model would certainly benefit from the future addition of 
more structures to the dataset, it was still a viable and improved model, which resulted in 
a correlation coefficient of R = 0.910 and a cross-validated rcv = 0.849. Each of the 
screened compounds tested had the same common structural feature, i.e. an aromatic ring 
attached to an imino-guanidine moiety.  The majority of the molecules screened in the 
laboratory and predicted in these models have correlated well between observed and 
predicted inhibitory values (see Table 5.5 and Figures 5.3, 5.6, and 5.7). 
These computational models are vital tools in the development of future 
generations of arylidenamino-guanidino compounds, as they are able to predict inhibition 
of the NMDAR by this series of compounds in silico.  Arylidenamino-guanidino 
compounds with low predicted IC50Pot-values (i.e. high NMDAR inhibitory potency) will 
be synthesized and examined in the screening assays, while those compounds with high 
predicted IC50Pot-values (i.e. low NMDAR inhibitory potency) will be largely bypassed.   
In this way, a predictive structure-based in silico “pre-screening” of the compounds will 
save a substantial amount of otherwise wasted time and cost in synthesis.    
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Furthermore, the ANN model would benefit from the addition of further sub-
libraries of compounds, which would add new structural “knowledge” as well as increase 
the accuracy of the model.  The ability of these models to evolve in accuracy and 
complexity with the addition of further training sets of arylidenamino-guanidino 
compounds makes them invaluable in the further development of NMDA receptor 
inhibitory modulators as potential drug candidates. 
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CHAPTER 6: PHARMACOPHORE MODEL 
 
6.1 Introduction 
 
 The information gathered in this study has been very informative, and the class of 
compounds which has resulted from the work is one which may be an excellent start 
towards identification of a potential candidate for pharmaceutical development.  Each of 
the first two specific aims has been achieved.  A library of several hundred agmatine 
analogs has been synthesized, screened, refined, and analyzed, and nine compounds in 
the arylidenamino-guanidine series have been identified as being more potent and 
selective for the agmatine binding site of the NMDA receptor complex than agmatine 
itself (Table 6.1).  Furthermore, three of these compounds yielded clear biphasic dose-
response curves for the displacement of [3H]MK-801.  These data reinforce the 
hypothesis that agmatine and its analogs can act at different sites, and specifically can 
interact with a high affinity site which can then be targeted therapeutically to inhibit the 
pathological overactivation of the NMDAR channel. 
 With the data that has already been obtained from the structure-activity studies 
undertaken in this work, along with the X-ray crystal structure data, a pharmacophore of 
this high-affinity agmatine binding site can be postulated.  The introduction of this 
pharmacophore model will constitute a summary of the general structure-activity 
relationship conclusions drawn from this work, and will also serve as a useful tool to 
further direct the development of this novel class of compound as potential therapeutic 
agents. 
 The two factors which are to be considered in terms of identifying a useful 
NMDAR inhibitor are potency and selectivity for the agmatine binding site.  As set forth 
in Chapter 1, the agmatine binding site is the site at which agmatine acts to reduce the 
channel-activating effects of the longer chain endogenous polyamines.  It is apparent that 
agmatine also acts at a low-affinity site to displace [3H]MK-801 down to the control 
levels of channel inhibitors such as dextromethorphan.  However, the reason that 
agmatine is a valid therapeutic lead is that it acts at a higher affinity “agmatine binding 
site”, reducing pathological effects, at a lower concentration than it acts at the low-
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affinity site, where it would reduce physiological effects mediated by the NMDA 
receptor.  The measurement for potency at the agmatine binding site is approximated as 
the IC50Pot-value, which is the concentration of ligand necessary to reduce the amount of 
MK-801 bound to NMDA receptors by 50% of the difference between the spermidine-
potentiated “pathological state” levels and the control “physiological state” levels.  This 
measurement assumes that there are different mechanisms operating for a) a ligand to 
reduce binding from the SPD-potentiated levels to the non-potentiated control levels, and 
b) a ligand to reduce the binding from the non-potentiated control levels to the complete 
channel blockage control levels obtained with a high dose of dextromethorphan.  With 
these assumptions, the IC50Pot is an approximation of the IC50 for mechanism “a”.  The 
IC50 value for mechanism “b” can easily be obtained from the dose-response curve 
obtained for MK-801 displacement in the absence of added spermidine.  The selectivity 
for the agmatine binding site is given as a ratio of the IC50-values for mechanisms “a” 
and “b”, and is expressed as a “ratio of potentiation”, or RatioPot, which is simply the 
IC50Pot divided by the IC50 of the non-potentiated dose-response curve (i. e. the two values 
mentioned above).  In the case of compounds 21, 24, and 31, which were sufficiently 
selective for the agmatine binding site to yield biphasic dose-response curves, the 
separation between these two mechanisms was visibly evident, and both the IC50Pot and 
RatioPot values can be calculated from the graphical data without approximation. 
 Section 6.2 will examine closely the impact of the structural features of the 
compounds tested on the selectivity for, and potency at, the agmatine binding site of the 
NMDA receptor channel complex, detailing the observations drawn from each chapter. 
 
6.2 Results and Discussion 
 
6.2.1 Chapter 2 Insight 
 
Chapter 2 focused largely on the early prepared compounds, which more closely 
resembled agmatine, while varying each part of the molecule in order to discriminate the 
structural features which might contribute to the potency and selectivity for the agmatine 
binding site of the NMDA receptor complex.  While these series of compounds were 
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primarily a stepping stone towards the arylidenamino-guanidino compounds of Chapter 
3, there were many important and interesting data which pertain to the interaction of 
these compounds with the agmatine binding sites. 
 
H2N
N
H
NH2
NHA. B.
C.
C1
C2
 
Figure 6.1 Modification sites on the agmatine molecule 
 
It was found that the best general substitution for Moiety B (Figure 6.1), the four 
carbon bridge between the terminal amine and the guanidino group, was an aromatic ring.  
In particular, a phenyl ring with an attached methylene bridge afforded more potent 
compounds than just a simple phenyl ring, and a xylene moiety with an attached 
methylene bridge on each side proved to be the best substitution of all the ones tested.  
While the larger intramolecular spacing may be important, the xylene linkers also 
provided more molecular flexibility than the simple aromatic linkers.  In addition, 
agmatine analogs containing a meta-xylene linker proved to be more selective for the 
agmatine binding site (i.e. had higher Ratiopot values) than compounds with a para-
xylene linker, which is likely due to the fact that the meta-xylene linker is closer in length 
to agmatine than the para-linker. While inclusion of an aromatic ring in the linker 
appears to increase the potency of these agmatine analogs at both the high-affinity 
agmatine site and the low-affinity agmatine site, these small changes in spacing 
accompanying the inclusion of the aromatic moiety may be crucial towards developing 
this new agmatine binding site pharmacophore. 
As early attempts to substitute groups for the terminal amino functionality did not 
improve the inhibitory properties of the resulting agmatine analogs, Moiety A remained 
unchanged in the majority of the compounds described in Chapter 2.  Variation of Moiety 
C (Figure 6.1 above) proved to be unproductive, and did not lead to any improvement in 
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NMDAR inhibition, as every structural modification of the guanidine group attempted 
resulted in a less potent compound than the parent molecule (i.e. the molecule with the 
intact, unsubstituted guanidine group. 
The ratio of potentiation for each bis-guanidinium compound tested was close to 
1:1.  These data indicate that none of these compounds binds to the same polyamine site 
as agmatine, although the significance difference in hill slope indicates that none of these 
compounds act as inhibitors of the channel site.  It is thus postulated that these bis-
compounds, which are structurally related to arcaine, bind at another polyamine 
recognition site, and act allosterically as more potent inhibitors in the absence of 
spermidine than in its presence.  Thus, while these arcaine analogs are NMDAR 
inhibitors, they do not act at the high affinity agmatine binding site. 
 
6.2.2 Chapter 3 Insight 
 
 The research described in Chapter 3 was clearly focused around the lead sub-
library of compounds, the arylidenamino-guanidino compounds.  Each of the compounds 
within this series was shown to be an NMDAR inhibitor to some degree.  The nine 
compounds which possessed both a low IC50Pot-value and a high ratio of potentiation 
(RatioPot) are listed in Table 6.1. 
 A discussion of the effects of the different aromatic ring substituents on potency 
and selectivity within the arylidenamino-guanidino compounds will be summarized from 
the groups of compounds described previously in Chapter 3, with the focus on 
determining the best structural modifications which will increase both inhibitory potency 
and selectivity for the agmatine binding site.  While these compounds can be broken 
down according to such structural factors as sterics and electronics, it is important to note 
that many of these compounds could possess multiple structural characteristics which 
could impact agmatine site binding.  While a certain structural feature (for example, a 
hydrogen bond acceptor group at the 4-position of the aromatic ring) may seem to have a 
positive effect on selectivity for the agmatine binding site, such a compound might also 
be too sterically bulky to fit into the site, and thus the “negative” steric effect may 
override the “favorable” H-bond acceptor effect.  Thus, the identification of an accurate 
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pharmacophore may be difficult, especially with a limited number of ligands and very 
little structural information about the actual binding site.  Nevertheless, such data may be 
vital in the further refinement of this class of possible NMDAR antagonists. 
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Table 6.1 Selective agmatine-site NMDAR inhibitors; IC50-values in the presence 
and absence of spermidine, IC50 of potentiation, and ratio of potentiation 
 
Compound Structure IC50 w/  SPD1
IC50 w/o  
SPD2 IC50
Pot 3 RatioPot
# (Code)  (μM) (μM) (μM)  
12 
(AG-12) 
N
H
N
H
NH2
NH2 Cl
O
H3C  
61.9 62.3 12.8 4.9 : 1 
17 
(JR-219) N
H
N
H
NH2
NH2 Cl
N
CH 3
H3C
 
71.7 94.4 7.9 11.9 : 1 
21 
(JR-223) N
H
N
H
NH2
NH2 Cl
N
OO
O
H3C
 
259.4* 219.8 7.8 28.2 : 1 
22 
(JR-218) 
N
H
N
H
NH2
NH2 Cl
Cl
 
41.2 52.6 7.1 7.4 : 1 
23 
(JR-217) N
H
N
H
NH2
NH2 Cl
Cl
 
78.7 117.6 18.4 6.4 : 1 
24 
(JR-220) 
N
H
N
H
NH2
NH2 Cl
Cl
 
124.5* 124.5 3.6 34.6 : 1 
31 
(JR-213) N
H
N
H
NH2
NH2 Cl
 
117.8* 77.2 8.7 8.9 : 1 
33 
(JR-204) N
H
N
H
NH2
NH2 Cl
H 3C
 
48.9 80.3 11.5 7.0 : 1 
36 
(AG-2) 
N
H
N
H
NH2
NH2 ClN
H
 
279.6 443.7 59.3 7.5 : 1 
Agmatine 
N
H
NH2
NH2
H3N
SO4
 
902.3 1296 274.2 4.7 : 1 
 
 
1 - IC50 w/ SPD: the measurement of IC50 derived from the data collected in the spermidine-potentiated [3H] MK-801 
displacement assay. 
2 - IC50 w/o SPD: the measurement of IC50 derived from the data collected in the non-spermidine-potentiated [3H] MK-
801 displacement assay, in which the spermidine solution was replaced with buffer. 
3 - IC50 of Pot: from the spermidine-potentiated curve, the concentration corresponding to one-half of the difference in 
DPM between the SPD-potentiated control and the blank control. 
* - This measurement is the IC50 of the lower phase, as these SPD-potentiated curves were clearly biphasic in nature. 
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Aliphatic and Aromatic Substitution in Arylidenamino-Guanidino Compounds: 
 From the SAR data obtained on the arylidenamino-guanidino compounds with 
strictly aliphatic substituents on the aromatic ring, it appears that the addition of non-
functional substituents, which strictly act as steric bulk, improves potency but not 
selectivity for the agmatine binding site.  Compared to the unsubstituted compound 1 
(which possesses a 4.6 RatioPot, very close to the 4.7 value of agmatine itself), none of the 
aliphatic-substituted compounds prepared had a high ratio of potentiation.  These 
aliphatic substituents included methyl, isopropyl, n-butyl, and tert-butyl groups.  Thus, 
addition of aliphatic substituents affords no improvement over either the parent 
unsubstituted molecule or agmatine, and does not belong in the pharmacophore. 
 
N
H
N
H
NH2
NH2 Cl
 
Compound 1 
IC50pot = 73.1 μM 
Ratiopot = 4.6 : 1 
 
 Aromatic substituents introduced into the main aromatic ring afford structure-
activity relationships that are more difficult to interpret.  As with a number of the more 
bulky molecules screened in the study described in Chapter 2, the biphenyl compound 
29, as well as the indolyl compounds 39-42, appeared to be potent ligands at the low-
affinity binding site, but not at the high-affinity agmatine binding site.  However, the 
naphthyl analogs, compounds 30-33, did not fit this mold.  This set of four bicyclic 
naphthyl compounds included two compounds (30 and 32) with low RatioPot values (2.2 : 
1 and 1.5 : 1, respectively), and two compounds (31 and 33) with high RatioPot values 
(8.9 : 1 and 7.0 : 1, respectively).  As was discussed in Chapter 3, the only discernable 
difference between these two sets of compounds is the location of their methyl and 
phenyl substituents.  While compounds 30 and 32 have substituents at the ortho- and 
meta-positions, compounds 31 and 33 can be viewed as a benzylidenamino-guanidine 
with substituents at the meta- and para-positions.  Interestingly, these two positions are 
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substituted in one of the most selective arylidenamino-guanidine compounds discovered 
in the entire work, compound 21 (Figure 6.2). It can thus be postulated that while a 
second ring is generally not an indicator of agmatine selectivity, an exception is made 
when there are two substituents at the meta- and para-positions. 
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Compound 30 
IC50pot = 21.4 μM 
Ratiopot = 2.2 : 1 
Compound 31 
IC50pot = 8.7 μM 
Ratiopot = 8.9 : 1 
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Compound 32 
IC50pot = 26.5 μM 
Ratiopot = 1.5 : 1 
Compound 33 
IC50pot = 11.5 μM 
Ratiopot = 7.0 : 1 
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Compound 33 Structurally Conserved Moiety  
Figure 6.2 Structurally-conserved substitutions in compounds 21, 31, and 33 
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Hydrogen Bond Donor Ligands: 
 A very important component in the binding of small molecule ligands to proteins 
is hydrogen bonding between the ligand and electronegative sites (normally from oxygen, 
sulfur, or nitrogen) on the surface of the protein molecule.  These hydrogen bond 
interactions are roughly 10% as strong as covalent bonds.  In an attempt to determine the 
residues which may be present in the binding site, the ligands which have the ability to 
form hydrogen bonds with receptor protein residues will be discussed (Figure 6.3). 
The molecules most likely to exhibit hydrogen bond donation properties at the 
receptor binding site would be those containing protonic functionalities such as amino 
groups or hydroxyl groups.  The former group includes compounds 15 and 16, which 
possess primary amino moieties at the meta- and para-positions of the phenyl ring, 
respectively, and compound 40, which is an indolyl compound with essentially a non-
basic secondary amino group at the para-position.  The latter group, with hydroxyl 
substituents, includes two arylidenamino-guanidine compounds, compound 11, 
disubstituted with hydroxyl groups at the ortho- and para-positions of the phenyl group, 
and compound 20, which has a hydroxyl group at the meta-position of the phenyl group.  
Not one of these compounds has a Ratiopot-value higher or equal to that of agmatine.  
While these compounds may be more potent NMDAR antagonists than agmatine, they 
are not as selective as agmatine for the agmatine binding site.  Therefore, it is likely that 
the agmatine binding site does not contain any amino acid residues which could 
participate as hydrogen bond acceptors, in the binding of ligands with hydrogen-bond 
donating properties.  Therefore, hydrogen bond donor groups which are directly attached 
to the phenyl ring of arylidenamino-guanidino compounds are not favored as selective 
agmatine binding site antagonists. 
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Compound 15 
IC50pot = 199.5 μM 
Ratiopot = 3.9 : 1 
Compound 16 
IC50pot = 104.2 μM 
Ratiopot = 1.2 : 1 
Compound 40 
IC50pot = 50.6 μM 
Ratiopot = 1.3 : 1 
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Compound 11 
IC50pot = 167.5 μM 
Ratiopot = 1.7 : 1 
Compound 20 
IC50pot = 199.5 μM 
Ratiopot = 3.9 : 1 
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Figure 6.3 Interaction of direct ring-substituted hydrogen bond donor 
substituents (D) with an acceptor moiety (A) on the surface of the NMDAR protein 
 
Three compounds containing heteroatomic moieties in their structures that have 
potential to act as hydrogen bond donors were also synthesized.  These compounds all 
have the imino-guanidine moiety attached to five-membered nitrogen-containing 
aromatic rings (Figure 6.4).  Compound 36 is a 2-pyrrole group which has a single 
proton attached to its ring nitrogen at physiological pH, and was shown to be more 
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selective and potent than agmatine in the [3H]MK-801 displacement assay.  Compounds 
39 and 42 are 3-indolyl compounds, with the latter containing a 6-methyl group.  
Compound 39 was shown to maintain the level of selectivity of agmatine, while 
compound 42 was less selective than agmatine (perhaps due to the steric bulk of the 
added 6-methyl group).  However, both compounds showed a 10-fold increase in 
NMDAR potency.  These data appear to indicate that protonated heteroatoms in the 
aromatic ring directly attached to the imino-guanidine moiety can act as hydrogen bond 
donors with residues on the surface of the agmatine binding site. 
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Compound 36 
IC50pot = 59.3 μM 
Ratiopot = 7.5 : 1 
Compound 39 
IC50pot = 36.9 μM 
Ratiopot = 4.7 : 1 
Compound 42 
IC50pot = 32.9 μM 
Ratiopot = 2.3 : 1 
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Figure 6.4 Interaction of ligands containing ring heteroatoms that can act as 
a hydrogen bond donor (D) with an acceptor moiety (A) on the surface  
of the NMDA receptor protein 
 
Hydrogen Bond Acceptor Ligands: 
Compounds that have aromatic ring substituents which may act as hydrogen bond 
acceptors were also synthesized.  These structures were much more varied in structure, 
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selectivity, and potency.  In addition, these molecules contained atoms which were 
capable of forming hydrogen bonds; these atoms were directly attached to the aromatic 
ring in these molecules, e.g. the oxygen atom of a methoxy group or a nitro group.  It 
should also be noted that the oxygen atom of hydroxy group (as well as the nitrogen atom 
of an unprotonated amino group) can act as a hydrogen bond acceptor, as well as a 
hydrogen bond donor, as seen in the previous section. 
Hydrogen bond acceptor moieties which are directly attached to the aromatic ring 
(Figure 6.5) in the ortho-position include the hydroxy group of compound 11, and the 
methoxy group substituents of compounds 12 and 14.  Compound 12, with no other 
substituents, is more potent and slightly more selective than agmatine.  Compound 11 is 
substituted with a second hydroxyl group at the para-position, and compound 14 
possesses a second methoxy group substituent at the para-position; both are less selective 
than agmatine, and less potent than compound 12.  As none of these compounds were 
subjected to X-ray structure determination, it cannot be definitively stated as to which 
phenyl ortho-position protamer is preferred; however, it is reasonable to assume that 
compounds 12 and 14 have their ortho-methoxy groups at the same position (due to 
favorable intramolecular hydrogen bonding, assumedly the 2-position of the phenyl ring, 
going clockwise from the imine).  Thus, whether these compounds are all substituted at 
the 2- or 6-positions, as long as the substituent location is constant, it does not appear to 
have any particular effect on inhibitory activity.  Therefore, while a hydrogen bond 
accepting moiety directly attached to the ring at the ortho-position may be beneficial to 
selectivity for the agmatine binding site, compounds with another such moiety at the 
para-position appear to afford lower potency and selectivity.   
 
N
H
N
H
NH2
NH2 Cl
OHHO
 
N
H
N
H
NH2
NH2 Cl
O
H3C  
N
H
N
H
NH2
NH2 Cl
O
O
H3C
H3C
 
Compound 11 
IC50pot = 167.5 μM 
Ratiopot = 1.7 : 1 
Compound 12 
IC50pot = 12.8 μM 
Ratiopot = 4.9 : 1 
Compound 14 
IC50pot = 28.8 μM 
Ratiopot = 2.4 : 1 
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Compounds with hydrogen bond acceptor moieties incorporated into the ring at 
the para-position were more numerous, and included compounds 11 and 14 mentioned 
above, as well as compounds 13, 17, 20, 21, and 34.  Of these molecules, compounds 
17 and 21 were the only ones that were more selective for the agmatine binding site than 
either compound 1 or agmatine.  Compound 17, with an attached dimethylamino group, 
is the most sterically-hindered hydrogen bond acceptor group in this series of 
compounds.  The other six compounds in this series all possess oxygen-containing 
moieties at the para-position of their phenyl rings, and may be more likely to act as 
hydrogen bond acceptors with agmatine binding site residues.  Compound 13, contains a 
para-methoxy group, and has very similar activity to compound 14, which contains the 
same group (in addition to its ortho-methoxy substituent); both have low selectivity for 
the agmatine binding site.  Likewise, compounds 20 and 34 both have hydrogen bond 
acceptor groups at the meta- and para-positions.  Compound 21 has a para-methoxy 
group, just like compounds 13, 14, and 20.  However, compound 21 has a nitro group at 
the meta-position of the aromatic ring, and is so potent and selective for the agmatine 
binding site that it yielded a biphasic dose-response curve with a 28.2 : 1 RatioPot.  Thus, 
while these results are not definitively conclusive, it appears that a hydrogen bond 
acceptor atom attached directly to the aromatic ring at the para-position can be present 
in a compound which is selective for the agmatine binding site, but it may also serve to 
reduce the selectivity of an otherwise promising compound (i.e. compound 11). 
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Compound 11 
IC50pot = 167.5 μM 
Ratiopot = 1.7 : 1 
Compound 14 
IC50pot = 28.8 μM 
Ratiopot = 2.4 : 1 
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Compound 13 
IC50pot = 34.7 μM 
Ratiopot = 3.4 : 1 
Compound 17 
IC50pot = 7.9 μM 
Ratiopot = 11.9 : 1 
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Compound 20 
IC50pot = 199.5 μM 
Ratiopot = 3.9 : 1 
Compound 21 
IC50pot = 7.8 μM 
Ratiopot = 28.2 : 1 
Compound 34 
IC50pot = 7.9 μM 
Ratiopot = 11.9 : 1 
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Figure 6.5 Interaction of ligands containing a direct ring-substituted 
hydrogen bond acceptor moiety (A) with a donor moiety (D) on the surface of the 
NMDA receptor protein 
 
 Compounds with hydrogen bond acceptor atoms separated from the aromatic ring 
by another atom (Figure 6.6) included three different types of moieties: a methyl-ester 
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group or a nitro group, both of which represent groups with two possible hydrogen bond 
acceptor interactions, or a cyano group, having a single site for hydrogen bonding.  
Compounds were prepared with all three of these aromatic substituents in either the meta- 
or para-positions: i.e. the meta-methyl-ester compound 8, the para-methyl-ester 
compound 9, the meta-nitro compound 18, the para-nitro compound 19, the meta-cyano 
compound 6, and the para-cyano compound 7.  These six compounds were neither 
especially potent inhibitors at the NMDA receptor, nor more selective inhibitors of the 
agmatine binding site than compound 1.  Interestingly, compound 21 did not fit the 
general SAR within their group; the inclusion of the meta-nitro group in compound 21 
resulted in an increase in selectivity and potency over the para-methoxy compound 13, 
which was otherwise structurally the same. Thus, compounds with a hydrogen bond 
acceptor atom one atom separated from the aromatic ring were not notable inhibitors 
without additional functionalities, i.e. the para-methoxy group of compound 21. 
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Compound 8 
IC50pot = 71.1 μM 
Ratiopot = 4.6 : 1 
Compound 9 
IC50pot = 72.4 μM 
Ratiopot = 2.0 : 1 
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Compound 18 
IC50pot = 149.3 μM 
Ratiopot = 2.0 : 1 
Compound 19 
IC50pot = 78.0 μM 
Ratiopot = 2.8 : 1 
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Compound 6 
IC50pot = 43.4 μM 
Ratiopot = 1.9 : 1 
Compound 7 
IC50pot = 231.2 μM 
Ratiopot = 1.8 : 1 
Compound 21 
IC50pot = 7.8 μM 
Ratiopot = 28.2 : 1 
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Figure 6.6 Interaction of ligands containing a hydrogen bond acceptor 
moiety (A) one atom removed from the aromatic ring with a donor moiety (D) on 
the surface of the NMDA receptor protein 
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 In addition, there are four arylidenamino-guanidine compounds which contain 
heteroatoms in their aromatic moieties that have the potential to act as hydrogen bond 
acceptors (Figure 6.7).  These are the 3-pyridyl and 4-pyridyl compounds (37 and 38, 
respectively), the 3-thiophene compound (43), and the 2-furano compound (which also 
has a 5-para-nitrophenyl substituent) (35).  This small sub-set of compounds is entirely 
comprised of nonselective and relatively impotent compounds, and thus it can concluded  
that aromatic rings containing hydrogen bond accepting heteroatoms do not interact in a 
positive way with the agmatine binding site of the NMDA receptor. 
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Figure 6.7 Interaction of ligands containing an aromatic ring  
heteroatom (A) that can act as a hydrogen bond acceptor with a hydrogen bond 
donor moiety (D) on the surface of the NMDA receptor protein 
 
Electronic effects: 
 Aromatic substituents can have direct effects on the electronics of a phenyl or 
heteroaromatic ring, generally grouped into inductive and resonance effects.  Inductive 
effects are exerted by electronegative atoms, which serve to pull σ electrons toward the 
more electronegative atom, and away from the phenyl ring or its other substituents.  This 
has the effect of generating partial negative charges on electronegative atoms such as a 
halogen, while the carbons of the ring become slightly positively-charged, resulting in 
more polarized carbon-carbon bonds (Figure 6.8).  The strongest electron-withdrawing 
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inductive effects will be exerted by the most electronegative functional groups, which 
include halogeno, trifluoromethyl, nitro, and ester moieties.   
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Figure 6.8 Inductive effects exerted by phenyl group substituents 
(Q = electron withdrawing group, e.g. Cl, CF3, NO2) 
 
Resonance (or electromeric) effects serve to delocalize π electrons through 
conjugated double bonds, and are often observed in phenyl groups with electron-
withdrawing functionalities such as nitro groups (Figure 6.9 A), and electron-donating 
functionalities with nonbonding electron pairs, such as amino, dimethylamino, hydroxy, 
and methoxy groups (Figure 6.9 B).  Halogens, while possessing strong electron-
withdrawing inductive effects, are also able to act as electron donors and resonance 
stabilize the aromatic ring.  Fluorine is the most electronegative halogen, yet 
fluorobenzene is the most reactive halobenzene, due to the size of the fluorine atom, 
relative to carbon.  Donation of an electron pair from fluorine arises from orbital overlap 
between the 2p orbital of fluorine and the 2p orbital of the adjoining carbon atom.  The 
larger halogens, such as chlorine in this study, are relatively poor electron donors, as they 
are significantly larger than carbon and their nonbonding pairs are further from their 
nuclei and therefore do not overlap well with the 2p orbital of the carbon molecule to 
which they are bound. 
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Figure 6.9 Resonance effects observed with phenyl group substituents, whether 
electron-withdrawing (A.) or electron-donating (B.) 
 
Phenyl ring substituents which have electron-withdrawing inductive and 
resonance effects include nitro, cyano, and ester groups.  As previously mentioned, the 
two compounds with ester phenyl substituents, the meta-methyl-ester compound 8 and 
the para-methyl-ester compound 9, were neither potent nor selective for the agmatine 
binding site.  Neither were the two compounds with a single nitro substituent, 
compounds 18 and 19. However, compound 21, with a meta-nitro and para-methoxy 
substituent, was extremely potent and selective.  The meta-cyano and para-cyano 
compounds (6 and 7, respectively) had similar activity as their corresponding nitro-
substituted compounds, i.e. low potency and selectivity for the agmatine binding site. 
The ortho-trifluoromethyl aromatic substituent of compound 10 has a strong 
electron-withdrawing inductive effect on the ring, but is unable to form any resonance 
structures.  This compound also possessed low potency and selectivity for the agmatine 
binding site. 
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Phenyl substituents which are the most electron-donating include amino groups, 
substituted amino groups, hydroxyl groups, and methoxy groups.  While nitrogen and 
oxygen atoms are slightly more electrophilic than carbon, and can have a small electron-
withdrawing inductive effect, the resonance effects of these compounds are much 
stronger, and in general, they freely donate their 2p electrons to the similar-sized carbon 
atoms of the phenyl ring to which they are attached.  The substituents which have strong 
electron-donating substituents are those with nonbonded electron pairs, and thus this 
subset of arylidenamino-guanidino compounds mirrors the subset of compounds which 
have substituents that act as hydrogen bond acceptors (see the previous sections and 
Figure 6.5).  The results remain true in this section as well, that electron-donating 
substituents attached directly to the aromatic ring at the ortho- or para-position 
generally do not improve the selectivity or potency of the parent compound for the 
agmatine binding site.  However, in several cases such as compounds 21 and 34, a para-
substituent with electron-donating character was present, but not as the sole substituent. 
Perhaps the most interesting results in this sub-set of arylidenamino-guanidine 
compounds were produced by the halogeno-compounds. As previously described, the 
halogen atoms are electrophilic (having an electron-withdrawing inductive effect on the 
phenyl ring), but are also able to donate nonbonding electrons to the phenyl ring (having 
an electron-donating resonance effect on the phenyl ring).  Four compounds in this group 
with aromatic fluoro substituents (the most electronegative halogen atom) were prepared 
and tested: i.e. compound 26, containing an aromatic ortho-fluoro substituent; 
compound 27, with a para-fluoro substituent; compound 28, containing both ortho- and 
para-fluoro substituents.  None of these compounds exceeded a 4.0 : 1 RatioPot, nor were 
they remarkably potent NMDAR inhibitors.  The four compounds that contained 
aromatic chloro substituents afforded better results.  While the 2,4-difluoro compound 
25 was potent, but not especially selective for the agmatine binding site, the three mono-
chloro arylidenamino-guanidines were among the best lead compounds discovered.  All 
of these compounds had IC50Pot values below 20 μM.  The RatioPot was 7.4 : 1 for the 
ortho-chloro compound 22, 6.4 : 1 for the meta-chloro compound 23, and a staggering 
34.6 : 1 for the para-chloro compound 24.  The differences between chlorine and 
fluorine atoms are mainly related to their size; a fluorine atom is a much smaller and 
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better electron-donating group to a phenyl ring due to its similar size to carbon.  The 
nonbonding electrons in the 2p orbitals of fluorine overlap well with the 2p orbitals of 
carbon, but the 3p orbitals of chlorine atoms, which hold their nonbonding electron pairs, 
do not. 
This group of data does not seem to follow an inflexible rule which pertains to the 
electronic effects of these substituents on activity, but several points can be made.  1) 
Electron-withdrawing substituents which exhibit inductive effects may contribute to 
selectivity, but 2) electron-withdrawing groups which induce resonance effects (i.e. 
electron sinks), pulling π-bond characteristic from the imine and guanidine  moieties, do 
not contribute to agmatine-site selectivity, and may indeed reduce any activity conferred 
by beneficial inductive effects.  In addition, the fact that the aromatic chloro analogs were 
more potent and selective agmatine binding site inhibitors than the aromatic fluoro 
analogs demonstrates that 3) electron-donating phenyl substituents may also reduce the 
inhibitory activity of arylidenamino-guanidino compounds. 
  
6.2.3 Chapter 4 Insight 
 The information gleaned from the X-ray structure analysis was very important in 
that it provided a definitive look at several different arylidenamino-guanidine 
compounds, with bond geometries and angles.  While there were not found to be any 
effects from the different ring substituents on bond conjugation, geometry, or length in 
the imino-guanidino part of the molecule, the similarities exhibited by the molecules 
provide a good reflection of the geometrical form in which this group of compounds 
binds to the high-affinity agmatine binding site. 
Each of the salt forms of the tested molecules had a very similar structure, with 
regard to their phenylidenamino-guanidine moieties, and the boxed section of the 
structure of compound 21 in Figure 6.10 provides this general feature in these 
molecules.  The guanidine moiety was shown to exist with the double bond 
characteristics primarily shared between the exo C-N bonds, and roughly 20% of the 
double bond characteristic was localized in the endo C-N bond.  Thus, 80% of the unit 
positive charge of the protonated guanidine moiety is localized on the exo nitrogen 
atoms, which infers that these positively charged exo C-N moieties could interact with 
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similar negatively charged polar moieties, such as the ionized carboxylate of an aspartic 
or glutamic acid residue.  Measurements of the torsion angles and bond angles between 
the phenyl ring and the guanidino group show that these compounds are almost 
completely planar: the torsion angles along the chain between the phenyl ring and the 
guanidine group are close to 180°, and the bond angles are very close to 120°.  These data 
also show that the observed planarity is not just a result of the crystal packing, but a result 
of significant double-bond conjugation throughout the molecules. Each of the bonds 
between the phenyl ring and the guanidine moiety were observed to be strictly in the E 
geometrical form, which extends the guanidine moiety away from the phenyl ring and its 
binding domain, and into a different region of the agmatine binding site. 
 
 
Figure 6.10 X-ray structure of compound 21 with boxed “conserved moiety” 
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6.2.4 Chapter 5 Insight 
 
The information gleaned from the partial least squares and artificial neural 
network models (see Chapter 5) was very informative, and supported many of the 
observations thus  far postulated in this chapter, with respect to the pharmacophore 
model.  For instance, the ANN model predicted that the descriptor which measures 
unprotonated aromatic heteroatoms should be minimized; this is in agreement with the 
observations in Section 6.2.2 that hydrogen bond acceptors within the aromatic ring 
detract from the ability of arylidenamino-guanidino ligands to inhibit NMDAR activity. 
However, there is a striking limitation in the therapeutic value of these models 
with regards to the pharmacophore of the agmatine binding site: in developing such 
models, the input variable to be optimized is the IC50Pot.  For example, the computer 
models were instructed that compound 3, with an IC50Pot-value of 6.0 μM, is “better” 
than compound 21, which has an IC50Pot-value of 7.8 μM.  However, the latter compound 
is over six times as selective for the agmatine binding site than the former compound, 
making it a much better therapeutic candidate. 
The conclusions put forth in Chapter 5 are by no means without value or merit.  
Quite the contrary, several of them have been stated earlier in this chapter as relevant to 
our understanding of the agmatine binding site.  More importantly, these models are a 
vital tool in the development of potent arylidenamino-guanidino NMDAR inhibitors, as 
they are able to predict potency in silico.  Therefore, structurally similar compounds with 
high predicted IC50Pot-values (i.e. low NMDAR inhibitory potency) can remain 
unsynthesized and untested in lieu of compounds with low predicted IC50Pot-values (i.e. 
high NMDAR inhibitory potency); while the agmatine site selectivity of the compounds 
will have to be determined experimentally, a substantial amount of cost and time can be 
saved by synthesis of only the arylidenamino-guanidino compounds with the highest 
predicted NMDAR potency.  Regardless, the data from the models are not suitable for the 
current task of introducing a high-affinity agmatine binding site pharmacophore. 
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6.3 Conclusions  
 
 The data collected throughout this work has been examined with the intent of 
gathering structure-activity relationship information in order to propose a pharmacophore 
for the agmatine binding site on the NMDA receptor complex.  The conclusions drawn 
from each section are compiled below. 
 
I. Inclusion of an aromatic ring in the linker between the terminal amino group and 
the guanidino moiety of an agmatine analog seems to increase its potency for both 
the high-affinity agmatine site and the low-affinity site 
II. Every structural modification of the guanidine group attempted resulted in a less 
potent compound than the parent molecule (i.e. the molecule with the intact, 
unsubstituted guanidine group.   
III. Bis-compounds, which are structurally related to arcaine, bind at another 
polyamine recognition site, and act allosterically as more potent inhibitors in the 
absence of spermidine than in its presence. 
IV. Addition of aliphatic substituents to the phenyl ring affords no improvement over 
either the parent unsubstituted molecule or agmatine. 
V. While a second aromatic ring adjoined to the first is generally not an indicator of 
agmatine selectivity, an exception is made when there are two substituents at the 
meta- and para-positions 
VI. Hydrogen bond donor groups which are directly attached to the phenyl ring of 
arylidenamino-guanidino compounds are not favored in selective agmatine 
binding site antagonists. 
VII. Protonated heteroatoms in the aromatic ring directly attached to the imino-
guanidine moiety can act as hydrogen bond donors with residues on the surface of 
the agmatine binding site. 
VIII. Aromatic rings containing hydrogen bond accepting heteroatoms do not interact 
in a positive way with the agmatine binding site of the NMDA receptor. 
IX. Direct ring-substituted hydrogen bond donors are not favored in selective ligands. 
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X. A hydrogen bond accepting moiety directly attached to the aromatic ring at the 
ortho-position may be beneficial to selectivity for the agmatine binding site. 
XI. A hydrogen bond acceptor moiety attached directly to the aromatic ring at the 
para-position can be present in a compound which is selective for the agmatine 
binding site, but it may also serve to reduce the selectivity of an otherwise 
promising compound. 
XII. Compounds with a hydrogen bond acceptor atom one atom separated from the 
aromatic ring were not notable inhibitors without additional functionalities. 
XIII. Electron-donating substituents attached directly to the aromatic ring at the ortho- 
or para-position generally do not improve the selectivity or potency of the parent 
compound for the agmatine binding site.  However, in several cases of selective 
and potent NMDAR agmatine binding site inhibitory molecules a para-substituent 
with electron-donating character was present, but not as the sole substituent. 
XIV. Electron-withdrawing aromatic substituents which exhibit inductive effects may 
contribute to selectivity. 
XV. Electron-withdrawing aromatic substituents which induce resonance effects (i.e. 
electron sinks), pulling π-bond characteristic from the imine and guanidine  
moieties, do not contribute to agmatine-site selectivity, and may indeed reduce 
any activity conferred by beneficial inductive effects. 
XVI. Positively charged terminal amino groups of a guanidine moiety could interact 
with negatively charged polar residue, such as an aspartic or glutamic acid. 
XVII. Each of the bonds between the phenyl ring and the guanidine moiety were 
observed to be strictly in the E geometrical form, which extends the guanidine 
moiety away from the phenyl ring and its binding domain, and into a different 
region of the agmatine binding site. 
 
Based on these observations, along with the conserved moiety from the X-ray structure 
displayed in Figure 6.10, the following pharmacophore has been proposed (Figure 6.11).  
This important piece of information will be a helpful tool in the development of 
therapeutically useful drug molecules which target this agmatine binding site on the 
NMDA receptor complex. 
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Figure 6.11 Putative pharmacophore of the agmatine binding site of the  
NMDA receptor complex 
 
D - H = hydrogen bond donor   
A = hydrogen bond acceptor  
(D)-H indicates that the aromatic ring can be a 5-membered ring with a non-basic 
protonated heteroatom which acts as a hydrogen bond donor. 
Dashed oval represents the “planar surface” which interacts with the 
phenyl ring and possibly the conjugated imino and guanidino moieties. 
 
“E” indicates the geometry of the imine double bond, or 
the N-N bond which possesses double-bond character 
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